

=> b reg
 FILE 'REGISTRY' ENTERED AT 13:41:59 ON 21 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9
 DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l9
 L5 STR

Hy[^]Cb[^]Hy
 1 2 3

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GG CAT IS UNS AT 2
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E2 N AT 1
 ECOUNT IS E3 C E1 N E1 O AT 3

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE
 L7 11618 SEA FILE=REGISTRY ABB=ON PLU=ON NC2NC2/ES AND NCOC2/ES
 L9 2527 SEA FILE=REGISTRY SUB=L7 SSS FUL L5

100.0% PROCESSED 11618 ITERATIONS 2527 ANSWERS
 SEARCH TIME: 00.00.01

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 13:42:30 ON 21 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8
 FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitr 113 tot

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
 AN 2003:786700 HCAPLUS
 DN 139:307798
 TI Preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel
 IN antiinfective compounds and pharmaceutical compositions containing them
 LOhray, Braj Bhushan; Lohray, Vidya Bhushan; Srivastava, Brijesh Kumar
 DA Cadila Healthcare Limited, India
 SO PCT Int. Appl., 78 pp.
 CODEX: PXX32
 DT Patent
 LA English
 FAN.CNT 1

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003082864	A2	20031009	2003WO-IN00081	20030326	
WO2003082864	A3	20031113			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	FW:	GH, GM, KE, LS, MW, ME, SD, SH, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG			
IN2002MU00310	A	20050318	2002IN-MU00310	20020401	
CA-----2478502	A1	20031009	2003CA-2478502	20030326	
AU2003231920	A1	20031013	2003AU-0231920	20030326	
EP-----1495021	A2	20050112	2003EP-0745394	20030326	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR2003008837	A	20050201	2003BR-0008837	20030326	
US2006229316	A1	20061012	2005US-0509892	20050517 <--	
ZA-200406844	A	20060531	2004ZA-0006844	20060327	
PRAI 20021IN-MU00310	A	20020401			
2003WO-IN00081	W	20030326			
OS MARPAT 139:307798					
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Ar = (un)substituted Ph, 5-6 membered heteroaryl; R1, R2 = H, halo, alkyl, etc.; Y = II-IV (wherein R3, R4 = H, alkyl, halo, etc.; X = O, S, NR5; R5 = H, alkyl, aryl; A = (un)substituted (un)saturated single or fused ring optionally containing one or more heteroatoms selected from N, S, O; T = H, alkyl, CN, etc.); W = OH, N3, NMe2, NCS, etc.], useful for treating bacterial infections, psoriasis, arthritis, were prepared. Thus, amidation of (5)-N-((3-(3-fluoro-4-(N-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide with 3-(2-thienyl)acrylic acid afforded 534 (SI)-V. The compds. I inhibited the growth of bacteria such as *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Enterococcus faecalis* with MIC's in a range of about 0.25 µg/mL to about 64 µg/mL. Pharmaceutical composition comprising the compound I is claimed.

IT 612054-71-4P 612054-72-5P 612054-73-6P
 612054-74-7P 612054-75-8P 612054-76-9P
 612054-77-0P 612054-78-1P 612054-79-2P
 612054-80-5P 612054-81-6P 612054-82-7P
 612054-83-8P 612054-84-9P 612054-85-0P
 612054-86-1P 612054-87-2P 612054-88-3P
 612054-89-4P 612054-90-7P 612054-91-8P
 612054-92-9P 612054-93-0P 612054-94-1P
 612054-95-2P 612054-96-3P 612054-97-4P
 612054-98-5P 612054-99-4P 612055-00-2P
 612055-01-3P 612055-02-4P 612055-03-5P
 612055-04-6P 612055-05-7P 612055-06-8P
 612055-07-9P 612055-08-0P 612055-09-1P
 612055-10-4P 612055-11-5P 612055-12-6P


L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
 612055-13-7P 612055-14-8P 612055-15-9P
 612055-16-0P 612055-17-1P 612055-18-2P
 612055-19-3P 612055-20-6P 612055-21-7P
 612055-22-8P 612055-23-9P 612055-24-0P
 612055-25-1P 612055-26-2P 612055-27-3P
 612055-28-4P 612055-29-5P 612055-30-8P
 612055-31-9P 612055-32-0P 612055-33-1P
 612055-34-2P 612055-35-3P 612055-36-4P
 612055-37-5P 612055-38-6P 612055-39-7P
 612055-40-0P 612055-41-1P 612055-43-3P
 612055-44-4P 612055-45-5P 612055-46-6P
 612055-47-7P 612055-48-8P 612055-49-9P
 612055-50-2P 612055-51-3P 612055-52-4P
 612055-53-5P 612055-54-6P 612055-55-7P
 612055-56-8P 612055-57-9P 612055-58-0P
 612055-59-1P 612055-60-4P 612055-61-5P
 612055-62-6P 612055-63-7P 612055-64-8P
 612055-65-9P 612055-66-0P 612055-67-1P
 612055-68-2P 612055-69-3P 612055-70-6P
 612055-71-7P 612055-72-8P 612055-73-9P
 612055-74-0P 612055-75-1P 612055-76-2P
 612055-77-3P 612055-78-4P 612055-79-5P
 612055-80-8P 612055-81-9P 612055-82-0P
 612055-83-1P 612055-84-2P 612055-85-3P
 612055-86-4P 612055-87-5P 612055-88-6P
 612055-89-7P 612055-90-0P 612055-91-1P
 612055-92-2P 612055-93-3P 612055-94-4P
 612055-95-5P 612055-96-6P 612055-97-7P
 612055-98-8P 612055-99-9P 612056-00-5P
 612056-01-6P 612056-02-7P 612056-03-8P
 612056-05-0P 612056-06-1P 612056-07-2P
 612056-08-3P 612056-09-4P 612056-10-7P
 612056-11-8P 612056-12-9P 612056-13-0P
 612056-14-1P 612056-15-2P 612056-16-3P
 612056-17-4P 612056-18-5P 612056-19-6P
 612056-20-9P 612056-21-0P 612056-22-1P
 612056-23-2P 612056-24-3P 612056-25-4P
 612056-26-5P 612056-27-6P 612056-28-7P
 612056-29-8P 612056-30-1P 612056-31-2P
 612056-32-3P 612056-33-4P 612056-34-5P
 612056-35-6P 612056-36-7P 612056-37-8P
 612056-38-9P 612056-39-0P 612056-40-3P
 612056-41-4P 612056-42-5P 612056-43-6P
 612056-44-7P 612056-45-8P 612056-46-9P
 612056-47-0P 612056-48-1P 612056-49-2P
 612056-50-5P 612056-51-6P 612056-52-7P
 612056-53-8P 612056-54-9P 612056-55-0P
 612056-56-1P 612056-57-2P 612056-58-3P
 612056-59-4P 612056-61-8P 612056-62-9P
 612056-63-0P 612056-64-1P 612056-65-2P
 612056-66-3P 612056-67-4P 612056-68-5P
 612056-69-6P 612056-70-9P 612056-71-0P
 612056-72-1P 612056-73-2P 612056-74-3P
 612056-75-4P 612056-76-5P 612056-77-6P
 612056-78-7P 612056-79-8P 612056-80-1P
 612056-81-2P 612056-82-3P 612056-83-4P
 612056-84-5P 612056-85-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 3-(4-piperazinophenyl) substituted oxazolidinones as novel antiinfective compds. and pharmaceutical compns. contg. them)
 IT 154590-43-9 154590-66-4 216869-31-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel antiinfective compds. and pharmaceutical compns. containing them)
 IT 612056-04-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
 antiinfective compds. and pharmaceutical compns. contg. them)
 IT 612054-71-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(4-piperazinophenyl) substituted oxazolidinones as novel antiinfective compds. and pharmaceutical compns. containing them)
 RN 612054-71-4 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-[(4-[(2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



=> d bib abs hitrn fhitstr l20 tot


L20 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:548793 HCAPLUS
 DN 145:201959
 TI 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: A novel class of antibacterial agents
 AU Lohray, B. B.; Gandhi, Neha; Srivastava, Brijesh Kumar
 ; Lohray, Vidya Bhushan
 CS Zyus Research Centre, Cadila Healthcare Ltd, Moraiya, Gujarat, Ahmedabad, 382210, India
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3817-3823
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Three-dimensional QSAR studies for N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones were conducted using QSAR 3.3. The in vitro activities (MICs) of the compds. against Staphylococcus aureus ATCC 25923 exhibited a strong correlation with the prediction made by the model developed in the present study.
 IT 612054-71-4 612054-72-5 612054-75-8
 612054-76-9 612054-81-6 612054-84-9
 612054-85-0 612054-86-1 612054-87-2
 612054-88-3 612054-89-4 612054-91-9
 612054-94-1 612055-05-7 612055-06-8
 612055-11-5 612055-12-6 612055-16-0
 612055-34-2 612055-36-4 612055-40-0
 612055-41-1 612055-43-3 612055-45-5
 612055-50-2 612055-94-4 612055-95-5
 612055-97-7 612055-98-8 612055-99-9
 612056-01-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (QSAR of novel antibacterial agents arylacryloylpiperazin phenyl-oxazolidinones)
 IT 612054-71-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (QSAR of novel antibacterial agents arylacryloylpiperazin phenyl-oxazolidinones)
 RN 612054-71-4 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L20 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:128496 HCAPLUS
 DN 144:370048
 TI Novel 4-N-substituted arylpent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials
 AU Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Srivastava, Brijesh Kumar; Gupta, Sunil; Solanki, Manish; Pandya, Purvi; Kapadnis, Prashant
 CS Zyus Research Centre, Ahmedabad, 382210, India
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1557-1561
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:370048
 AB A few substituted piperazinyloxazolidinones having substitution on the distant nitrogen atom of piperazine ring scaffold have been synthesized and evaluated for their antibacterial activity in Gram-pos. bacteria. A few compds. showed superior in vitro antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, and Streptococcus pyogenes than linezolid and eperzolid.
 IT 612055-00-2P 612055-01-3P 612055-02-4P
 612055-04-6P 612055-07-9P 612055-09-1P
 612055-48-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 4-N-substituted arylpent-2-ene-1,4-dione derivs. of piperazinyloxazolidinones as antibacterials)
 IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 4-N-substituted arylpent-2-ene-1,4-dione derivs. of piperazinyloxazolidinones as antibacterials)
 IT 612055-00-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 4-N-substituted arylpent-2-ene-1,4-dione derivs. of piperazinyloxazolidinones as antibacterials)
 RN 612055-00-2 HCAPLUS
 CN Acetamide, N-[(1S)-3-[4-{4-[(2E)-1,4-dioxo-4-phenyl-2-butenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (RCT) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:241539 HCAPLUS
 DN 142:403458
 TI Novel anti-infective compounds
 AU Lohray, Vidya; Lohray, Braj B.; Srivastava, Brijesh Kumar
 CS Zyus Research Centre, Cadila Healthcare Ltd., Moraiya, Ahmedabad, 382 210, India
 SO Pure and Applied Chemistry (2005), 77(1), 195-200
 CODEN: PACBAS; ISSN: 0033-4545
 PB International Union of Pure and Applied Chemistry
 DT Journal
 LA English
 OS CASREACT 142:403458
 AB A set of substituted piperazinyloxazolidinone derivs. has been studied for their antibacterial activity in a few gram-pos. bacteria. The structural modifications have provided a superior compound than linezolid, the only drug of this class in the market at present.
 IT 612054-71-4P 612054-74-7P 612054-75-8P
 612054-76-9P 612054-85-0P 612054-86-1P
 612054-88-3P 612054-93-0P 612054-94-1P
 612054-97-4P 612055-34-2P 612055-38-6P
 612055-45-5P 612056-01-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-infective compds.)
 IT 154590-66-6 216869-31-7 612055-59-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (anti-infective compds.)
 IT 612054-71-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-infective compds.)
 RN 612054-71-4 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:881223 HCAPLUS
 DN 142:71396
 TI Novel Mannich ketones of oxazolidinones as antibacterial agents
 AU Srivastava, Brijesh Kumar; Kapadnis, Prashant B.; Pandya, Purvi;
 Lohray, Vidya Bhushan
 CS Zydus Research Centre, Ahmedabad, Moraiya, 382210, India
 SO European Journal of Medicinal Chemistry (2004), 39(11), 989-992
 CODEN: EJMCAS; ISSN: 0223-5234
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 142:71396
 GI

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB A few Mannich ketones of piperazinyloxazolidinone derivs. were synthesized and their antibacterial activity in various Gram-pos. organisms, such as *Bacillus subtilis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Enterococcus faecalis* were evaluated by MIC determination. Compound I showed comparable activity to linezolid and superior to eperzolid.
 IT 612055-27-3P 612055-28-4P 612055-29-5P
 612055-30-8P 612055-32-0P 612056-68-5P
 612056-69-6P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 TI (novel Mannich ketones of oxazolidinones as antibacterial agents)
 IT 154590-66-6 612056-04-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 IT 612055-27-3P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 TI (novel Mannich ketones of oxazolidinones as antibacterial agents)
 RN 612055-27-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)methyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)
 Absolute stereochemistry.




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:403812 HCAPLUS
 DN 141:157051
 TI Oxazolidinone: search for highly potent antibacterial
 AU Lohray, Braj Bhushan; Lohray, Vidya Bhushan;
 Srivastava, Brijesh Kumar; Gupta, Sunil; Solanki, Manish;
 Kapadnis, Prashant; Takale, Vijay; Pandya, Purvi
 CS Zydus Research Centre, Medicinal Chemistry Department, Cadila
 Healthcare Ltd., Ahmedabad, 382210, India
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3139-3142
 CODEN: BMCL88; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 141:157051
 GI



AB A number of substituted piperazinyloxazolidinones I (R1 = Ph, 4-HOC6H4, 4-O2NC6H4, 3,4-F2C6H3, piperonyl, etc.; R2 = MeCO, MeCS, H2NCS) have been synthesized and their antibacterial activities were evaluated by min. inhibitory concentration (MIC) determination. A systematic structure-activity relationship study was carried out to get highly potent oxazolidinone derivs.
 IT 612054-75-8P 612054-82-7P 612054-93-0P
 612054-94-1P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 IT (preparation of substituted piperazinyloxazolidinones as potent antibacterial agents)
 IT 612054-74-7P 612054-77-0P 612054-80-5P
 612054-81-6P 612054-83-8P 612054-85-0P
 612054-88-3P 612054-89-4P 612054-97-4P
 612054-98-5P 612054-99-6P 612055-03-5P
 612055-33-1P 612055-34-2P 612055-38-6P
 612055-45-5P 612055-96-6P 612056-01-6P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 IT (preparation of substituted piperazinyloxazolidinones as potent antibacterial agents)
 IT 216869-31-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 IT (preparation of substituted piperazinyloxazolidinones as potent antibacterial agents)
 IT 612054-75-8P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 IT (preparation of substituted piperazinyloxazolidinones as potent antibacterial agents)
 RN 612054-75-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 122 tot

L22 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:28963 HCAPLUS

DN 147:95697

TI Oxazolidinone derivatives as antimicrobials

IN Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra,

Sonali; Rattan, Ashok

PA Ranbaxy Laboratories, India

SO Indian Pat. Appl., 128pp.


CODEN: INKXNQ

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN2007DE00027	A	20050311	2001IN-DE00027	20010803 <--
PRAI 2001IN-DE00027		20010803	<--	
OS CASREACT 147:95697				
GI				



AB Oxazolidinones I [T = 5-7-membered heterocycle, aryl; R = CN, acyl, (un)substituted CO₂H, NH₂, CONH₂, alkyl, alkenyl, CH₂NOH, CH₂NO₂, NO₂; W = CH₃, CO, CH₂OH, NHCH₂, S, CHCO, (un)substituted CH₂NHCH₂; X = CH, CH₃, CHO, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = H, F, Cl, Br, I, (un)substituted alkyl; R₁ = acyl, (un)substituted alkyl, cycloalkyl, alkoxy; n = 0-3] were prepared. I are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci. Thus, (S)-N-[3-(4-piperazin-1-ylphenyl)-2-oxo-5-oxazolidinylmethyl]acetamide was acylated with furoyl chloride to give the furoylpiperazine derivative which had an IC₅₀ of 2 µg/mL against MRSA 15187.

IT 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 4-substituted piperazinylphenylloxazolidinylmethylacetamides as antimicrobials against MRSA)

RN 154590-66-6 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-

oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:492705 HCAPLUS

DN 139:69253

TI Preparation of phenyl oxazolidinone derivatives as potential antimicrobials

IN Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra,

Sonali; Rattan, Ashok

PA Ranbaxy Laboratories Limited, India

SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 906,215.

CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US2003119817	A1	20030626	2002US-0051784	20020117 <--
US-----6956040	B2	20050108		
US2002103186	A1	20020801	2001US-0906215	20010716 <--
US-----6734307	B2	20040511		
IN2004DN00176	A	20050401	2004IN-DN00176	20040123
IN2004DN00176	A	20050401	2004IN-DN00176	20040123 <--
PRAI 2001US-0906215	A2	20010716	<--	
2000IN-DE00654	A	20000717	<--	
2002WO-IB01609	W	20020118	<--	
2002WO-IB01609	W	20020510	<--	
OS CASREACT 139:69253; MARPAT 139:69253				
GI				

L22 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



RE.CNT 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Substituted Ph oxazolidinones, e.g. of formula I [T = heterocyclic ring, aryl; R = alkyl, halo, CN, CHO, NH₂, NO₂, etc.; X = CH, CH-5, CH-O, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = alkyl, F, Cl, Br, etc.; W = CH₃, CO, CH₂OH, etc.; R₁ = NHCH₂, NHCH₂; R₂ = H, alkyl, cycloalkyl, alkoxy, etc.], are prepared. This invention also relates to pharmaceutical compds. containing the compds. of the present invention as antimicrobials. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, II was prepared and showed antibacterial activity against several strains.

IT 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 154590-66-6 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-


oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L22 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2003:31962 HCAPLUS
 DN 138:139143
 TI Preparation of dual action bactericides comprising a oxazolidinone and a quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria
 IN Hubschwerlen, Christian; Specklin, Jean-Luc
 PA Morphochem Aktiengesellschaft fuer Kombinatorische Chemie, Germany
 SO PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CMI 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003032962	A2	20030424	2002MO-EP11163	20021004 <--
WO2003032962	A3	20030717		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2460572	A1	20030424	2002CA-2460572	20021004 <--
AU2002361948	A1	20030428	2002AU-0361948	20021004 <--
AU2002361948	B2	20070329		
EP---1432705	A2	20040630	2002EP-0796533	20021004 <--
EP---1432705	B1	20070808		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR2002013063	A	20040928	2002BR-0013063	20021004 <--
HU2004002126	A2	20050228	2004HU-0002126	20021004 <--
CN---1630655	A	20050622	2002CN-0819724	20021004 <--
JP2005529061	T	20050929	2003JP-0535766	20021004 <--
NZ---531879	A	20051028	2002NZ-0531879	20021004 <--
AZ---369363	T	20070815	2002AZ-0796533	20021004 <--
ES---2287354	T3	20071216	2002ES-0796533	20021004 <--
IN2004MN00158	A	20050218	2004IN-MN00158	20040304 <--
ZA2004001909	A	20050309	2004ZA-0001909	20040309 <--
US2005096343	A1	20050505	2004US-0491519	20041217 <--
PRAI 2001US-327162P	P	20011104	<--	
2002MO-EP11163	W	20021004		
OS MARPAT 138:139143				
GI				

L22 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




AB The present invention relates to compds. of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria. The present invention relates to oxazolidinones having a quinolone or naphthyridinone moiety (shown as I; variables defined below; e.g. 7-[4-(4-[(5S)-5-(acetylaminoethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (shown as II)) that are useful antibacterial agents and effective against a variety of multi-drug resistant bacteria. For I: A is a bond, NH, O, S, SO, SO2, SO2NH, PO4, -NH-CO-NH-, -CO-NH-, -CO-, -CO-O-, -NH-CO-O-, alkylene, alkenylene, alkynylene, heteroalkylene, arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkylarylene or heteroalkylarylene or a combination of two or more of these atoms or groups. X is CR5 or N; Y is CR6 or N; U is F or Cl; n = 0-3; R1 is H, F, Cl, Br, I, OH, NH2, alkyl or heteroalkyl; R2 is H, F or Cl; R3 is H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroalkylaryl; R4 is heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroalkylaryl; R5 is H, F, Cl, OH, NH2, alkyl or heteroalkyl, or R3 and R5 can be linked via an alkylene, an alkenylene or heteroalkylene or be a part of a cycloalkylene or heterocycloalkylene group, in which case R3 is not H and R5 is not H, F, OH, NH2 or Cl; R6 is H, F, Cl or OMe. Although the methods of preparation are not claimed, 30 example preps. are included; the examples of this patent and many of the claims are the same as those of WO 03/031443 A1. All examples were tested against several gram pos. and gram neg. bacteria; typical MIC ranges (mg/L) are: S. aureus (MRSA: 0.125-2; MSSA: 0.06-1), E. faecalis (50.03-1), E. faecium (50.03-1), and S. pneumoniae (50.03-1). They all have a broader and more pronounced activity than the corresponding quinolone and oxazolidinone as well as a 1:1 combination of these two compds.

II 154590-43-9, N-[(3-[3-Fluoro-4-(piperazin-1-yl)phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 154590-66-6, N-[(5S)-3-[3-Fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]acetamide
 RL RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dual action bactericides comprising oxazolidinone and quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria)
 RN 154590-43-9 HCAPLUS
 CN Acetamide, N-[(3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

L22 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN


AN 2003:301084 HCAPLUS
 DN 138:304189
 TI Preparation of dual action bactericides comprising a oxazolidinone and a quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria
 IN Hubschwerlen, Christian; Specklin, Jean-Luc
 PA Morphochem Aktiengesellschaft fuer Kombinatorische Chemie, Germany
 SO PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CMI 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003031443	A1	20030417	2002MO-EP10766	20020925 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU2002338792	A1	20030422	2002AU-0338792	20020925 <--
CN---1630655	A	20050622	2002CN-0819724	20021004 <--
AT---369363	T	20070815	2002AT-0796533	20021004 <--
ES---2287354	T3	20071216	2002ES-0796533	20021004 <--
ZA2004001909	A	20050309	2004ZA-0001909	20040309 <--
PRAI 2001US-327162P	P	20011104	<--	
2002MO-EP10766	W	20020925		
OS MARPAT 138:304189				
GI				



AB The present invention relates to oxazolidinones having a quinolone or naphthyridinone moiety (shown as I; variables defined below; e.g. 7-[4-(4-[(5S)-5-(acetylaminoethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (shown as II)) that are useful antibacterial agents and effective against a variety of multi-drug resistant bacteria. For I: A is a bond, NH, O, S, SO, SO2, SO2NH, PO4, -NH-CO-NH-, -CO-NH-, -CO-, -CO-O-, -NH-CO-O-, alkylene, alkenylene, alkynylene, heteroalkylene, arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkylarylene or heteroalkylarylene or a combination of two or more of these atoms or groups. X is CR5 or N; Y is CR6 or N; U is F or Cl; n = 0-3; R1 is H, F, Cl, Br, I, OH, NH2, alkyl or heteroalkyl; R2 is H, F or Cl; R3 is H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroalkylaryl; R4 is heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroalkylaryl; R5 is H, F, Cl, OH, NH2, alkyl or heteroalkyl, or R3 and R5 can be linked via an alkylene, an alkenylene or heteroalkylene or be a part of a cycloalkylene or heterocycloalkylene group, in which case R3 is not H and R5 is not H, F, OH, NH2 or Cl; R6 is H, F, Cl or OMe. Although the methods of preparation are not claimed, 30 example preps. are included; the examples of this patent and many of the claims are the same as those of WO 03/031443 A1. All examples were tested against several gram pos. and gram neg. bacteria; typical MIC ranges (mg/L) are: S. aureus (MRSA: 0.125-2; MSSA: 0.06-1), E. faecalis (50.03-1), E. faecium (50.03-1), and S. pneumoniae (50.03-1). They all have a broader and more pronounced activity than the corresponding quinolone and oxazolidinone as well as a 1:1 combination of these two compds.


L22 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 heterocycloalkylene, alkylarylene or heteroarylalkylene or a combination of two or more of these atoms or groups. X is CR5 or N; Y is CR6 or N; U is F or Cl; n = 0-3; R1 is H, F, Cl, Br, I, OH, NH2, alkyl or heteroalkyl; R2 is H, F or Cl; R3 is H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroarylalkyl; R4 is heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroarylalkyl; R5 is H, F, Cl, OH, NH2, alkyl or heteroalkyl, or R3 and R5 can be linked via an alkylene, an alkenylene or heteroalkylene or be a part of a cycloalkylene or heterocycloalkylene group, in which case R3 is not H and R5 is not H, F, OH, NH2 or Cl; R6 is H, F, Cl or OMe. Although the methods of prepn. are not claimed, 30 example preps. are included. All examples were tested against several gram pos. and gram neg. bacteria; typical MIC ranges (mg/L) are: *S. aureus* (MSSA: 0.125-2; MSSA: 0.06-1), *E. faecalis* (50.03-1), *E. faecium* (50.03-1), and *S. pneumoniae* (50.03-1). They all have a broader and more pronounced activity than the corresponding quinolone and oxazolidinone as well as a 1+1 combination of these two compds.
 IT 154590-43-9, N-[(3-[3-fluoro-4-(piperazin-1-yl)phenyl]-2-oxo-5-oxazolidin-5-yl)methyl]acetamide 154590-66-6, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]acetamide
 PL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dual action bactericides comprising oxazolidinone and quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria)
 RN 154590-43-9 HCAPLUS
 CN Acetamide, N-[(3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)



RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


L22 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2003:301082 HCAPLUS
 DN 138:304288
 TI Preparation of dual action bactericides comprising a oxazolidinone and a quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria
 IN Hubschwerlen, Christian; Specklin, Jean-Luc
 PA Morphochem Aktiengesellschaft fuer Kombinatorische Chemie, Germany
 SO PCT Int. Appl., 95 pp.
 COBEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003031441	A1	20030417	2002WO-EP10765	20020925 <--
W1: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NZ, OM, PH, PL, PT, PG, RU, SD, SE, SG, SI, SK, SL, TJ, ZM, TR, TT, TE, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
PW: GH, GM, KE, LS, MW, ME, SD, SI, SZ, TE, UG, ZM, AM, AZ, BY, KG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CI, CE, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG				
AU2002338790	A1	20030422	2002AU-0338790	20020925 <--
PRAI 2001US-27208P	P	20011104		
2002WO-EP10765	M	20020925		
MARPAT 138:304288				
GI				




AB The present invention refers to novel multiple action compds., i.e., to compds. which contain at least two pharmaceutically active components in one mol. The compds. have a higher stability than corresponding compds. of the prior art. Although the present invention does not claim any specific compds. or even a Markush expression, the examples involve oxazolidinones having a quinolone or naphthyridinone moiety (shown as I; variables defined below; e.g., 7-[4-[(5S)-3-(acetaminomethyl)-2-oxo-5-oxazolidin-3-yl]-2-fluorophenyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (shown as II)) that are useful antibacterial agents and effective against a variety of multi-drug resistant bacteria. For I: A is a bond, NH, O, S, SO, SO2, SO2NH, PO4, -NH-CO-NH-, -CO-NH-, -CO-, -CO-O-, -NH-CO-O-, alkylene, alkenylene, alkynylene, heteroalkylene, arylene, heteroarylene, cycloalkylene,

L22 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 heterocycloalkylene, alkylarylene or heteroarylalkylene or a combination of two or more of these atoms or groups. X is CR5 or N; Y is CR6 or N; U is F or Cl; n = 0-3; R3 is H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroarylalkyl; R4 is heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl or heteroarylalkyl; R5 is H, F, Cl, OH, NH2, alkyl or heteroalkyl, or R3 and R5 can be linked via an alkylene, an alkenylene or heteroalkylene or be a part of a cycloalkylene or heterocycloalkylene group, in which case R3 is not H and R5 is not H, F, OH, NH2 or Cl; R6 is H, F, Cl or OMe. Although the methods of prepn. are not claimed, 30 example preps. are included. All examples were tested against several gram pos. and gram neg. bacteria; typical MIC ranges (mg/L) are: *S. aureus* (MSSA: 0.125-2; MSSA: 0.06-1), *E. faecalis* (50.03-1), *E. faecium* (50.03-1), and *S. pneumoniae* (50.03-1). They all have a broader and more pronounced activity than the corresponding quinolone and oxazolidinone as well as a 1+1 combination of these two compds. The examples of this patent are the same as those of WO 03/031443 A1.
 IT 154590-43-9 154590-66-6
 PL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dual action bactericides comprising oxazolidinone and quinolone or naphthyridinone moiety effective against multi-drug resistant bacteria)
 RN 154590-43-9 HCAPLUS
 CN Acetamide, N-[(3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)



RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

L22 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2003:22874 HCAPLUS
 DN 138:89799
 TI Preparation of fluoroquinolonyl derivatives of oxazolidinones as antibacterial agents
 IN Mourelle Mancini, Marisabel; Huguet Clotet, Juan; Hidalgo Rodriguez, Jose; Del Castillo, Juan Carlos
 PA Vita-Invest, S.A., Spain
 SO PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003002560	A1	20030109	2002WO-IB02408	20020624 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NI, OM, PH, PL, PT, RO				
RW: GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NI, OM, PH, PL, PT, RO				
ES---2186550	A1	20030501	2001ES-0001559	20010627 <--
ES---2186550	B2	20031116		
CA---2450982	A1	20030109	2002CA-2450982	20020624 <--
AU2002311541	A1	20030303	2002AU-0311541	20020624 <--
EE-200400004	A	20040216	2004EE-0000004	20020624 <--
EP---1401834	A1	20040331	2002EP-0738497	20020624 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP2004521147	T	20040715	2003JP-0508941	20020624 <--
CN---1520412	A	20040811	2002CN-0812852	20020624 <--
HU2004000370	A2	20040830	2004HU-0000370	20020624 <--
BR2002010667	A	20041005	2002BR-010667	20020624 <--
NE---530206	A	20050729	2002NE-0530206	20020624 <--
US2004147545	A1	20040729	2003US-0469283	20030828 <--
NO2003005791	A	20040219	2003NO-0005791	20031222 <--
BG---108498	A	20050331	2003BG-0108498	20031222 <--
IN2003DN02284	A	20060120	2003IN-DN02284	20031229 <--
MX2004PA00185	A	20040318	2004MX-PA00185	20040107 <--
2001ES-0001559	A	20010627		
2002WO-IB02408	W	20020624		
OS MAPPAT 138:89799				
GI				

L22 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



II


AB This invention discloses new fluoroquinolonyl derivs. of oxazolidinones (shown as I; variables defined below; e.g. 7-[4-[5-(5-(acetylaminoethyl)-2-oxoxazolidin-3-yl]-2-fluorophenyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (shown as II)) and processes for obtaining them, the corresponding pharmaceutical compns. and use thereof for manufacturing a medicament for the treatment of microbial infections. These new compns. are useful as antibacterial agents. Furthermore phenalen-type compns. according to (II) are disclosed. Compds. I show activity as antibacterial agents; MIC values for .apprx.15 compds. are included. Advantageously they possess a broad spectrum of activity against gram-pos. bacteria such as Staphylococcus, Streptococcus, Enterococcus and the like, as well as against gram-neg. bacteria such as E. Coli, H. Influenzae, M. Catarrhalis, etc., and even against strains resistant to known antibiotics such as methicillin, vancomycin, penicillin, etc. They are also active against anaerobic microorganisms such as Bacteroides fragilis. Thirty-five example preps. of I plus 38 example preps. of intermediates are included. It was prepared from 7-[4-[5-(5-(acetylaminoethyl)-2-oxoxazolidin-3-yl]-2-fluorophenyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid diacetoxyboron chelate in H₂O and MeCN using 1N NaOH at room temperature; the chelate was prepared from N-[(3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-2-oxoxazolidin-5-(5-yl)methyl)acetamide, 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid diacetoxyboron chelate and Et₃N in MeCN at reflux for 16 h. For I: X = CR₆ or N; R₁ = Cl-C₄-alkyl, C₃-C₆-cycloalkyl, C₂-C₄-alkenyl, 2-hydroxyethyl, 2-fluoroethyl, or Ph optionally substituted by 1 or 2 atoms of F; R₂: H, alkyl Cl-C₄ or phenyl; R₃ = H, halogen, Cl-C₄-alkyl or Cl-C₄-alkoxy, amino; R₄ = H or halogen; R₅ = H, halogen, Cl-C₄-alkyl, Cl-C₄-haloalkoxy or else R₁ and R₆ together form a bridge of structure -CHMe-CH₂-O-, -CHMe-CH₂-S-, -CHMe-CH₂-CH₂-. R₆ = H, halogen, OCH₃, Cl-C₄-alkoxy, Cl-C₄-alkyl or Cl-C₄-haloalkyl; A = -CH₂-NH-R₇, -CHOH-C.tpbond.CH; wherein R₇ = isoxazol, -CO-R₈, -CS-R₈, -CS-OR₈, -COOR₈, -CONHR₈, -CSNHR₈, -SO₂R₈ or COCH₂CH₂Ar (Ar = R₉-substituted phenyl) wherein R₈ = Cl-C₄-alkyl, Cl-C₄-haloalkyl, C₂-C₄-alkenyl, aryl, Cl-C₄-alkyl substituted by an Cl-C₄-alkoxy group, Cl-C₄-carboxyalkyl, cyano, or amino. R₉ = H, Cl-C₄-alkyl, C₂-C₄-alkenyl, OH, Cl-C₄-alkoxy, NR₁₂R₁₃, NO₂, halogen, or CO-R₁₂; R₁₂ and R₁₃ = H or Cl-C₄-alkyl; W = acetylidyl, pyrrolidinyl, arenyl, and piperazinyl derivs. as more fully described in the claims.

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of fluoroquinolonyl derivs. of oxazolidinones as antibacterial agents)

RN 154590-66-6 HCAPLUS

L22 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.



IT 216869-31-7P, 3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-5-(R)-(hydroxymethyl)oxazolidin-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of fluoroquinolonyl derivs. of oxazolidinones as antibacterial agents)

RN 216869-31-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:539929 HCAPLUS

DN 137:106476

TI Oxazolidinone photoaffinity probes, uses and compounds

IN Colca, Jerry R.; McDonald, William Gerald; Shinabarger, Dean L.

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO200202056013	A2	20020718	2001WO-US48455	20011214 <--
WO200202056013	A3	20031106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NE, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA----2432162	A1	20020718	2001CA-2432162	20011214 <--
AU2002245127	A1	20020724	2002AU-0245127	20011214 <--
EP----1386153	A2	20040204	2001EP-0993282	20011214 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP2004537265	T	20041216	2002JP-0556217	20011214 <--
PRAI 2000US-256053P	P	20001215	<--	
2001WO-US48455	W	20011214	<--	

OS MARPAT 137:106476

AB Disclosed are novel methods of identifying biol. targets of comps. that have antimicrobial activity. Also disclosed are novel methods of identifying comps. that can have antimicrobial activity.

IT 154590-66-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(oxazolidinone photoaffinity probes, uses and compds.)

RN 154590-66-6 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:465999 HCAPLUS

DN 137:33287

TI Preparation of oxazolidinone photoaffinity probes

IN Thomasco, Lisa Marie; Gadwood, Robert C.

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002048139	A2	20020620	2001WO-US48063	20011214 <--
WO2002048139	A3	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NE, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US2003073696	A1	20030417	2000US-0738022	20001215 <--
US----6861433	B2	20050301		
CA----2432739	A1	20020620	2001CA-2432739	20011214 <--
AU2002034016	A1	20020624	2002AU-0034016	20011214 <--
EP----1368326	A2	20031210	2001EP-0985023	20011214 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP2004502028	T	20040708	2002JP-0549670	20011214 <--
US2003232840	A1	20031218	2003US-0359766	20030206 <--
US----6858635	B2	20050122		
US2003232008	A1	20031218	2003US-0359767	20030206 <--
US----6875871	B2	20050405		
PRAI 2000US-0738022	A	20001215	<--	
2001WO-US48063	W	20011214	<--	
OS MARPAT 137:33287				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X, Y = F, H, CH3; R1 = H, F, I; R2 = H, F, OH; R16 = H, F; R17 = H, F; R3 = H, alkyl; L = bond, OCH2C(O); Q = e.g., I; P4 = H, CH3, CH2CH3, cyclopropyl; S = 0, 5 and related analogs] were prepared. For instance, (S)-N-[(3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide was coupled to 4-azidosalicylic acid (DMF, EDCI, DMAP). This intermediate was reacted with chloroamine-T/NaOH/12S12 to afford III. I are useful as photoaffinity probes.

IT 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of oxazolidinone photoaffinity probes)


RN 154590-66-6 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L22 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



L22 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:72093 HCAPLUS

DN 136:134748

TI Oxazolidinone derivatives as antimicrobials

IN Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok

PA Ranbaxy Laboratories Limited, India

SO PCT Int. Appl., 126 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002006278	A1	20020124	2001WO-IB01262	20010716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NE, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN----193550	A1	20040724	2000IN-DE00654	20000717 <--
CA----2415965	A1	20020124	2001CA-2415965	20010716 <--
AU2001069370	A	20020130	2001AU-0069370	20010716 <--
EP----1303511	A1	20030423	2001EP-0947730	20010716 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR2001012826	A	20030624	2001BR-0012826	20010716 <--
HU2003002918	A2	20031229	2003HU-0002918	20010716 <--
JP2004504321	T	20040212	2002JP-0512181	20010716 <--
RU----523700	A	20041126	2001RU-0523700	20010716 <--
RU----2292345	C2	20070127	2003RU-0103767	20010716 <--
WO2003008389	A1	20030130	2002WO-IB00167	20020118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NE, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, AM, AZ, BY, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2002219458	A1	20030303	2002AU-0219458	20020118 <--
EP----1409464	A1	20040421	2002EP-0787165	20020118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO2003007870	A2	20030130	2002WO-IB01609	20020510 <--
WO2003007870	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NE, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2002258054	A1	20030303	2002AU-0258054	20020510 <--
EP----1409465	A2	20040421	2002EP-0727869	20020510 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
MX2003PA00503	A	20031014	2003MX-PA00503	20030116 <--
ZA2003000471	A	20031029	2003ZA-0000471	20030117 <--
IN20040400176	A	20050401	2004IN-DN00176	20040123 <--
IN20040400178	A	20050401	2004IN-DN00178	20040123 <--
US20040242591	A1	20041202	2004US-0483905	20040713 <--
US20040254162	A1	20041216	2004US-0483904	20040713 <--
ZA2005001289	A	20050901	2005ZA-0001289	20050214 <--
PRAI 2000IN-DE00654	A	20000717	<--	
2001WO-IB01262	A	20010716	<--	
2002WO-IB00167	W	20020118	<--	


L22 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
2002WO-IB01609 W 20020510
OS MARPAT 136:134748
GI



AN	Oxazolidinones I [I = 7-membered heterocyclic ring, alyl; R1 = CH, acyl, (un)substituted CO2H, NH2, CONH2, alkyl, CH2CHCONH, CH=CH2, NO2; X = CH, CH3, CHO, N; Y = 2, 4, 6, alkyl, cycloalkyl, CO-3 bridging group; U, V = (un)substituted alkyl, alkyl, alkyl, H; P, Q, R = CH3, CO, CH2NH2, NHCO, (un)substituted CH2CHNH2, 5, CH2CO, NH; R1 = acylamino, (un)substituted NH2, NHCS2, NHCS2R2; R2 = H, (un)substituted alkyl, cycloalkyl, alkoxyl; n = 1-4. These compounds are useful as anti-infective agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp., Clostridia, and Listeria, and fungi, such as organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, the furyl derivative II was prepared from the 4-unsubstituted piperidine fragment and 2-mercapto-1-methyl-4-methyl-5-methyl-1H-imidazole-4-carboxylic acid. The 2-mercapto-1-methyl-4-methyl-5-methyl-1H-imidazole-4-carboxylic acid is active against methicillin-resistant Staph. aureus 15167 and against Enterococcus faecalis 29212 of 2 µg/mL.
IT	154590-66-4 Ru: RCT (Reactant); RACT (Reactant or reagent) (preparation of aracycloalkylphenyloxazolidinones as antimicrobials)
RN	154590-66-6
CH	NCAPUS Oxazolidinone, N-[(1S)-1-[(3S)-4-[(4S)-1-piperazinyl]-2-oxo-5-oxo-oxazolidinyl)methyl]-
	CH (CN INDEX NAME)

Absolute stereochemistry.

L22 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


```

A22 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
AN AN1:482178 HCAPLUS
DN 135:76881
TI Preparation of N-(oxoconazolidinylmethyl)thioamides and analogs as
bactericides
IN Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles;
Poel, Ron-Jo
PA Pharmacia & Upjohn Company, USA
SO U.S., 93 pp., Cont.-in-part of U.S. 6,238,413.
DT CODEN: USXXAM
LA Patent
LA English
FAN CNT 2


PATENT NO. KIND DATE APPLICATION NO. DATE
-----
PI US--6255304 B1 20010703 1998U5-0200904 19981127 <--
US--6218413 B1 20010417 1998U5-0080751 19980518 <--
US--6462189 B1 20020326 1998U5-0712055 20001114 <--
US--6342513 B1 20020129 2000U5-0713739 20001115 <--
US2001041728 A1 20011115 2001U5-0822072 20010330 <--
US--6537968 B2 20030325
US2002016323 A1 20020207 2001U5-0822666 20010330 <--
PPAI 1997U5-048342P P 19970350 <--
1998U5-0080751 A 19980518 <--
1998U5-0200904 A3 19981127 <--
OS MARPAT 135:76881
GI

```

L22 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB RZHCXHCX [I; R = e.g., N-attached-(oxo)thiaacetylalkoxy]; R1 = H,
(alkyl)amino, alkyl, alkoxy, etc.; Z = e.g., phenylene, 2,1 = e.g.,
2-oxoacoxalidine-3,5-diyl were prepared. Thus, 1,4-hexanethiothiazepine was
prepared by the reaction of N-oxoacoxalidine and the reduced and N-protected product
cyclocondensed with (R1-*glycidyl*) butyrate to give, in 4 addn. steps,
title compound II. Data for biol. activity of I were given.


IT 216683-31-79
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-(oxoacoxalidinylmethyl)thioamides and analogs as
steroids)

RN 216689-31-7 HCAPULS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(hydroxymethyl)-,
(SR) = (CA INDEX NAME).

Absolute stereochemistry.

L22 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2000:384192 HCAPLUS
 DN 133:30719
 TI Oxazolidinone antibacterial agents having a thiocarbonyl functionality
 IN Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles;
 Poel, Toni-Jo
 PA Pharmacia & Upjohn Company, USA
 SO PCT Int. Appl., 183 pp.
 CODEN: PFXK32
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2000032599	A1	20000608	1998WO-US25308	19981127 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, ND, NG, NL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
PW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, GH, GM, ML, MR, NE, SN, TD, TG			
CA---2351062	A1	20000608	1998CA-2351062	19981127 <--
AU---9917053	A	20000619	1999AU-0017053	19981127 <--
AU---764980	B2	20030904		
EP---1133493	A1	20010919	1998EP-0961822	19981127 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP2002531455	T	20020924	2000JP-0585241	19981127 <--
NZ---511963	A	20031031	1998NZ-0511963	19981127 <--
MX2001PA05287	A	20000821	2001MX-PA05287	20010525 <--
PRA1 1998WO-US25308	W	19981127	<--	
OS MARPAT 133:30719				
GI				




AB The title compds. (I) [wherein R2 = SO2, S(O), S, O, or (un)substituted NH; n = 0-3; R23 and R24 = independently H or F; R1 = H, NH2, NH(alkyl), N(alkyl)2, arimidinyl, azetidinyl, pyrrolidinyl, piperidinyl, alkyl(thio), alkoxy(carbonyl), CN, or cycloalkyl] were prepared by various methods, including conversion of the corresponding amides to (alkyl)thioureas or thioamides. Replacement of the O atom with S atom unexpectedly improved the antimicrobial properties of the compds. For example, II was prepared by treating the corresponding acetamide with Lawesson's Reagent. II inhibited growth of tested gram pos. organisms at concns. 2-4 times lower than the comparison carbonyl-containing compound

IT 216869-31-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent);
 (preparation of antibacterial oxazolidinone (alkyl)thioamides or thioureas from the corresponding amides or amines)

RN 216869-31-7 HCAPLUS

L22 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2000:26717 HCAPLUS
 DN 132:207679
 TI Synthesis and in vitro antibacterial activity of quaternary ammonium cephalosporin derivatives bearing oxazolidinone moiety
 AU Chung, In Hwa; Kim, Choong Sup; Seo, Jae Hong; Chung, Bong Young
 CS Biochemicals Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
 SO Archives of Pharmacal Research (1999), 22(6), 579-584
 CODEN: APHROD; ISSN: 0253-6269
 PB Pharmaceutical Society of Korea
 DT Journal
 LA English
 GI




AB Several oxazolidinones having amine moiety were prepared to form a quaternary ammonium salt with cephalosporin nucleus, and antibacterial activity of the quaternary ammonium cephalosporin derivs. (e.g., I) bearing oxazolidinone moiety were examined particularly with expectation of dual activity. However, the cephalosporin-oxazolidinone compds. revealed rather weaker antibacterial activity in vitro than their parent oxazolidinone and cephalosporin without showing any characteristic activity as expected.

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antibacterial activity of quaternary ammonium oxazolidinonecephalosporin derivs.)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1-piperazinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 1999:639887 HCAPLUS
 DN 132:22897
 TI Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles
 AU Pae, Ae Nim; Kim, Hye Yeon; Joo, Hyun Jin; Kim, Bo Hyung; Cho, Yong Seo; Choi, Kyung Il; Choi, Jung Hoon; Koh, Sun Yeong
 CS Biochemicals Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(18), 2679-2684
 CODEN: BMCLB8; ISSN: 0960-894X
 DT Journal
 LA English
 AB Two series of oxazolidinone derivs. having substituted isoxazoles were synthesized and tested for antibacterial activities against several Gram-pos. strains including the resistant strains of Staphylococcus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed in vitro activities (MIC) comparable or superior to the reference compound vancomycin.

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and antibacterial activity of isoxazolyl-substituted oxazolidinones)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:784995 HCAPLUS
 DN 130:38373
 TI Preparation of thiocarbonyloxazolidinones as antibacterial agents
 IN Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles;
 Poel, Toni-Jo
 PA Pharmacia & Upjohn Company, USA; Hester, Jackson B., Jr.
 SO PCT Int. Appl., 118 pp.
 CODEN: PXXD2
 DT Patent
 LA English
 FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-----9854161	A1	19981203	1998WO-0509889	19980518 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, GN, GU, MG, MP, NE, SN, TD, TG			
AU-----9874883	A	19981230	1998AU-0074883	19980513 <--
AU-----737995	B2	20010906		
CA-----2288750	A1	19981203	1998CA-2288750	19980518 <--
EP-----984947	A1	20000315	1998EP-0922303	19980518 <--
EP-----984947	B1	20050420		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR-----9815518	A	20001121	1998BR-0015518	19980518 <--
HU2000001393	A2	20010628	2000HU-0001393	19980518 <--
HU2000001393	A3	20010730		
NZ-----501412	A	20011130	1998NZ-0501412	19980518 <--
JP2002501530	T	20020115	1999JP-0500722	19980518 <--
RU-----2208613	C2	20030720	1999RU-0128083	19980518 <--
AT-----293609	T	20050515	1998AT-0922303	19980518 <--
ES-----224280	T3	20051101	1998ES-0922303	19980518 <--
NO-----9905846	A	20000128	1999NO-0005846	19991129 <--
NO-----315798	B1	20031027		
FI-----9902555	A	19991130	1999FI-0002555	19991130 <--
MX-----9911069	A	20000430	1999MX-0011069	19991130 <--
HK-----1027569	A1	20040618	2000HK-0106696	20001023 <--
PRAI 199705-048342P	P	19970530	<--	
1998WO-0509889	M	19980518	<--	
OS MARPAT 130:38373				
GI				



AB Chiral title compds. AGCH2NHCSR [A is (un)substituted Ph, indolyl; G is 2-oxo-5-oxazolidinyl; R is H, NH2, alkyl, cycloalkyl, etc.] or pharmaceutical acceptable salts are prepared, from amines with Lawesson's Reagent or 1,1'-thiocarbonyl-2(1H)-pyridone, as antibacterial agents.

L22 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:219349 HCAPLUS
 DN 128:270612
 TI Preparation of azolypiperazinylphenyloxazolidinones as antimicrobials.
 IN Gadwood, Robert C.; Barbachyn, Michael Robert; Toops, Dana Scott; Smith, Herman Walden; Vaillancourt, Valerie Ann
 PA Pharmacia & Upjohn Company, USA
 SO U.S., 34 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-----5736545	A	19980407	1997US-0803469	19970220 <--
PRAI 199705-0803469		19970220	<--	
OS MARPAT 128:270612				
GI				



AB Title compds. [I: R1 = CHO, Ac, COCH3, CO2Me, SO2CH3, COCH2OH; X1, X2 = H, F, Cl; Q = specified azolyl, were prepared. Thus, title compound I (Q = 6-nitrobenzothiazol-2-yl; R1 = Ac; X1 = F; X2 = H) (preparation given) inhibited Staphylococcus aureus with a min. inhibitory concentration of 0.5 µg/mL.

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of azolypiperazinylphenyloxazolidinones as antimicrobials)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Title compds. I and II were tested in vitro by std. agar diln. method.
 IT 216869-31-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiocarbonyloxazolidinones as antibacterial agents)
 RN 216869-31-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 1997:579705 HCAPLUS
 DN 127:278210
 TI Preparation of 3-[4-(4-azolyl-1-piperazinyl)phenyl]oxazolidin-2-ones as bactericides
 IN Gadwood, Robert C.; Barbachyn, Michael R.; Toops, Dana S.; Smith, Herman W.; Vaillancourt, Valerie A.
 PA Pharmacia & Upjohn Co., USA; Gadwood, Robert C.; Barbachyn, Michael R.; Toops, Dana S.; Smith, Herman W.; Vaillancourt, Valerie A.
 SO PCT Int. Appl., 79 pp.
 CODEN: PXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----9720981	A1	19970828	1997WO-0501970	19970218 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG			
ZA-----9701287	A	19980814	1997ZA-0001287	19970214 <--
CA-----2243706	A1	19970828	1997CA-2243706	19970218 <--
CA-----2243706	C	20051004		
AU-----9719547	A	19970810	1997AU-0019547	19970218 <--
AU-----703831	B2	19990401		
EP-----683611	A1	19981216	1997EP-0907574	19970218 <--
EP-----683611	B1	20020731		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
CN-----1206410	A	19990127	1997CN-0191516	19970218 <--
CN-----1082952	B	20020417		
JP20000505084	T	20000425	1997JP-0530192	19970218 <--
NZ-----331011	A	20000428	1997NZ-0331011	19970218 <--
AT-----221521	T	20020815	1997AT-0907574	19970218 <--
ES-----2180945	T3	20030216	1997ES-0907574	19970218 <--
IN19970800407	A	20050311	1997IN-0800407	19970220 <--
TW-----442460	B	20010623	TW 1997-8610205	19970221 <--
HK-----1017033	A1	20020802	1999HK-0102256	19990524 <--
PRAI 1996US-012316P	P	19960226	<--	
1997WO-0501970	M	19970218	<--	
OS MARPAT 127:278210				
GI				




AB Title compds. (I: R = azolyl; R1 = CHO, Ac, CO2Me, etc.; R1, R3 = H, F, Cl) were prepared. Thus, I (R1 = Ac, R2 = F, R3 = H) (II: R = H) was N-arylated by 2-chlorobenzothiazole to give II (R = 2-benzothiazolyl). Data for biol. activity of I were given.

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-[4-(4-azolyl-1-piperazinyl)phenyl]oxazolidin-2-ones as bactericides)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L22 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




L22 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 1997:539252 HCAPLUS
 DN 127:190756
 TI Preparation of N-hydroxyacetyl-N'-oxooxazolidinylphenylpiperazines as
 antibacterials.
 IN Brickner, Steven J.; Barbachyn, Michael R.; Hutchinson, Douglas K.
 PA Pharmacia & Upjohn Co., USA
 SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 155,988, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US----5652238	A	19970729	1996US-0640899	19960509 <--
WO----3514684	A1	19950601	1994WO-US10582	19940927 <--
W:	AM, AI, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ			
FW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, MI, MR, NE, SN, TD, TG			
PRAI 1993US-0155988	B2	19931122	<--	
OS 1994WO-US10582	W	19940927	<--	
GI MARPAT 127:190756				





AB Title compds. [I: R = COR1, PO32-, PO3H2; R1 = alkyl, N(R4)2, alkyl-N(R4)2, C6H4N(R4)2, C6H4NHC(O)CH2NH2, C2H4-morpholinyl, pyridinyl, hydroxyalkyl, methoxyalkyl, acetylaalkyl, methoxyalkoxy, piperazinyl, piperazinylalkyl (optionally substituted with alkyl), imidazolyl, carboxyalkyl, C(CH2OH)2CH3; R2, R3 = H, F; ≥1 of R2, R3 = F; R4 = H, alkyl], were prepared. Thus, hydroxyacetic acid, 2-[4-[4-[5-[(acetilamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-1-piperazinyl]-2-oxoethyl ester (preparation given) showed an ED50 = 1 mg/kg orally against *Staphylococcus aureus*.
 IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-hydroxyacetyl-N'-oxooxazolidinylphenylpiperazines as antibacterials)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[[1(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L22 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



L22 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 1996:537790 HCAPLUS
 DN 125:221870
 TI (Piperazinylphenyl)oxazolidinone antimicrobials
 IN Hutchinson, Douglas K.; Barbachyn, Michael R.; Brickner, Steven J.; Gammill, Ronald B.; Patel, Mahesh V.
 PA Upjohn Co., USA
 SO U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 880, 432, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US----5547950	A	19960820	1994US-0332822	19941031 <--
HU----72296	A2	19960429	1994HU-0003208	19930421 <--
CE----281884	B6	19970312	1994CE-0002505	19930421 <--
PT----640077	T	20021129	1993PT-0912267	19930421 <--
ES----2180545	T3	20030216	1993ES-0912267	19930421 <--
ZA----9302855	A	19941024	1993ZA-0002855	19930422 <--
IL----105855	A	19980715	1993IL-0105855	19930429 <--
CN----1079964	A	19931229	1993CN-0105039	19930508 <--
CN----1044236	B	19990721		
US----5700799	A	19971223	1996US-0610031	19960304 <--
LV----13075	B	20040120	2003LV-0000070	20030626 <--
PRAI 1992US-0880432	B2	19920508	<--	
OS 1994US-0332822	A3	19941031	<--	
GI MARPAT 125:221870				



AB Title compds. I or pharmaceutically acceptable salts thereof wherein: each n is independently 1 to 3; Y is chosen from, e.g., (a) C(O)Cl-6 alkyl, C(O)Cl-6 alkyl or benzoyl, (b) N(R3)2 where R3 is independently hydrogen, Cl-4 alkyl or Ph which can be substituted with one to three F, Cl, OCH3, OH, NH2, or Cl-4 alkyl, wherein each occurrence of said Cl-6 alkyl may be substituted with one or more F, Cl, Br, I, OR1, CO2R1, CN, SR1, or R1 (where R1 is a hydrogen or Cl-4 alkyl); X and Z are independently Cl-6 alkyl, C3-12 cycloalkyl or hydrogen, or X and Z form a CO-3 bridging group, preferably X and Z are hydrogen; U, V and W are independently Cl-6 alkyl, F, Cl, Br, hydrogen or a Cl-6 alkyl substituted with one or more of F, Cl, Br or I, preferably U and V are F and W is hydrogen; R is hydrogen, Cl-12 alkyl, C3-12 cycloalkyl, Cl-6 alkoxy, Cl-6 alkyl substituted with one or more F, Cl, Br, I or OH; and q is 0 to 4 inclusive, are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as *Mycobacterium tuberculosis* and *Mycobacterium avium*. Thus, e.g., arylation of piperazine with 3,4-difluorobenzene afforded 1-(4-fluoro-4-nitrophenyl)piperazine; Boc protection followed by reduction provided 1-(tert-butoxycarbonyl)-4-(2-fluoro-4-aminophenyl)piperazine; the latter was converted to the Cbz


L22 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
deriv. and then allylated to give 1-(tert-butoxycarbonyl)-4-(2-fluoro-4-benzoyloxycarbonylallylamino)piperazine; dihydroxylation followed by cyclization afforded 3-[3-fluoro-4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl]-5-hydroxymethyl-2-oxazolidinone; the 5-hydroxymethyl group was converted to a 5-acetylaminoethyl group by mesylation, acidification, hydrogenation, and acetylation; finally, Boc deprotection followed by treatment with MeO2CCL afforded oxazolidinone II which exhibited antibacterial activity: ED50 of 1.8 mg/kg PO against *S. aureus* vs. 1.8 mg/kg SC for vancomycin, and 2.3 mg/kg PO against *S. pyogenes* vs. 2.6 mg/kg SC for clindamycin.

154590-43-9P 154590-66-6P
IT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
((piperazinyl)phenyl)oxazolidinone antimicrobials)
RN 154590-43-9 HCAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)



RN 154590-66-6 HCAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



L22 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
86.5% I (R = R2 = H, R3 = F). Reaction of this with carbonyldiimidazole in THF gave 024 I (R = O, R2 = H, R3 = F) (II), which had aq. soly. of 1.4 mg/mL in phosphate buffer at pH 7. In a test against lethal infection of mice with *Staphylococcus aureus*, II had an oral and s.c. ED50 of 2 mg/kg, equiv. to that of vancomycin s.c. in the same test.


154590-66-6
IT RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of esters of [(hydroxyacetyl)piperazinyl]phenyl)oxazolidinones as antimicrobials)
RN 154590-66-6 HCAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
AN 1985:909447 HCAPLUS
DN 123:314020
TI Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones as antimicrobials
IN Brickner, Steven J.; Barbachyn, Michel R.; Hutchinson, Douglas K.
PA Upjohn Co., USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO-----9514684 A1 19950601 1994WO-US10582 19940927 <--
W: AM, AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ
RW: KE, MW, SD, SE, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA-----2174107 A1 19950601 1994CA-2174107 19940927 <--
CA-----2174107 C 20050412
AU-----9480103 A 19950613 1994AU-0080103 19940927 <--
AU-----698699 B2 19981105
EP-----730591 A1 19960911 1994EP-0931278 19940927 <--
EP-----730591 B1 19990714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
CN-----1135752 A 19961113 1994CN-0194241 19940927 <--
CN-----1046276 B 19991110
JP-----09505582 T 19970603 1995JP-0515048 19940927 <--
JP-----3698724 B2 20050921
AT-----182142 T 19990715 1994AT-0931278 19940927 <--
ES-----2133588 T3 19990916 1994ES-0931278 19940927 <--
EA-----9407885 A 19960409 1994EA-0007885 19941007 <--
TW-----427987 B 20010401 TW 1994-83109509 19941013 <--
US-----5652238 A 19970729 1996US-0640899 19960509 <--
GR-----3031420 T3 20000131 1999GR-0402509 19991007 <--
LV-----125938 B 20001120 2000LV-0000091 20000714 <--
PRAI 1993US-0155988 A2 19931122 <--
1994WO-US10582 W 19940927 <--
OS MARPAT 123:314020
GI




AB Comps. I and pharmaceutically acceptable salts are claimed [wherein R = COR1, PO3, or P(O)(OH)2; R1 = C1-6 alkyl, N(R4)2, C1-6 alkyl-N(R4)2, -C6H4N(R4)2, C6H4NHCOCH2NH2, C2H4-morpholinyl, pyridinyl, C1-6 alkyl-OH, C1-6 alkyl-OMe, C1-6 alkyl-Ac, OC1-6 alkyl-OMe, CO-3 alkyl-piperazinyl (optionally substituted with C1-3, imidazolyl, C1-6 alkyl, -CO2H, C(CH2OH)2CH3; R2 and R3 = H or F (1 or both must = F); R4 = H or C1-6 alkyl], and 30 examples were prepared and tested. The comps. are water soluble (data given), and are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including multiply-resistant staphylococci, enterococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as *Mycobacterium tuberculosis*. For example, reaction of (S)-N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with PhCH2OCH2COCl and Et3N gave I (R = PhCH2, R2 = H, R3 = F), which underwent hydrogenolysis over Pd/C to give

L22 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2008 ACS ON STN
AN 1994:323599 HCAPLUS
DN 120:323599
TI Oxazolidinones antibiotics containing a substituted diazine moiety
IN Hutchinson, Douglas K.; Brickner, Steven Joseph; Barbachyn, Michael Robert; Gammill, Ronald B.; Patel, Mahesh V.
PA Upjohn Co., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO-----9323384 A1 19931125 1993WO-US03570 19930421 <--
W: AT, AU, BB, BG, BR, CA, CH, CE, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
SK-----283420 B6 20030701 1994SK-001337 19920421 <--
AU-----9342877 A 19931213 1993AU-0042877 19930421 <--
AU-----648733 B2 19960516
EP-----640077 A1 19950301 1993EP-0912267 19930421 <--
EP-----640077 B1 20020626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT
JP-----07506829 T 19950727 1993JP-0502026 19930421 <--
JP-----3255920 B2 20020512
HU-----72296 A2 19960429 1994HU-0032208 19930421 <--
CE-----281884 B6 19970312 1994CE-002505 19930421 <--
RU-----2105003 C1 19980220 1994RU-0046031 19930421 <--
PL-----174850 B1 19980930 1993PL-0231588 19930421 <--
PL-----174909 B1 19981030 1993PL-0306030 19930421 <--
AT-----219770 T 20020715 1993AT-0912267 19930421 <--
PT-----640077 T 20021129 1993PT-0912267 19930421 <--
ES-----2180545 T3 20030216 1993ES-0912267 19930421 <--
CA-----2133079 C 20040803 1993CA-2133079 19930421 <--
ZA-----9302855 A 19941024 1993ZA-0002855 19930422 <--
IL-----105555 A 19980715 1993IL-0105555 19930429 <--
CN-----1079964 A 19931129 1993CN-0105039 19930508 <--
CN-----1044236 B 19990721
NO-----9404237 A 19950104 1994NO-0044237 19941107 <--
NO-----306112 B1 19990920
FI-----9405246 A 19941108 1994FI-0005246 19941108 <--
LV-----13075 B 20040120 2003LV-0000070 20030626 <--
PRAI 1992US-0880432 A1 19920508 <--
1993WO-US03570 W 19930421 <--
OS MARPAT 120:323599
GI




AB The title comps. [I; R = H, (un)substituted C1-6 alkyl, C3-12 cycloalkyl, C1-6 alkoxy, etc.; U, V, W = (un)substituted C1-6 alkyl, F, Cl, Br, H; X, Z = C1-6 alkyl, C3-12 cycloalkyl, H; Y = H, C1-6 alkyl, aryl, OH, (un)substituted PhO, (un)substituted piperidino, etc.], effective against members of human and veterinary pathogens, including multiple-drug-resistant staphylococci, streptococci, anaerobic organisms such as bacteroides and clostridia, and acid-fast organisms such as *Mycobacterium tuberculosis* and *Mycobacterium avium*, are prepared. Thus, Me 4-[4-[5-[(acetilamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinecarboxylate, prepared from 3,4-difluorobenzene in 12 steps, demonstrated 50% oral ED in the Murine Assay procedure using female mice injected with *S. aureus* (UC9 6685) of 4.0 mg/kg, vs. 6.6 for ciprofloxacin.

L22 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 IT 154590-43-9 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation as intermediate in preparation of oxazolidinone antibiotics)
 RN 154590-43-9 HCAPLUS
 CN Acetamide, N-([3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)



RN 154590-66-6 HCAPLUS
 CN Acetamide, N-([3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitind hitstr 127 tot

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:90855 HCAPLUS

TI Preparation of oxazolidinone derivatives as antibacterial agents
IN Ramachandran, Uma; Guha, Mrinal Kanti; Tadiparthi, Ravikumar; Prabhu, Ganesh; Vadarevu, Vijayalakshmi; Pushpan, Sini; Anantharaman, Veena; Subramanian, Santhosh; Solanki, Shakti Singh; Samuel, Matte Marianna; Koppolu, Kesavan

PA Orchid Research Laboratories Limited, India

SO PCT Int. Appl., 45pp.


CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2008010070	A2	20080124	2007MO-ISO2019	20070718
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SS, TZ, UG, ZM, AM, AS, BY, KG, KE, MD, RU, TJ, TM			
IN2006CH01253	A	20080201	2006IN-CH01253	20060719
PRAI 2006IN-CH01253	A	20060719		
GI				



AB Title compds. represented by the formula I (wherein X = O or S; R1 = H, (un)substituted (halo)alkyl, NH2, etc.; R2, R3 = independently H, halo, hydroxy, etc.; R4, R5 = independently H, cyano, nitro, etc.; R = H, halo, alkyl, etc.; Z = O, S or (un)substituted N; n = 0 or 1; and their derivs., analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compns., metabolites and produgs thereof) were prepared as antibacterial agents. For example, substitution of N-[(1S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with 4-methoxyphenyl bromide, and followed by oxidation with HONH2*HCl to gave the target product II. I showed no growth of the inoculated culture for *S. aureus*, *S. epidermidis*, *E. faecium* and *E. faecalis* in the anti-microbial activity test. The compds. of the present invention are effective against a number of human or animal pathogens, clin. isolates, including Vancomycin and Methicillin resistant organisms.

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 10, 63

IT 1003193-77-8P

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

1003193-76-7P 1003193-78-9P 1003193-79-0P

1003193-80-3P 1003193-81-4P 1003193-82-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)


RN 1003193-58-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 2-A



RN 1003193-59-6 HCAPLUS

CN Acetamide, N-[(1S)-3-[3-fluoro-4-[4-(2-oxopropyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); RACT (Reactant or reagent);

USES (Uses)

(prepn. of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)

IT 1003193-58-5P 1003193-59-6P 1003193-60-9P

1003193-61-0P 1003193-62-1P 1003193-63-2P

1003193-64-3P 1003193-65-4P 1003193-66-5P

1003193-67-6P 1003193-68-7P 1003193-69-8P

1003193-70-1P 1003193-71-2P 1003193-72-3P

1003193-73-4P 1003193-74-5P 1003193-75-6P

1003193-76-7P 1003193-78-9P 1003193-79-0P

1003193-80-3P 1003193-81-4P 1003193-82-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)

IT 79-36-7, Dichloroacetyl chloride 111-77-3, 2-(2-Methoxyethoxy)ethanol

118-41-2 381-73-7, Difluoroacetic acid 2632-13-5, 4-Methoxyphenacyl

bromide 6160-65-2 19810-31-2, Benzoyloxyacetyl chloride 154590-65-5

154590-66-6 268209-15-0 640772-88-9 1003193-90-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)

IT 1003193-77-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); RACT (Reactant or reagent);


USES (Uses)

(preparation of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)

RN 1003193-77-8 HCAPLUS

CN Acetamide, N-[(1S)-3-[4-[3,5-dimethyl-4-[2-(phenylmethoxy)acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



IT 1003193-58-5P 1003193-59-6P 1003193-60-9P

1003193-61-0P 1003193-62-1P 1003193-63-2P


1003193-64-3P 1003193-65-4P 1003193-66-5P

1003193-67-6P 1003193-68-7P 1003193-69-8P

1003193-70-1P 1003193-71-2P 1003193-72-3P

1003193-73-4P 1003193-74-5P 1003193-75-6P

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1003193-60-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry unknown.




RN 1003193-61-0 HCAPLUS

CN Acetamide, N-[(1S)-3-[3-fluoro-4-[4-[2-(4-fluorophenyl)-2-oxoethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1003193-62-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 2-A



RN 1003193-63-2 HCAPLUS


L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 1003193-65-4 HCAPLUS
CN Acetamide, N-[(1S)-3-[3-fluoro-4-[4-[2-(4-methylphenyl)-2-oxoethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1003193-66-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.


PAGE 1-A



L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1003193-64-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 1003193-67-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




RN 1003193-68-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry unknown.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1003193-69-8 HCAPLUS
 CN Acetamide, 2,2-dichloro-N-[(5S)-3-[3-fluoro-4-{4-(methoxythioxomethyl)-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1003193-73-4 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-{4-(propoxythioxomethyl)-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1003193-74-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 1003193-70-1 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-{4-(methoxythioxomethyl)-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1003193-71-2 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-{4-[(1-methylethoxy)thioxomethyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1003193-72-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1003193-75-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1003193-76-7 HCAPLUS
 CN Acetamide, 2,2-dichloro-N-[(5S)-3-[3-fluoro-4-{4-[(1-methylethoxy)thioxomethyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1003193-78-9 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-[4-(2-phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1003193-79-0 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)-3,5-dimethyl-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1003193-80-3 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1003193-81-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1003193-82-5 HCAPLUS
 CN Acetamide, 2,2-dichloro-N-[(5S)-3-[3-fluoro-4-[4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)

L27 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (prepn. of 3-(piperazinylphenyl)-1,3-oxazolidin-2-one derivs. as antibacterial agents)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)



Absolute stereochemistry.



L27 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
 RN 2008:17214 HCAPLUS
 TI Method for preparation of thiadiazol contained oxazolidone and application as antibacterial agent
 IN Shi, Xiulan
 PA Shenyang Zhonghai Biological Technology Development Co., Ltd., Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp.
 CUDEN: CNXEXV
 DT Patent
 LA Chinese
 FAN.CNT 1


PAIENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN-101096369	A	20080102	CN 2006-1009078E	20060630
PRAI CN 2006-10090788		20060630		

 GI



AB The invention relates to thiadiazol contained oxazolidone its salt and/or hydrate I (R = H, F; m = 1-4). The salt comprises hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid etc. Title compds. were prepared from (S)-N-([3-[3-fluoro-5-substituent-4-(1-piperazinyl)phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide and Cl(CH₂)_mCN in the presence of organic base or inorg. base in polar solvent to form II, then reacting with aminothiurea in the presence of acid to provide the title products. The claimed compds. can be used for treating bacterial infection in mammalian.
 CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT 1003582-28-2P 1003582-29-3P 1003582-30-6P
 1003582-31-7P 1003582-32-8P 1003582-33-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiadiazol contained oxazolidone and application as antibacterial agent)
 IT 154590-33-7P 154590-61-1P 154590-66-6P 174649-03-7P
 174649-04-8P 174649-05-9P 174649-06-0P 903594-02-5P 1003582-34-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiadiazol contained oxazolidone and application as antibacterial agent)
 IT 1003582-28-2P 1003582-29-3P 1003582-30-6P
 1003582-31-7P 1003582-32-8P 1003582-33-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiadiazol contained oxazolidone and application as antibacterial agent)
 RN 1003582-28-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


L27 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Absolute stereochemistry.



● HCl

RN 1003582-29-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 1003582-30-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 1003582-31-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


L27 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 1003582-32-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 1003582-33-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

IT 154590-66-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiadiazol contained oxazolidone and application as antibacterial agent)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-([[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 AN 2007:1396431 HCAPLUS
 DN 148:133715
 IT Phosphonated oxazolidinones and uses thereof for the prevention and
 treatment of bone and joint infections and their preparation
 IN Delorme, Daniel; Houghton, Tom; Lafontaine, Yanick; Tanaka, Kelly;
 Dietrick, Evelyn; Kang, Ting; Rafai Far, Adel
 PA Targanta Therapeutics Inc., Can.
 SO PCT Int. Appl., 15pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN_CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2007139381	A2	20071206	2006WO-IN04233	20061013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SI, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MS, NA, SD, SI, SZ, TS, UG, ZM, ZW, AM, AS, BY, KG, KZ, MD, RU, TJ, TM P 20051014 PRAI 2005US-726202P OS MARPAT 148:133715 GI				



AB The invention relates to phosphonated derivs. of oxazolidinones of
 [B]-[n]-A (I). These compds. are useful as antibiotics for prevention
 and/or the treatment of bone and joint infections, especially for the
 prophylaxis and/or treatment of osteomyelitis. Compds. of formula I
 wherein A is oxazolidinone; B is phosphonated group; L a bond and covalent
 linker; n is 1, 2 and 3; are claimed. Example compound II was prepared by a
 multistep procedure (procedure given). All the invention compds. were
 evaluated for their antimicrobial activity (data given).
 IC 10W 961K
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 29, 63
 IT 154590-66-6P 165800-04-4P, Eprexolid
 959601-26-4P 959601-28-6P 959601-30-0P
 959601-34-4P 959601-36-6P 959601-38-8P
 RL: PAC (Pharmacological activity); PHT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of phosphonated oxazolidinones)

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 as antibiotics useful in the prevention and treatment of bone and joint
 infections)
 IT 165800-03-3P, Linezolid 959601-25-3P 959601-27-5P
 959601-29-7P 959601-31-1P 959601-33-3P
 959601-35-5P 959601-37-7P 959601-39-9P
 959601-40-2P 959601-41-3P 959601-42-4P
 959601-43-5P 959601-44-6P 959601-45-7P 959601-46-8P
 959601-47-9P 959601-61-7P
 RL: PAC (Pharmacological activity); PHT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phosphonated oxazolidinones as antibiotics
 useful in the prevention and treatment of bone and joint infections)
 IT 154590-66-6P 165800-04-4P, Eprexolid
 959601-26-4P 959601-28-6P 959601-30-0P
 959601-34-4P 959601-36-6P 959601-38-8P
 RL: PAC (Pharmacological activity); PHT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of phosphonated oxazolidinones
 as antibiotics useful in the prevention and treatment of bone and joint
 infections)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 165800-04-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(2-hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 959601-26-4 HCAPLUS
 CN Propanoic acid, 3,3-bis(dimethoxyphosphinyl)-, 2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)
 Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 959601-28-6 HCAPLUS
 CN Benzoic acid, 4-[2,2-bis[bis(1-methylethoxy)phosphinyl]ethyl]-, 2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)
 Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 959601-30-0 HCAPLUS
 CN Pentanoic acid, 5-[(bis(diethoxyphosphinyl)methylamino)-5-oxo-, 2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)
 Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 959601-34-4 HCAPLUS
 CN Pentanoic acid, 5,5-bis[bis(1-methylethoxy)phosphinyl]-, 2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 959601-36-6 HCAPLUS
 CN Pentanoic acid, 5-[[4-[[bis(diethoxyphosphinyl)methyl]phenyl]amino]-5-oxo-, 2-[4-[[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 959601-38-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



IT 959601-25-3P 959601-27-5P 959601-29-7P
 959601-31-1P 959601-33-3P 959601-35-5P
 959601-37-7P 959601-39-9P 959601-40-2P
 959601-41-3P 959601-42-4P 959601-43-5P
 959601-41-7P
 RL: PAC (Pharmacological activity); PKT
 (Pharmacokinetics); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (drug candidate; preparation of phosphonated oxazolidinones as antibiotics
 useful in the prevention and treatment of bone and joint infections)
 RN 959601-55-3 HCAPLUS
 CN Phosphonic acid, P,P'-[2-[4-[[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]carbonyl]phenyl]ethylidene]bis-
 (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 959601-27-5 HCAPLUS
 CN Propanoic acid, 3,3-diphosphono-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester
 (CA INDEX NAME)


Absolute stereochemistry.



RN 959601-29-7 HCAPLUS
 CN Benzoic acid, 4-(2,2-diphosphonoethyl)-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 959601-31-1 HCAPLUS
 CN Pentanoic acid, 5-[(diphosphonomethyl)amino]-5-oxo-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl] ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959601-33-3 HCAPLUS
 CN Butanoic acid, 4-[(diphosphonomethyl)amino]-4-oxo-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 959601-35-5 HCAPLUS
 CN Pentanoic acid, 5,5-diphosphono-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl] ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959601-37-7 HCAPLUS
 CN Pentanoic acid, 5-[(4-(diphosphonomethyl)phenyl)amino]-5-oxo-, 1-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl] ester (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



RN 959601-39-9 HCAPLUS
 CN Phosphonic acid, P,P'-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]ethyldene]bis- (CA INDEX NAME)


Absolute stereochemistry.



RN 959601-40-2 HCAPLUS
 CN Phosphonic acid, P,P'-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-4-oxobutylidene]bis- (CA INDEX NAME)


L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 959601-41-3 HCAPLUS
 CN Phosphonic acid, P,P'-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-5-oxopentylidene]bis- (CA INDEX NAME)

Absolute stereochemistry.




RN 959601-42-4 HCAPLUS
 CN Phosphonic acid, P,P'-[2-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3,4-dioxobutylamino]phenyl]ethyldene]bis- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A





RN 959601-43-5 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 5,5-diphosphopentyl ester (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1310585 HCAPLUS

DI 1481:121618
 TI Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBX 8700
 AU Rudra, Sonali; Tedav, Ajay; Rao, A. V. S. Raja; Srinivas, A. S. S. V.; Pandya, Manisha; Bhateja, Preyaz; Mahtur, Tarun; Malhotra, Sunita; Rattan, Ashok; Salman, Mohammed; Mehta, Anita; Cliffe, Ian A.; Das, Biswajit
 CS Department of Medicinal Chemistry, New Drug Discovery Research, R&D III, Ranbaxy Laboratories Limited, Gurgaon, Haryana, 122015, India
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(24), 6714-6719
 CODEN: BMCLES; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 GI



AB Several potent oxazolidinone antibacterial agents were obtained by systematic modification of the linker between the five-membered heterocycle and the piperazinyl ring of RBX 7644 (Ranbexoloid, I) and its thienyl analog, leading to the identification of an expanded spectrum compound RBX 8700 (II).


CC 28-4 (Heterocyclic Compounds (More Than One Hetero Atom))
 II Section cross-reference(s): 1, 10
 II 392659-28-8P 612056-67-4P 657390-39-1P
 657390-40-4P 657390-42-6P 657390-44-8P
 73732-46-2P 864075-42-3P 864075-72-9P
 1000987-07-4P 1000987-09-6P 1000987-15-4P
 1000987-19-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, antibacterial activity, and SAR of heterocyclic oxazolidinones)
 II 645-12-5, 5-Nitro-2-furanicarboxylic acid 823-73-4, 2-Bromo-5-nitrofurran 2160-62-5, 2-Bromo-5-cyano-thiophene 4701-17-1, 2-Bromothiophene-5-carboxaldehyde 5275-69-4, 2-Acetyl-5-nitrofurran 5370-25-2, 2-Acetyl-5-bromothiophene 6281-23-8 6237-37-9, 5-Nitro-2-thiophenecarboxylic acid 13195-50-1, 2-Nitro-5-bromothiophene 17163-22-3 39565-00-9, 2-Acetyl-5-nitrothiophene 154590-66-6 657390-56-2 864075-73-0 862185-27-5 1000987-37-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation, antibacterial activity, and SAR of heterocyclic oxazolidinones)
 II 392659-28-8P 612056-67-4P 657390-39-1P
 657390-40-4P 657390-42-6P 657390-44-8P
 73732-46-2P 864075-42-3P 864075-72-9P
 1000987-07-4P 1000987-09-6P 1000987-15-4P
 1000987-19-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

L27 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A

RN 959601-41-7 HCAPLUS
 CN Phosphonic acid, P,P'-[3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-oxopropylidene]bis- (CA INDEX NAME)


Absolute stereochemistry.




L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (prepn., antibacterial activity, and SAR of heterocyclic oxazolidinones)

RN 392659-28-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612056-67-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[3-(5-nitro-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 657390-39-1 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 657390-40-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(5-formyl-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 657390-42-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(5-nitro-2-furanyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 657390-44-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 733732-46-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 864075-42-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-(5-cyano-2-thienyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864075-72-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000987-07-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[1-(5-nitro-2-furanyl)ethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1000987-09-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[1-(5-nitro-2-thienyl)ethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1000987-15-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[3-(5-nitro-2-thienyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 1000987-19-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



L27 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation, antibacterial activity, and SAR of heterocyclic oxazolidinones)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 2007:480532 HCAPLUS
 DN 147:95632
 TI Synthesis and evaluation of urea and thiourea derivatives of oxazolidinones as antibacterial agents
 AU Aaranadaka, Sunil Kumar Reddy; Guha, Mrinal Kanthi; Prabhu, Ganesh; Kini, Suvarna Ganesh; Vijayan, Magesh
 CS New Drug Discovery, Orchid Chemicals and Pharmaceuticals, Ltd., Chennai, 600019, India
 SO Chemical & Pharmaceutical Bulletin (2007), 55(2), 236-240
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 OS CASREACT 147:95632
 GI



AB Urea and thiourea derivs. of oxazolidinones, e.g., I, were synthesized and their inhibitory activity (MIC) was determined on the bacterial strains which includes clin. isolates and quality control organisms. The structure activity relationships were studied and a 3D-QSAR model was built using Genetic Function Approximation. Interestingly it was found that electron withdrawing groups at the ortho position of the Ph ring enhances the activity.
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT Section cross-reference(s): 1, 10
 942196-81-8P 942196-82-9P 942196-83-0P
 942196-84-1P 942196-86-3P 942196-87-4P
 942196-88-5P 942196-89-6P 942196-90-9P
 942196-91-0P 942196-92-1P 942196-93-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, antibacterial activity, and QSAR of oxazolidinone urea/thiourea derivs.)
 IT 1592-00-3, 2-Bromophenylisocyanate 1985-12-2, 4-Bromophenylisothiocyanate 2131-55-7, 4-Chlorophenylisothiocyanate 2131-59-1, 3-Bromophenylisothiocyanate 2392-68-9, 3-Chlorophenylisothiocyanate 2493-02-9, 4-Bromophenylisocyanate 2740-81-0, 2-Chlorophenylisothiocyanate 6590-93-8, 3,5-Dichlorophenylisothiocyanate 6590-95-0, 2,6-Dichlorophenylisothiocyanate 16382-04-0, Ethoxycarbonylisothiocyanate 22138-55-8, 3-Bromophenylisocyanate 40398-01-4, 2-Chloro-6-methylphenylisocyanate 41513-02-4 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation, antibacterial activity, and QSAR of oxazolidinone urea/thiourea derivs.)
 IT 942196-81-8P 942196-82-9P 942196-83-0P
 942196-84-1P 942196-86-3P 942196-87-4P
 942196-88-5P 942196-89-6P 942196-90-9P
 942196-91-0P 942196-92-1P 942196-93-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, antibacterial activity, and QSAR of oxazolidinone urea/thiourea derivs.)
 RN 942196-81-8 HCAPLUS


L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Acetamide, N-[[[(5S)-3-[4-[[[(4-chlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 942196-82-9 HCAPLUS
 CN Carbamic acid, N-[[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]thioxomethyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 942196-83-0 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[[[(4-bromophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 942196-84-1 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 942196-86-3 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[[[(3,5-dichlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 942196-87-4 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[[[(3-chlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 942196-88-5 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[[[(3-bromophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 942196-89-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(2-chlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 942196-90-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(2,6-dichlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 942196-93-2 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-3-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(2-chloro-6-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A


IT 154590-66-6
 RL; RCT (Reactant); RACT (Reactant or reagent)

L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 942196-91-0 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-3-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(3-bromophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 942196-92-1 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-3-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(2-bromophenyl)- (CA INDEX NAME)

L27 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (prepn., antibacterial activity, and QSAR of oxazolidinone urea/thiourea derivs.)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L27 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2007:2495721 HCAPLUS
 DN 147:455721
 TI Preparation of oxazolidinone derivative bactericides
 IN Agarwal, Shiv Kumar; Pandey, Surendrakumar Satyanarayan; Badiger, Sangamesh; Samuel, Matte Marianna
 PA Orchid Chemicals & Pharmaceuticals Ltd., India
 SO Indian Pat. Appl., 22pp.
 COCEN: INKXWQ
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN2004CH00295	A	20051202	2004IN-CH00295	20040331
PRAI 2004ID-CH00295		20040331		
OS CASREACT 147:455721				
GI				




AB The oxazolidinone derivs. I [Z = O or S; R1 = halo, NO2, CN, etc.; R2, R3 = H, halo, OH, alkyl or alkoxy; R4, R5 = H, CN, NO2, NH2, OH, halo, (un)substituted (halo)alkyl, alkoxy, alkylthio, etc.; Ar = (un)substituted cycloalkyl, aryl, aralkyl, etc; Y = C(NOR6), C(OR6), C(OR6), etc.; R6 = (un)substituted alkyl, acyl, alkylcarboxy, etc.] as well as their analogs, stereoisomers, hydrates, solvates, and salts, are prepared as medical bactericides.
 IC ICM A01N-037/00
 CC 63-8 (Pharmaceuticals)
 Section cross-reference(s): 10, 28
 IT 66215-73-2 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of oxazolidinone derivative bactericides)
 IT 952236-80-5P
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as bactericide)
 IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of oxazolidinone derivative bactericides)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L27 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




IT 952236-80-5P
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as bactericide)
 RN 952236-80-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-(2-amino-4-thiazolyl)-2-(methoxymino)acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry unknown.




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2007:140327 HCAPLUS
 DN 146:265006
 TI 3D QSAR analysis of oxazolidinone antibacterials: can we predict?
 AU Gandhi, Neha
 SO School of Biomedical Sciences, Curtin University of Technology, Bentley, 6845, Australia
 CS ARKIVOC (Gainesville, FL, United States) (2006), (16), 109-121
 CODEN: AGUAVR
 URL: http://content.arkat-usa.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2006/06-226/FP420as420published420mainmanuscript.pdf
 PB Arkat USA Inc.
 DI Journal: (online computer file)
 LA English
 AB Three-dimensional QSAR studies for substituted aryloxazolidinones 3-9 were conducted using TSAR 3.3. The in vitro activities (MICs) of the compds. against Staphylococcus aureus and Enterococcus faecalis exhibited a good correlation with the prediction made by the model using heat of formation and LUMO energies.
 CC 1-3 (Pharmacology)
 IT 392659-24-4 392659-25-5 392659-31-3
 392659-33-5 392659-38-0 392659-46-0
 392659-49-3 392659-58-4 392659-73-3 392659-86-8
 392659-87-9 548762-73-0 548762-75-0
 548762-76-1 612054-71-4 612054-72-5
 612054-75-8 612054-76-9 612054-81-6
 612054-84-9 612054-85-0 612054-86-1
 612054-87-2 612054-88-3 612054-89-4
 612054-92-9 612054-94-1 612055-05-7
 612055-06-8 612055-11-5 612055-12-6
 612055-16-0 612055-34-2 612055-36-4
 612055-40-0 612055-41-1 612055-43-3
 612055-45-5 612055-50-2 612055-94-4
 612055-95-5 612055-97-7 612055-98-8
 612055-99-9 612056-01-6 657390-55-1
 735276-46-7 735276-47-8 735276-48-9
 735276-56-9 735276-57-0 735276-59-2
 735276-60-5 735276-62-7 735276-64-9
 735276-66-1 735276-70-7 735276-72-9
 735276-73-0 735276-75-2 735276-80-9
 735276-81-0 735276-83-2 735276-84-3
 735276-85-4 735276-86-5 735276-87-6
 735276-88-7 735276-89-8 735276-90-1
 735276-91-2 735276-92-3 735276-93-4
 735276-94-5 735276-95-6 866539-20-0
 866539-21-1 866539-22-2 866539-23-3
 866539-24-4 866539-25-5 866539-27-7
 866539-28-8 866539-30-2 866539-31-3 866585-25-3
 903870-98-4 903870-99-5 903871-00-1
 903871-02-3 903871-03-4 903871-04-5
 927681-74-1 927681-95-6
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (3D QSAR anal. of oxazolidinone derivs. as antibacterials)
 IT 392659-24-4 392659-25-5 392659-31-3
 392659-33-5 392659-38-0 392659-46-0
 392659-49-3 392659-86-8 392659-87-9
 548762-73-8 548762-75-0 548762-76-1
 612054-71-4 612054-72-5 612054-75-8
 612054-76-9 612054-81-6 612054-84-9
 612054-85-0 612054-86-1 612054-87-2
 612054-88-3 612054-89-4 612054-92-9
 612054-94-1 612055-05-7 612055-06-8
 612055-11-5 612055-12-6 612055-16-0
 612055-34-2 612055-36-4 612055-40-0
 612055-41-1 612055-43-3 612055-45-5
 612055-50-2 612055-94-4 612055-95-5
 612055-97-7 612055-98-8 612055-99-9
 612056-01-6 735276-46-7 735276-47-8
 735276-48-9 735276-56-9 735276-57-0
 735276-59-2 735276-60-5 735276-62-7
 735276-64-9 735276-66-1 735276-70-7
 735276-72-9 735276-73-0 735276-75-2
 735276-80-9 735276-81-0 735276-83-2

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


735276-84-3 735276-85-4 735276-86-5
 735276-87-6 735276-88-7 735276-89-8
 735276-90-1 735276-91-2 735276-92-3
 735276-93-4 735276-94-5 735276-95-6 86653
 9-20-0 866539-21-1 866539-22-2
 866539-23-3 866539-24-4 866539-25-5
 866539-27-7 866539-28-8 903870-98-4
 903870-99-5 903871-00-1 903871-02-3
 903871-03-4 903871-04-5 927681-95-6
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (3D QSAR anal. of oxazolidinone derivs. as antibacterials)
 RN 392659-24-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(5-formyl-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.



RN 392659-25-5 HCAPLUS
 CN 2-Furancarboxylic acid, 5-[[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-, ethyl ester (CA INDEX NAME)
 Absolute stereochemistry.




RN 392659-31-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.



RN 392659-33-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(2-furanylmethyl)-1-


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 392659-38-0 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-46-0 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-49-3 HCAPLUS
CN Acetamide, N-([(5S)-3-[4-[4-[(5-[(acetyloxy)methyl]-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 548762-75-0 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-(hydrazinylidenemethyl)-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 548762-76-1 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-(hydroxymethyl)-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612054-71-4 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 392659-86-8 HCAPLUS
CN Acetamide, N-([(5S)-3-[4-[4-[(5-cyano-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-87-9 HCAPLUS
CN 2-Furancarboxylic acid, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 548762-73-8 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-(hydroxymethyl)-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


RN 612054-72-5 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 612054-75-8 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 612054-76-9 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 612054-81-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[(2E)-3-(3,4-difluorophenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 612054-84-9 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(1H-indol-3-yl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 612054-87-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 612054-88-3 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 612054-85-0 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(3-hydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 612054-86-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2E)-3-(3-hydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612054-89-4 HCAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 4-[(1E)-3-[4-[(4S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-oxo-1-propen-1-yl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 612054-92-9 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(3-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612054-94-1 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-05-7 HCAPLUS


CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(5-nitro-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 612055-06-8 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-[5-(hydroxymethyl)-2-furanyl]-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-11-5 HCAPLUS

CN Acetamide, N-[(5S)-3-[4-{4-[(2E)-3-[5-(acetyloxy)methyl]-2-furanyl]-1-oxo-2-propen-1-yl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-12-6 HCAPLUS


CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(5-methyl-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 612055-16-0 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-(1H-pyrrol-2-yl)-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-34-2 HCAPLUS

CN Ethanethioamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A


RN 612055-36-4 HCAPLUS

CN Ethanethioamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-40-0 HCAPLUS

CN Ethanethioamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 612055-41-1 HCAPLUS

CN Ethanethioamide, N-[(5S)-3-[3-fluoro-4-{4-[(2E)-3-(1H-indol-3-yl)-1-oxo-2-propen-1-yl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 612055-43-3 HCAPLUS
 CN Ethanethioamide, N-(((5S)-3-([3-fluoro-4-((2E)-1-oxo-3-(4-pyridinyl)-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




RN 612055-45-5 HCAPLUS
 CN Ethanethioamide, N-(((5S)-3-([3-fluoro-4-((2E)-1-oxo-3-phenyl-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 2-A




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 612055-95-5 HCAPLUS
 CN Thiourea, N-(((5S)-3-([3-fluoro-4-((2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




RN 612055-97-7 HCAPLUS
 CN Thiourea, N-(((5S)-3-([3-fluoro-4-((2E)-3-(1H-indol-3-yl)-1-oxo-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 2-A




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 612055-50-2 HCAPLUS
 CN Ethanethioamide, N-(((5S)-3-([3-fluoro-4-((2E)-3-(5-nitro-2-furanyl)-1-oxo-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 612055-94-4 HCAPLUS
 CN Thiourea, N-(((5S)-3-([3-fluoro-4-((2E)-1-oxo-3-(2-thienyl)-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 612055-98-8 HCAPLUS
 CN Thiourea, N-(((5S)-3-([3-fluoro-4-((2E)-3-(2-furanyl)-1-oxo-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 612055-99-9 HCAPLUS
 CN Thiourea, N-(((5S)-3-([3-fluoro-4-((2E)-1-oxo-3-(4-pyridinyl)-2-propen-1-yl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 612056-01-6 HCAPLUS
 CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-{4-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 735276-46-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-5-[(2-pyridinyloxy)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 735276-47-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-5-[(pyrazinyloxy)methyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 735276-48-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 735276-56-9 HCAPLUS
 CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-phenyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735276-57-0 HCAPLUS
 CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-{4-(2-pyridinyl)-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 735276-59-2 HCAPLUS
 CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(2-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 1-A



RN 735276-60-5 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-([4-(3-chlorophenyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 735276-64-9 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-([3-fluoro-4-(2-methylphenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



RN 735276-66-1 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-([3-fluoro-4-(3-fluorophenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



RN 735276-72-9 HCAPLUS
 CN Carbamodithioic acid, N-([(5S)-3-([4-(3-chlorophenyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 735276-62-7 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-([4-(4-chlorophenyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 735276-64-9 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-([3-fluoro-4-(2-methylphenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 735276-70-7 HCAPLUS
 CN Carbamodithioic acid, N-([(5S)-3-([3-fluoro-4-(4-(2-pyridinyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 735276-72-9 HCAPLUS
 CN Carbamodithioic acid, N-([(5S)-3-([4-(3-chlorophenyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



RN 735276-73-0 HCAPLUS
 CN Carbamodithioic acid, N-[[[(5S)-3-[4-[4-(3-methoxyphenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 735276-75-2 HCAPLUS
 CN Carbamodithioic acid, N-[[[(5S)-3-[3-fluoro-4-(4-(2-methylphenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 735276-80-9 HCAPLUS
 CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(4-phenyl-1-piperazinyl)phenyl]-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




RN 735276-81-0 HCAPLUS
 CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(4-phenyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 2-A



RN 735276-84-3 HCAPLUS
 CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(4-(2-pyridinyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



RN 735276-83-2 HCAPLUS
 CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(4-(2-methoxyphenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 735276-85-4 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[4-[4-(2-chlorophenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 735276-86-5 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[4-[4-(2-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 735276-87-6 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[4-[4-(3-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 735276-88-7 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-[4-(3-methoxyphenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 735276-89-8 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[4-[4-(4-chlorophenyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 735276-90-1 HCAPLUS
CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-[4-(2-methylphenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 2-A



RN 735276-91-2 HCAPLUS
 CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 735276-92-3 HCAPLUS
 CN Carbamothioic acid, N-[[[(5S)-3-[3-fluoro-4-(4-phenyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 735276-95-6 HCAPLUS
 CN Carbamothioic acid, N-[[[(5S)-3-[3-fluoro-4-(4-(3-methoxyphenyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 735276-93-4 HCAPLUS
 CN Carbamothioic acid, N-[[[(5S)-3-[3-fluoro-4-(4-(2-pyridinyl)-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 735276-94-5 HCAPLUS
 CN Carbamothioic acid, N-[[[(5S)-3-[4-(4-(3-chlorophenyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (CA INDEX NAME)


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 2-A




RN 866539-20-0 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[(5-chloro-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 866539-21-1 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866539-22-2 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(5-nitro-1H-pyrrol-2-yl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 866539-23-3 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1-methyl-5-nitro-1H-pyrrol-2-yl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 866539-24-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(4-[(5-nitro-3-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866539-25-5 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2-nitro-3-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 866539-27-7 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2-methyl-4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 866539-28-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[(3R,5S)-3,5-dimethyl-4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 903870-98-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2E)-3-(5-formyl-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 903870-99-5 HCAPLUS
 CN 2-Furancarboxylic acid, 5-[(1E)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-oxo-1-propen-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 903871-00-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2E)-3-(5-nitro-2-thienyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 903871-02-3 HCAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 4-[(1E)-3-[4-[(5S)-5-[(aminothioxomethyl)amino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-oxo-1-propen-1-ylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 903871-03-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2E)-3-(5-nitro-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 903871-04-5 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2E)-3-(5-nitro-2-furanyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 927681-95-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2E)-3-[4-[(methylsulfonyl)methyl]phenyl]-1-oxo-2-propen-1-yl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L27 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:855345 HCAPLUS
DN 145:419001
TI Short and practical enantioselective synthesis of linezolid and eperezolid via proline-catalyzed asymmetric α -aminooxylation
AU Narina, Srinivasarao V.; Sudalai, Arumugam
CS Chemical Engineering and Process Development Division, National Chemical Laboratory, Pune, 411 008, India
SO Tetrahedron Letters (2006), 47(38), 6799-6802
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 145:419001
AB An efficient enantioselective synthesis of the antibacterials, linezolid and eperezolid, using D-proline-catalyzed asym. α -aminooxylation of aldehydes as the key step is described. This is the first report on the enantioselective synthesis of linezolid and eperezolid using asym. catalysis.
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
IT 154590-66-6P 168828-82-8P 168828-84-0P 174649-04-8P 174649-06-0P 174649-08-2P 239438-37-0P 239438-48-3P 903593-97-5P 912552-54-6P 912552-55-7P 912552-56-8P 912552-57-9P 912552-59-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(short and practical enantioselective synthesis of linezolid and eperezolid via proline-catalyzed asym. α -aminooxylation of aldehydes)
IT 154590-66-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(short and practical enantioselective synthesis of linezolid and eperezolid via proline-catalyzed asym. α -aminooxylation of aldehydes)
RN 154590-66-6 HCAPLUS
CN Acetamide, N-[(1S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:716811 HCAPLUS
DN 145:188857
TI Preparation of Linezolid and Eperezolid as antibacterial agents
IN Xu, Guangyu; Wu, Xihan; Xie, Yuyuan
PA Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China
SO Fanfing Zhuangli Shengqing Gongkai Shuomingshu, 13pp.
CODEN: CNXKEV
DT Patent
LA Chinese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI CN----1673224 A 20050928 CN 2004-10017127 20040323
PRAI CN 2004-10017127 20040323
OS CASREACT 145:188857
AB The title Linezolid and Eperezolid were prepared as antibacterial agents (no data). For example, 3-fluoro-4-morpholinobenzenamine (preparation given) was reacted with L-glyceraldehyde acetone, followed by hydrogenation, methylsulfonylation, diazotization, reduction, and acetylation to give Linezolid in good yield.
IC ICM C07D-317/28
ICS C07D-263/20
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
IT 165800-03-3P, Linezolid 165800-04-4P, Eperezolid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of Linezolid and Eperezolid as antibacterial agents)
IT 2689-39-6P 93246-53-8P 154590-33-7P 154590-66-6P 168828-82-8P 168828-84-0P 174649-04-8P 174649-06-0P 174649-08-2P 174649-09-3P 239438-37-0P 239438-48-3P 903593-93-1P 903593-97-5P 903594-00-3P 903594-02-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of Linezolid and Eperezolid as antibacterial agents)
IT 165800-04-4P, Eperezolid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of Linezolid and Eperezolid as antibacterial agents)
RN 165800-04-4 HCAPLUS
CN Acetamide, N-[(1S)-3-[3-fluoro-4-(4-(2-hydroxyacetyl)-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 154590-66-6P


L27 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of Linezolid and Eperezolid as antibacterial agents)
RN 154590-66-6 HCAPLUS
CN Acetamide, N-[(1S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 RN 2006/463019 HCAPLUS
 DN 144:488638
 TI Oxazolidinone derivatives as antimicrobials, and their preparation,
 pharmaceutical composition and use for treatment of microbial infections
 IN Das, Biswajit; Yadav, Ajay, Singh; Ahmed, Shahadat; Gujrati, Arti; Ghosh,
 Soma; Rattan, Ashok
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN_CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO2006051408 A1 20060518 2005WO-1803390 20051110
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SI, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MM, MS, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 PRAI 2004IN-DEU2245 A 20041111
 OS CASREACT 144:488638; MARPAT 144:488638
 GI




AB Substituted phenyloxazolidinones of formula I and to processes for the
 synthesis thereof are disclosed. Also provided are pharmaceutical compns.
 comprising one or more compds. described herein. The compds. described
 can be useful antimicrobial agents, which can be effective against a number
 of human and veterinary pathogens, including gram-pos. aerobic bacteria,
 such as multiple-resistant staphylococci, streptococci and enterococci, as
 well as, anaerobic organisms, such as Bacterioides spp. and Clostridia
 spp. species, and acid fast organisms, such as Mycobacterium tuberculosis,
 Mycobacterium avium and Mycobacterium spp. Compds. of formula I where in
 U and V are independently H, F, Cl-6 alkyl, where bot U and V cannot
 simultaneously be H; R1 is arido, NHC(=O)R and derivs., SH and derivs.,
 NHNH and derivs., NHC(=O)NH2 and derivs., NH2 and derivs., or NHC(=O)R; Y
 is CO, CS, or SO2; T is O, S, N(CN), N(NO2), CHNO2; Ra is alkyl, alkenyl,
 alkynyl, cycloalkyl, (hetero)aryl(alkyl), or heterocyclylalkyl; O is
 (un)substituted 6-membered (hetero)aryl; R is (hetero)aryl, heterocyclyl,
 or cycloalkyl; and their pharmaceutically acceptable salts, solvates,
 enantiomers, diastereoisomers, or polymorphs as well as the process for
 preparing them are claimed. Example compound II was prepared by deprotection of

L27 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 887367-88-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[3-fluoro-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 887367-90-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[5-(3-furanyl)-2-pyrimidinyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 887368-03-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[4-(1H-pyrrol-1-yl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 tert-Bu 4-[(4-(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazine-1-carboxylate, the resulting N-[(5S)-3-[3-fluoro-4-piperazin-1-ylphenyl]-2-oxo-1,3-oxazolidine-5-yl]methyl]acetamide which reacted with 2,4-difluoronitrobenzene to give N-[(5S)-3-[3-fluoro-4-(3-fluoro-4-nitrophenyl)piperazin-1-ylphenyl]-2-oxo-1,3-oxazolidine-5-yl]methyl]acetamide, which underwent redn. to give N-[(5S)-3-[3-fluoro-4-(3-fluoro-4-aminophenyl)piperazin-1-ylphenyl]-2-oxo-1,3-oxazolidine-5-yl]methyl]acetamide, which reacted with 2,5-dimethoxytetrahydrofuran to give example compd. II. All the invention compds. were evaluated for their antimicrobial activity against Gram pos. and Gram neg. bacteria. The tested compds. exhibited in vitro antibacterial activity and the min. inhibitory concn. was detd. for several bacteria.
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 887367-84-2P 887367-86-4P 887367-88-6P
 887367-90-0P 887368-03-8P 887368-05-0P
 887368-07-2P 887368-08-3P 887368-10-7P
 887368-12-9P 887368-13-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazolidinone derivs. as antimicrobials use for treatment of microbial infections)
 IT 154590-66-6P 887367-92-2P 887367-93-3P 887367-95-5P
 887367-97-7P 887367-99-9P 887368-00-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of oxazolidinone derivs. as antimicrobials use for treatment of microbial infections)
 IT 887367-84-2P 887367-86-4P 887367-88-6P
 887367-90-0P 887368-03-8P 887368-05-0P
 887368-07-2P 887368-08-3P 887368-10-7P
 887368-12-9P 887368-13-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazolidinone derivs. as antimicrobials use for treatment of microbial infections)
 RN 887367-84-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 887367-86-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[3-fluoro-4-(5-oxazolyl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 887368-05-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[2-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 887368-07-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[5-(1H-pyrrol-1-yl)-2-pyridinyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 887368-08-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[2-fluoro-4-(5-oxazolyl)phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 887368-10-7 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[5-(2-thienyl)-2-pyridinyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 887368-12-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[5-(3-thienyl)-2-pyridinyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 887368-13-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[5-(3-furanyl)-2-pyridinyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:117385 HCAPLUS
 DN 144:370098
 TI Oxazolidinone derivatives, particularly benzoxadiazole phenyloxazolidinones, useful as antimicrobials, and processes for their preparation, pharmaceutical compositions containing them, and methods of their use for treating microbial infections
 IN Das, Biswajit; Rudra, Sonali; Salman, Mohammad; Rattan, Ashok
 SO Ranbaxy Laboratories Limited, India
 PA RCT Int. Appl., 79 pp.
 CODEN: PIXXDZ
 DT Patent
 LA English
 FHM.CYT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 WIPO2006/025283 A1 2006060406 200500-1902840 20050926
 W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, HE, LS, MG, ME, NA, SD, SG, SZ, TZ, UG, SN, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM
 PRAI 2004IN-0601843 A 20040927
 OS CASREACT 144:370098; MARPAT 144:370098
 GI



L27 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 Oxazolidin-3-yl]-5-fluorophenyl]piperidine-1-carboxylate 882185-06-0,
 N-[[[(5S)-3-[3,5-Difluoro-4-(trimethylstannyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 882185-27-5, N-[[[(5S)-3-[3-Fluoro-4-(piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide trifluoroacetate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; prepn. of benzoxadiazole-substituted phenyloxazolidinones as antimicrobials)
 IT 882185-01-SP, N-[[[(5S)-3-[3-Fluoro-4-[4-[(1-oxido-2,1,3-benzoxadiazol-5-yl)methyl]piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of benzoxadiazole-substituted phenyloxazolidinones as antimicrobials)
 RN 882185-01-5 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-Fluoro-4-[4-[(1-oxido-2,1,3-benzoxadiazol-5-yl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 882184-94-3P, (5R)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
 882184-95-4P, (5R)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-5-(2H-1,2,3-triazol-2-ylmethyl)-1,3-oxazolidin-2-one
 882184-97-6P, (5S)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-5-(isoxazol-3-ylamino)methyl]-1,3-oxazolidin-2-one
 882184-99-8P, (5S)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-5-(isoxazol-3-ylamino)methyl]-1,3-oxazolidin-2-one
 882185-02-6P, N-[[[(5S)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)methyl]piperazin-1-yl]-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 882185-04-8P, N-[[[(5S)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 882185-22-0P, (5R)-3-[4-[4-(2,1,3-Benzoxadiazol-5-yl)piperazin-1-yl]-3-fluorophenyl]-5-(isoxazol-3-ylamino)methyl]-1,3-oxazolidin-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of benzoxadiazole-substituted phenyloxazolidinones as antimicrobials)
 RN 882184-94-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 882185-02-6 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-(2,1,3-benzoxadiazol-5-yl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 882185-04-8 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 882185-05-9 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 882184-95-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-5-(2H-1,2,3-triazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 882184-97-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 882184-99-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-5-(3-isoxazolylmethyl)-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 882185-22-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-(2,1,3-benzoxadiazol-5-yl)-1-piperazinyl]-3-fluorophenyl]-5-[(3-isoxazolylmethyl)-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 154590-66-6, N-[[[(5S)-3-[3-Fluoro-4-(piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of benzoxadiazole-substituted phenyloxazolidinones as antimicrobials)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 AN 20051005983 HCAPLUS
 DN 1431306339
 TI Preparation of piperazinyl oxazolidine compounds as antibacterial agents
 IN Agarwal, Shiv Kumar; Pandey, Surendrakumar Satyanarayan; Singh, Gajendra;
 Chithra, Santhanagopalan; Samuel, Matte Marianna
 PA Orchid Chemicals & Pharmaceuticals Ltd., India
 SO U.S. Pat. Appl. Publ., 16 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US2005203102	A1	20050915	2005US-0074637	20050309
IN2005CR000214	A	20070316	2005IN-CN00214	20050307
WO2005090339	A1	20050929	2005WO-IN00585	20050309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, VE, VN, VU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG

PRAI 2004US-551048P P 20040309
 OS CASREACT 143:306339; MARPAT 143:306339
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors prepared the title compds. I [R = cyano, NH₂, alkyl, alkoxy, NO₂, acyl, halo, CO₂H, etc.; R₁ = halo, N₂, NO₂, cyano, AM₆, NR₇AR₇b, A = O, S, M₆ = H, alkyl, cycloalkyl, aryl, aralkyl, acyl; R₇a, R₇b = H, CHO, C1-C4-alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, amino acid, etc.; R₂, R₃ = H, halo, OH, alkyl, alkoxy; R₄, R₅ = H, cyano, NO₂, NH₂, halo, OH, (unsubstituted C1-C4-alkyl, haloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C3-C6-cycloalkyl; R₄R₅ = oxo, thioxo; R₁₃ = H or R₁₃2 = bond; X = oxo, thioxo; Y = NR₉, S, O, R₉ = H, (unsubstituted alkyl, alkenyl, CH₂CO₂R₁₀, aryl, counter ion, R₁₀ = H, alkyl; W = O, S; Z = CR₁₁, S; R₁₁X = S- or 6-membered fused aromatic or heteroarom. ring; Z1 = O, S] as antibacterial agents. For example, reacting 4-FC₆H₄CHO with (oxazolidinylmethyl)acetamide II gave the desired compound III.


IC ICM A61K-031/496
 ICS C07D-417/14
 INCL 514254020; 544369000; 514151000
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 10, 43
 IT 864665-05-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 IT 864665-07-6P 864665-09-7P 864665-20-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 IT 864665-11-2P 864665-25-8P 864665-27-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 IT 864665-06-5P 864665-09-8P 864665-10-1P
 864665-16-7P 864665-21-4P 864665-22-5P

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


Absolute stereochemistry.
 Double bond geometry unknown.



Absolute stereochemistry.
 Double bond geometry unknown.




Absolute stereochemistry.
 Double bond geometry unknown.




L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 864665-23-6P 864665-24-7P 864665-26-9P
 864665-28-1P 864665-29-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of piperazinyl oxazolidine compds. as antibacterial agents)
 IT 59-48-3 141-84-4 459-57-4, 4-Fluorobenzaldehyde 2295-31-0, 5,4-Thiazolidinedione 5718-83-2 154590-44-4 154590-66-6 221201-21-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 IT 864665-05-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 RN 864665-05-4 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-Fluoro-4-[4-(4-formylphenyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




IT 864665-07-6P 864665-08-7P 864665-20-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 RN 864665-07-6 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-[4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN Acetamide, N-[[[(5S)-3-[4-[4-[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.



L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


864665-23-6P 864665-24-7P 864665-26-9P

864665-28-1P 864665-29-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of piperazinyl oxazolidine compds. as antibacterial agents)

RN 864665-06-5 HCAPLUS
 CN 3-Thiazolidineacetic acid, 5-[[4-[[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]phenyl]methylene]-4-oxo-2-thioxo- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 864665-09-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[[4-[[4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 864665-10-1 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[[4-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 1-B

OMe

RN 864665-22-5 HCAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-[[4-[[4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.




RN 864665-23-6 HCAPLUS

CN 3-Thiazolidineacetic acid, 5-[[4-[[4-[(5S)-5-[(ethoxycarbonyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]phenyl]methylene]-4-oxo-2-thioxo- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 864665-16-7 HCAPLUS

CN Carbamothioic acid, [[[(5S)-3-[4-[[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 0-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 864665-21-4 HCAPLUS

CN 3-Thiazolidineacetic acid, 5-[[4-[[4-[[2-fluoro-4-[(5S)-5-[(methoxycarbonyl)amino]methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-piperazinyl]phenyl]methylene]-4-oxo-2-thioxo- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



PAGE 1-A

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 1-B

OEt

RN 864665-24-7 HCAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-[[4-[[4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 864665-26-9 HCAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[[4-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


OEt

RN 864665-28-1 HCAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[[4-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methyl]phenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




PAGE 1-B

OMe

RN 864665-29-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(4-oxo-2-thioxo-5-thiazolidinyl)methyl]phenyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of piperazinyl oxazolidine compds. as antibacterial agents)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L27 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of rifamycin oxime derivs. for therapeutic use as antibiotics which are effective against drug-resistant microbes)
 IT 864443-12-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of rifamycin oxime derivs. for therapeutic use as antibiotics which are effective against drug-resistant microbes)
 RN 864443-12-9 HCAPLUS
 CN Rifamycin, 1,4-dideoxy-1,4-dihydro-1,4-dioxo-, 11-[0-[[2-[[4-[(5S)-5-[[acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]ethyl]oxime] (RCT) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

L27 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN


AN 2005:1005976 HCAPLUS
 RN 143:286218
 TI Preparation of rifamycin oxime derivatives for therapeutic use as antibiotics which are effective against drug-resistant microbes
 IN Li, Jing; Ding, Charles Z.; Ma, Zhenkun
 PA Cumbre Inc USA
 SO U.S. Pat. Appl. Publ., 63 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN_CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US2005203076	A1	20050915	2005US-0076172	20050309
US-7256187	B2	20070814		
PRAI 2004US-551684P	P	20040310		
OS CASREACT 143:286218; MARPAT 143:286218				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Rifamycin oximes, such as I (L3, L11 = bond or linking group, such as -NH-, -O-, -CO-, -SOn-, alkylene, alkenylene, alkynylene, R = H, alkyl, etc., n = 0-2; X3, X11 = H, ME2, CO2H, CN, halogen, alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, therapeutic antimicrobial moiety, such as ciprofloxacin, gatifloxacin, moxifloxacin, etc.; L3-X3 = morpholinyl; Y = O, N-0-12-X2), were prepared for use in pharmaceutical compns. as antimicrobial agents. This invention relates to rifamycin derivs. having antimicrobial activity against drug-resistant microorganisms, in particular, rifamycin-resistant microbes. Thus, rifamycin 5 derivative II was prepared starting from rifamycin 5 via formation of rifamycin 5 oxime I (L3-X3 = L11-X11 = H, Y = O), an O-alkylation reaction of the oxime with 1,2-dibromomethane, and finally, an N-alkylation reaction of the intermediate 2-bromomethyl oxime I (L1-X3 = H, L11-X11 = (CH2)2Br, Y = O) with ciprofloxacin to form the desired coupled product. The prepared rifamycin oximes were assayed in vitro for antimicrobial activity against a number of bacterial species, such as *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Enterococcus faecalis*.


IC ICM A61K-031/343
 CCS C07D-491/14
 INCL 514183000; 540457000; 514468000
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1, 10, 63
 IT 864443-01-6P 864443-02-7P 864443-04-9P 864443-05-0P 864443-06-1P
 864443-07-2P 864443-09-4P 864443-10-7P 864443-11-8P
 864443-12-9P 864443-13-0P 864443-14-1P 864443-15-2P
 864443-16-3P 864443-17-4P 864443-18-5P 864443-19-6P 864443-20-9P
 864443-21-0P 864443-22-1P 864443-23-2P 864443-26-5P 864443-27-6P
 864443-28-7P 864443-29-8P 864443-30-1P 864443-31-2P 864443-32-3P
 864443-33-4P 864443-35-6P 864443-36-7P 864443-37-8P 864443-38-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of rifamycin oxime derivs. for therapeutic use as antibiotics which are effective against drug-resistant microbes)
 IT 74-88-4, Iodomethane, reactions 79-04-9, Chloroacetyl chloride
 102-71-6, reactions 106-93-4, 1,2-Dibromomethane 106-95-6, Allyl
 bromide, reactions 108-49-6, 2,6-Dimethylpiperazine 109-01-3,
 1-Methylpiperazine 110-91-8, Morpholine, reactions 593-56-6,
 Methoxyamine hydrochloride 1011-17-2, 2-Piperazin-1-ylphenol
 2759-28-6, 4-Benzylpiperazine 3970-21-6, 2-Methoxyethoxymethyl chloride
 5382-16-1, 4-Hydroxypiperidine 5470-11-1 6066-82-6,
 N-Hydroxysuccinimide 6928-85-4, 1-Amino-4-methylpiperazine 13292-22-3,
 3-Formylrifamycin 5V 14897-39-3, Rifamycin 5V sodium salt 15532-75-9,
 1-(3-Trifluoromethylphenyl)piperazine 19206-05-9, 1-(Morpholin-4-yl)rifamycin 5 20295-82-3 34803-66-2, 1-Pyridin-2-ylpiperazine
 38945-21-0, Allyloxamine hydrochloride 39178-35-3, Isonicotinoyl
 chloride hydrochloride 55686-22-1 85721-33-1, Ciprofloxacin 1
 105956-99-8, Clinafloxacin hydrochloride 110408-11-2 112811-59-3,
 Gatifloxacin 151096-09-2, Moxifloxacin 154590-66-6
 861805-10-9



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of rifamycin oxime derivs. for therapeutic use as antibiotics which are effective against drug-resistant microbes)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN

AN	2005:694920	HCAPLUS			
DN	143:193856				
TI	Preparation of rifamycin derivatives for use in antibiotic pharmaceutical compositions which are effective against drug-resistant microbes				
IN	Ma, Zhenkun; Jin, Yafei; Li, Jing; Ding, Charles Z.; Minor, Keith P.; Longgood, Jamie C.; Kim, In Ho; Marran, Susan; Combrink, Keith; Morris, Timothy W.				
PA	Cubure Inc., USA				
SO	PCT Int. Appl., 141 pp.				
DT	CODEN: PIXXD2				
LA	Patent				
FAN.CNT	1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005070940	A2	20050804	2005WO-US00943	20050112
	WO2005070940	A3	20050929		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DK, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KS, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US2005261262	A1	20051124	2005US-0034195	20050112
	US---7247634	B2	20070724		
	EP---1730154	A2	20061213	2005EP-0705550	20050112
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	2004US-535990P	P	20040113		
	2005MO-US00943	W	20050112		
OS	MAPPAT 143:193856				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Rifamycin S and SV derivs., such as I and II [X = bond, heterocyclic and/or heteroacyclic linking group; A = antibacterial agent or its pharmacophore], were prepared and were claimed for therapeutic use as antibacterial agents. The inventive rifamycin derivs. were uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent. Thus, rifamycin S derivative III was prepared via a condensation reaction with 10% yield of 3-bromorifamycin S with sodium ciprofloxacin. The prepared rifamycin derivs. were assayed for antimicrobial activity organisms such as *Staphylococcus aureus*.

IC ICM C07D-498/00

CC 26-6 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 10, 63

IT 6998-60-3DP, Rifamycin, derivs. 861805-10-9P 861805-11-0P
861805-12-1P 861805-13-2P 861805-14-3P 861805-15-4P 861805-16-5P
861805-17-6P 861805-18-7P 861805-19-8P 861805-20-1P 861805-21-2P
861805-22-3P 861805-23-4P 861805-25-6P 861805-26-7P 861805-27-8P
861805-28-9P 861805-29-0P 861805-30-3P 861805-31-4P
861805-34-7P 861805-35-8P 861805-36-9P 861805-37-0P 861805-38-1P
861805-39-2P 861805-40-5P 861805-41-6P 861805-42-7P 861805-43-8P
861805-44-9P 861805-45-0P 861805-46-1P 861805-47-2P 861805-48-3P
861805-49-4P 861805-51-8P 861805-53-0P 861805-55-2P 861805-58-5P
861805-59-6P 861805-60-9P 861805-61-0P 861805-62-1P

L27 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

861805-63-2P 861805-66-5P 861805-67-6P 861805-68-7P 861805-69-8P
861805-70-1P 861805-71-2P 861805-72-3P 861805-73-4P 861805-75-6P
861805-76-7P 861805-78-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(prepn. of rifamycin derivs. for use in antibiotic pharmaceutical compns. which are effective against drug-resistant microbes)

IT 107-15-3, Ethylenediamine, reactions 110-85-0, Piperazine, reactions 498-94-2, Isonicotinic acid 574-98-1, N-(2-Bromoethyl)phthalimide 814-68-6, Acryloyl chloride 13292-22-3, 3-Formylrifamycin 13553-79-2, Rifamycin S 16898-52-5, 4,4'-Dimethylenedipiperidine 36476-78-5, 3-Azetidinecarboxylic acid 41979-39-3, 4-Piperidone hydrochloride 79099-07-3, 4-Oxopiperidine-1-carboxylic acid tert-butyl ester 81103-11-9, Clarithromycin 83905-01-5, Arithromycin 85721-33-1 86393-33-1, 1-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 91188-15-7, Azetidin-3-ylmethylenecarboxylic acid tert-butyl ester 93102-05-7 98079-52-8 99696-22-7 99735-41-8 100491-29-0 104456-02-2 105573-17-9 105956-99-8 112811-57-1 112811-59-3 112811-60-6, 7-(3-Aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 112811-72-0 114213-85-3 116183-82-5, (R)-(+)-3-Aminopyrrolidine 122536-76-9, (S)-Pyrrolidin-3-ylcarboxylic acid tert-butyl ester 122536-77-0, (R)-Pyrrolidin-3-ylcarboxylic acid tert-butyl ester 127294-64-8 128345-57-3, (S)-(-)-3-Aminopyrrolidine 138314-00-8 138951-16-3 156590-66-6 354812-41-2 861391-62-0 861391-66-4 861391-67-5 861805-50-7 861805-54-1 861805-74-5 861805-77-8 861805-79-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of rifamycin derivs. for use in antibiotic pharmaceutical compns. which are effective against drug-resistant microbes)

IT 861805-30-3P 861805-31-4P 861805-62-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)


(preparation of rifamycin derivs. for use in antibiotic pharmaceutical compns. which are effective against drug-resistant microbes)

RN 861805-30-3 HCAPLUS

CN Rifamycin, 3-[4-[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]ethylamino]-1,4-dideoxy-1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



L27 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 1-B




RN 861805-31-4 HCAPLUS
CN Rifamycin, 3-[[2-[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]ethylamino]-1,4-dideoxy-1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B




RN 861805-62-1 HCAPLUS
CN Rifamycin, 3-[3-[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]carbonyl]-1-azetidinyl]-1,4-dideoxy-1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as described by E or Z.

L27 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B




IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of rifamycin derivs. for use in antibiotic pharmaceutical
 compns. which are effective against drug-resistant microbes)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-(3-fluoro-4-(1-piperazinyl)phenyl)-2-oxo-5-
 oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 862780-21-0 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-pyrazinylphenyl)-5-(hydroxymethyl)-, (5R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862780-22-1 HCAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-(3-fluoro-4-pyrazinylphenyl)-, (5S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 862780-23-2P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN
 (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation)
 (orientation of oxazolidinones in active site of monoamine oxidase)
 RN 862780-23-2 HCAPLUS
 CN Acetamide, N,N'-[(1,5-dioxo-1,5-pentenediyl)bis[4,1-piperazinediyl(3-

L27 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN

RN 2005:581513 HCAPLUS

DN 143:224763

IT Orientation of oxazolidinones in the active site of monoamine oxidase
 AU Jones, Tadeusz E. E.; Fleming, Paul; Eyermann, Charles J.; Gravestock,
 Michael B.; Ramsay, Rona R.
 CS Centre for Biomolecular Sciences, University of St. Andrews, St. Andrews,
 Fife, KT16 9ST, UK

SO Biochemical Pharmacology (2005), 70(3), 407-416
 CODEN: BCPCAM; ISSN: 0006-2952

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 143:224763

AB Oxazolidinone inhibitors of monoamine oxidase (MAO) and oxazolidinone
 antibacterials are two distinct classes of drug, often with linear
 structures and overlapping activities for some derivs. By synthesizing
 novel dimerized derivs. with identical substitution of the two C-5 side
 chains, we have obtained exptl. evidence for the orientation of
 oxazolidinones in the active site of MAO A. Two types of spectral
 changes, either increasing the absorbance at 510 nm or decreasing it at
 495 nm depending on the group nearest to the flavin cofactor, were seen on
 ligand binding to MAO A. Side chain derivs. with aniline substituents are
 very poor substrates so that it was possible to examine the spectral
 change due to binding of a substrate before reduction of the flavin occurred.
 Binding of these amino derivative substrates to MAO A induced a spectral
 change characterized by a strong decrease in absorbance at 495 nm. These
 substrates reduced the enzyme fully without any trace of a semiquinone
 intermediate. Only oxazolidinone inhibitors with a bromo-imidazole
 substituent increased the yield of semiquinone intermediate obtained
 during chemical reduction. In accord with the exptl. data, results of docking
 expts. showed that binding of the oxazolidinone ring in the aromatic cage
 close to the flavin was favored and that the nitrogen of the derivs. that
 were substrates was within van der Waals distance of N-5 of the flavin.

CC 7-3 (Enzymes)

IT 146-14-5, PAD 165800-03-3 168828-82-8 196298-80-3 196298-93-8

591232-14-3 862780-20-9 862780-21-0

862780-22-1

RL: BSU (Biological study, unclassified); PRP (Properties);

BIOL (Biological study)

(orientation of oxazolidinones in active site of monoamine oxidase)

IT 862780-23-2P 862780-24-3P 862780-25-4P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN

(Synthetic preparation); BIOL (Biological study); PREP

(Preparation)

(orientation of oxazolidinones in active site of monoamine oxidase)

IT 369-34-6, 3,4-Difluoronitrobenzene 501-53-1, Benzyl chloroformate

505-66-8 2873-74-7, Glutaryl chloride 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(orientation of oxazolidinones in active site of monoamine oxidase)

IT 862780-20-9 862780-21-0 862780-22-1

RL: BSU (Biological study, unclassified); PRP (Properties);

BIOL (Biological study)

(orientation of oxazolidinones in active site of monoamine oxidase)

RN 862780-20-9 HCAPLUS


CN Acetamide, N-[(5S)-3-(3-fluoro-4-pyrazinylphenyl)-2-oxo-5-
 oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 fluoro-4,1-phenylene) [(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (orientation of oxazolidinones in active site of monoamine oxidase)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-(3-fluoro-4-(1-piperazinyl)phenyl)-2-oxo-5-
 oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 AN 2005:519255 HCAPLUS
 DN 143:43872
 TI Preparation of oxazolidone derivatives for treatment of infectious diseases
 IN Yang, Yushu; Cui, Yingjie; Ji, Ruyun
 DA Shanghai Drug Inst., Chinese Academy of Sciences, Peop. Rep. China
 SO Faming Shuanli Shenqing Gongkai Shuomingshu, No pp. given
 CUDEN: CNKXEV
 DT Patent
 LA Chinese
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN-1510032	A	20040007	2002CN-0157735	20021225
PRAI 2002CN-0157735		20021225		
OS CASREACT 143:43872; MARPAT 143:43872				
GI				



AB The title compds. I [wherein R = (un)substituted piperazinyl or amino] and its pharmaceutically acceptable salts thereof are prepared for the treatment of infectious diseases. For example, the compound II was prepared. I showed strong antibacterial activity.
 IC ICM C07D-263/20
 CCS A61K-031/496; A61P-031/04
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT Section cross-reference(s): 1
 IT 232951-00-7P 595582-86-8P 595582-89-1P 716319-24-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of oxazolidone derivs. for treatment of infectious diseases)
 IT 189038-59-3P 232951-72-3P 595582-79-9P
 595582-80-2P 595582-81-3P 595582-82-4P
 595582-83-5P 595582-84-6P 595582-85-7P
 595582-87-9P 595582-88-0P 595582-90-4P
 595582-91-5P 595582-92-6P 665012-18-0P
 716319-15-2P 716319-16-3P 716319-17-4P
 716319-18-5P 716319-19-6P 716319-20-9P 716319-21-0P
 716319-22-1P 716319-23-2P 716319-25-4P 716319-26-5P 716319-27-6P
 716319-28-7P 716319-29-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazolidone derivs. for treatment of infectious diseases)
 IT 69-72-7, reactions 98-09-9, Benzenesulfonyl chloride 98-58-8 98-68-0
 98-74-8 103-71-9, reactions 103-72-0 121-51-7 1694-92-4
 3919-74-2 13734-34-4 16629-19-9, 2-Thiophenesulfonyl chloride


L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 595582-92-6P 665012-18-0P 716319-15-2P
 716319-16-3P 716319-17-4P 716319-18-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prep. of oxazolidone derivs. for treatment of infectious diseases)
 RN 189038-59-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(4-methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 595582-79-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(3-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-80-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(phenylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 40182-17-0 69399-79-7 154590-66-6 181997-31-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of oxazolidone derivs. for treatment of infectious diseases)
 IT 595582-86-8P 595582-89-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of oxazolidone derivs. for treatment of infectious diseases)
 RN 595582-86-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-89-1 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(4-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 189038-59-3P 595582-79-9P 595582-80-2P
 595582-81-3P 595582-82-4P 595582-83-5P
 595582-84-6P 595582-85-7P 595582-87-9P
 595582-88-0P 595582-90-4P 595582-91-5P

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 595582-81-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-82-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 595582-83-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(4-bromophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-84-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(2-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


Absolute stereochemistry.




RN 595582-88-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(2-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 595582-90-4 HCAPLUS
 CN Acetamide, N-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A



RN 595582-85-7 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(3-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 595582-87-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(2-thienyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A



RN 595582-91-5 HCAPLUS
 CN Acetamide, N-[3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-92-6 HCAPLUS
 CN Acetamide, N-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 665012-18-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-[(phenylamino)thioxomethyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 716319-15-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-{[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl}-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 716319-16-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-{4-(2-hydroxybenzoyl)-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 716319-17-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-{[3-(2-amino-1-oxo-3-phenylpropyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 716319-18-5 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-{(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidone derivs. for treatment of infectious diseases)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




L27 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2005:490361 HCAPLUS
 DN 143:26641
 TI An improved process for synthesis of (benzyloxycarbonylamino)phenyl)piperazine-1-carboxylic acid derivative, a key intermediate for preparation of antimicrobial oxazolidinone derivatives
 IN Kumar, Yatendra; Kaul, Vijay Kumar; Singh, Nitu; Yadav, Gyan Chand
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 23 pp.
 CODEN: PIIXX2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005051933	A1	20050609	2004MO-IN03829	20041123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TE, UA, US, US, VC, VN, YU, ZA, ZM, ZW PW: BW, CH, GM, KE, LG, MW, NE, NA, SD, SL, SE, TE, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2003IN-DE01499	A	20031128		
OS CASREACT 143:26641; MARPAT 143:26641				
GI				

L27 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB The invention relates to a preparation of (benzyloxycarbonylamino)phenyl)piperazine-1-carboxylic acid derivative of formula I, a key intermediate for preparation of antimicrobial (oxazolidinone)pyrazolecarboxylate derivs. (no data).
 The invention compound I was prepared via hydrogenation of tert-Bu 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate and subsequent N-carboxylation by benzyl chloroformate with a purity of 97-99% by HPLC.
 IC ICM C07D-263/21/20; A61K-031/496; A61P-031/04
 CCS 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 CC Section cross-reference(s): 45
 IT 154590-43-9P 853082-49-2P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (claimed; improved process for synthesis of (benzyloxycarbonylamino)phenyl)piperazine-1-carboxylic acid derivative useful as intermediate for preparation of antimicrobial oxazolidinone derivs.)
 IT 154590-43-9P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (claimed; improved process for synthesis of (benzyloxycarbonylamino)phenyl)piperazine-1-carboxylic acid derivative useful as intermediate for preparation of antimicrobial oxazolidinone derivs.)
 RN 154590-43-9 HCAPLUS
 CN Acetamide, N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2004:857593 HCAPLUS
 DN 141:332221
 TI Preparation of N-aryl-2-oxazolidinone-5-carboxamides as antibacterials.
 IN Harris, Christina Renee
 PA Pharmacia & Upjohn Company, USA
 SO PCT Int. Appl., 40 pp.
 CODEN: PIIXX2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004087697	A1	20041014	2004MO-IN00943	20040322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TE, UA, US, US, VC, VN, YU, ZA, ZM, ZW PW: BW, CH, GM, KE, LG, MW, NE, NA, SD, SL, SE, TE, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US2004204463	A1	20041014	2004US-0795192	20040305
CA---2520723	A1	20041014	2004CA-2520723	20040322
EP---1615917	A1	20060118	2004EP-072352	20040322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR2004009143	A	20060328	2004BR-009143	20040322
JP2006522093	T	20060928	2006JP-0506408	20040322
PRAI 2003US-459444P	P	20030401		
OS 2004MO-IN00943	W	20040322		
GI MARPAT 141:332221				

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT 773127-81-4P 773127-83-6P 773127-85-8P
 773127-87-0P 773127-88-1P 773127-89-2P
 773127-91-6P 773127-92-7P 773127-93-8P
 773127-94-9P 773127-96-1P 773127-97-2P
 773127-98-3P 773127-99-4P 773128-00-0P
 773128-01-1P 773128-02-2P 773128-03-3P
 773128-04-4P 773128-05-5P 773128-07-7P
 773128-08-8P 773128-09-9P 773129-09-2P
 773894-58-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USE5 (Uses)
 (claimed compound; preparation of arylloxazolidinonecarboxamides as antibacterials)
 IT 773128-10-2P 773128-11-3P 773128-12-4P
 773128-13-5P 773128-14-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USE5 (Uses)
 (preparation of arylloxazolidinonecarboxamides as antibacterials)
 IT 106-96-7, Propargyl bromide 696-07-1 2916-68-9 6089-09-4, 4-Pentynoic acid 13329-40-3 53293-00-8, 5-Hexynoic acid 69113-59-3, 3-Cyanolodobenzene 133430-99-6 154590-66-6 174649-07-1 263551-43-5, tert-Butyl 3-iodobenzyloxycarbamate 773128-22-6 773128-23-7 773128-24-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylloxazolidinonecarboxamides as antibacterials)
 IT 773127-81-4P 773127-83-6P 773127-85-8P
 773127-87-0P 773127-88-1P 773127-89-2P
 773127-91-6P 773127-92-7P 773127-93-8P
 773127-94-9P 773127-96-1P 773127-97-2P
 773127-98-3P 773127-99-4P 773128-00-0P
 773128-01-1P 773128-02-2P 773128-04-4P
 773128-05-5P 773128-07-7P 773128-08-8P
 773128-09-9P 773129-09-2P 773894-58-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USE5 (Uses)
 (claimed compound; preparation of arylloxazolidinonecarboxamides as antibacterials)
 RN 773127-81-4 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-[6-[3-(aminomethyl)phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)






Absolute stereochemistry.

PAGE 1-A








AB Title compds. [I; A = Q1-Q4; B = Q5, Q6; W = NHC(X)R1, Het, YHet; X = O, S; Y = NH, O, S; Z = R5C2tpbond; C(CH2)2E; E = CH2, CO; R1 = H, R62; (substituted) NHA, A, alkenyl, alkyl, alkoxy, alkylthio, cycloalkyl(alkyl); A = alkyl; R2 = H, halo, alkyl; R4 = H, Me, F; R5 = H, (substituted) aryl, heteroaryl; m, n = 0-4; m+n = 2-5; p = 1-3; r = 0-6; Q7 = (CH2)n; Q8 = (CH2)m; Q9 = (CH2)p] were prepared. Thus, 5-hexynoic acid was coupled to the corresponding piperazine derivative using diphenylphosphoryl azide and Hunig's base to give N-[[[(5S)-3-[3-fluoro-4-(4-hex-5-ynyl)piperazin-1-yl]phenyl]-2-oxo-5-oxazolidin-5-yl]methyl]acetamide. The latter showed a min. inhibitory concentration of 1 µg/mL against SPNE 9912.
 IC ICM C07D-413/12
 CCS C07D-413/10; C07D-263/20; A61K-031/496; A61P-031/04

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)







L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[5-(4-hydroxyphenyl)-1-oxo-4-pentynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 1-A



PAGE 2-A




PAGE 1-A



L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 773127-94-9 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[7-(3-hydroxyphenyl)-1-oxo-6-heptynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 773127-96-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[7-(4-hydroxyphenyl)-1-oxo-6-heptynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 773127-97-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[11-oxo-5-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)-4-pentynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 773127-98-3 HCAPLUS
 CN 4-Octynoic acid, 8-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-


L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-amino-8-oxo-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 773127-99-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-[5-[4-aminophenyl]-1-oxo-4-pentynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 773128-00-0 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[6-[4-[(methylamino)methyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 773128-01-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[6-[4-(1H-imidazol-1-ylmethyl)phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 773128-02-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-[6-[4-(4-acetylphenyl)-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 773128-04-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[[4-[6-[(4-[(1E)-1-(hydroxyimino)ethyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 773128-05-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[[4-[6-[(3-cyanophenyl)-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 773128-07-7 HCAPLUS
 CN L-Phenylalanine, 4-[6-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-6-oxo-1-hexynyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CPN 773128-06-6
 CMF C31 H36 F N5 O6


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CPN 76-05-1
 CMF C2 H F3 O2




RN 773128-08-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[[4-[6-[(3-(aminomethyl)phenyl)-1-oxo-5-hexynyl]-1-piperazinyl]-2,3,5-trifluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 773128-09-9 HCAPLUS

CN Acetamide, N-[(5S)-3-[4-[6-[4-(aminomethyl)phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-2,3,5-trifluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 773129-09-2 HCAPLUS

CN Acetamide, N-[(5S)-3-[4-[6-[4-(aminomethyl)phenyl]-1-oxo-6-heptynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 773894-58-9 HCAPLUS


CN Acetamide, N-[(5S)-3-[4-[6-[4-[(2-amino(hydroxyimino)methyl]phenyl)-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



● HCl

IT 773128-10-2P 773128-11-3P 773128-12-4P

773128-13-5P 773128-14-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloxadiazolidinonecarboxamides as antibacterials)

RN 773128-10-2 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(1-oxo-4-pentynyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 773128-11-3 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(3-phenyl-2-propynyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 773128-12-4 HCAPLUS


CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[6-[4-[(1E)-1-(hydroxyimino)ethyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



● HCl

RN 773128-13-5 HCAPLUS

CN Acetamide, N-[(5S)-3-[4-[4-[5-[3-(aminomethyl)phenyl]-1-oxo-4-pentynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 773128-14-6 HCAPLUS


CN Acetamide, N-[(5S)-3-[4-[4-[3-[3-(aminomethyl)phenyl]-2-propynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)


L27 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(prepn. of aryloxazolidinonecarboxamides as antibacterials)

RN 154590-66-6 HCAPLUS

CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:565227 HCAPLUS

DN 141:89083

TI Preparation of oxazolidine derivatives as bactericides

IN Yang, Yushe; Cui, Yingjie; Ji, Ruyun; Chen, Kaixian

PA Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China; Nanjing Chang'ao Pharmaceutical Science and Technology Limited Company

SO PCT Int. Appl., 34 pp.


COSEN: PIXXD2

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004058732	A1	20040715	2002WO-CN00928	20021230
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, PG, HU, SD, SE, SG, SK, SI, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KE, MD, NU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU2002357561	A1	20040722	2002AU-0357561	20021230
PRAI 2002WO-CN00928	A	20021230		
OS CASREACT 141:89083; MARPAT 141:89083				
GI				



AB Oxazolidines I (R = 4-R1-piperazin-1-yl, NR2R3; R1 = optionally substituted alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl derived from amino acid, arylcarbonyl, arylaminocarbonyl, arylaminothiocarbonyl; R2 is optionally substituted alkylsulfonyl, arylsulfonyl, arylcarbonyl, heteroarylsulfonyl; R3 = H, alkyl) and their salts, useful as bactericides, are prepared I R = 4-(3-aminophenylsulfonyl)-1-piperazinyl was prepared and showed bactericidal activity superior to that of linezolid.

ICM C07D-263/20

ICS C07D-413/12; C07D-417/12; A61K-031/497; A61K-031/421; A61K-031/422

28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 232951-00-7P 595582-79-9P 595582-84-6P

595582-85-7P 595582-86-8P 595582-88-0P

595582-89-1P 716319-23-2P 716319-24-3P 716319-25-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent)

(preparation of oxazolidine derivs. as bactericides)

IT 189038-59-3P 232951-72-3P 595582-80-2P

595582-81-3P 595582-82-4P 595582-83-5P

595582-87-9P 595582-90-4P 595582-91-5P

595582-92-6P 665012-18-0P 716319-15-2P

716319-16-3P 716319-17-4P 716319-18-5P

716319-19-6P 716319-20-9P 716319-21-0P

716319-27-6P 716319-28-7P 716319-29-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)


(preparation of oxazolidine derivs. as bactericides)

IT 98-09-9, Phenyl sulfonyl chloride 98-58-8, 4-Bromo phenyl sulfonyl

chloride 98-59-9, 4-Methyl phenyl sulfonyl chloride 98-68-0, 4-Methoxy

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 phenyl sulfonyl chloride 98-74-8, 4-Nitro phenyl sulfonyl chloride
 103-72-0 121-51-7, 3-Nitro phenyl sulfonyl chloride 1694-92-4, 2-Nitro
 phenyl sulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl chloride
 63-91-2, L-Phenylalanine, reactions 49-72-7, 2-Hydroxybenzoic acid,
 reactions 103-71-9, Phenyl isocyanate, reactions 594-44-5,
 Ethanesulfonyl chloride 3919-74-2 5538-51-2, 2-Acetoxybenzoyl chloride
 154590-66-6 181997-31-9
 RL: RCT (Reactant)
 (prepn. of oxazolidine derivs. as bactericides)
 IT 595582-79-9P 595582-84-6P 595582-85-7P
 595582-86-8P 595582-88-0P 595582-89-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN
 (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidine derivs. as bactericides)
 RN 595582-79-9 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(3-aminophenyl)sulfonyl]-1-piperazinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-84-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(2-nitrophenyl)sulfonyl]-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 595582-85-7 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(3-nitrophenyl)sulfonyl]-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-86-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(4-nitrophenyl)sulfonyl]-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.




RN 595582-88-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(2-aminophenyl)sulfonyl]-1-piperazinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 595582-89-1 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(4-aminophenyl)sulfonyl]-1-piperazinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 189038-59-3P 595582-80-2P 595582-81-3P
 595582-82-4P 595582-83-5P 595582-87-9P
 595582-90-4P 595582-91-5P 595582-92-6P
 665012-18-0P 716319-15-2P 716319-16-3P
 716319-17-4P 716319-18-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)

(preparation of oxazolidine derivs. as bactericides)
 RN 189038-59-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-80-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(phenylsulfonyl)-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 595582-81-3 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-82-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 595582-83-5 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[(4-bromophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 595582-87-9 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[(2-thienyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.




L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 595582-90-4 HCAPLUS
 CN Acetamide, N-([2-[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



PAGE 2-A

RN 595582-91-5 HCAPLUS
 CN Acetamide, N-([3-[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-92-6 HCAPLUS

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 665012-18-0 HCAPLUS
 CN Acetamide, N-([4-[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-18-0 HCAPLUS
 CN Acetamide, N-([4-[[4-[(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 716319-15-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 716319-16-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(2-hydroxybenzoyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 716319-17-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(2S)-2-amino-1-oxo-3-phenylpropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L27 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 716319-18-5 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of oxazolidine derivs. as bactericides)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:453033 HCAPLUS
 DN 141:23519
 TI Preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivatives for therapeutic use as antibacterial agents
 IN Harris, Christina R.; Hester, Jackson Boling, Jr.
 PA Pharmacia & Upjohn Company, USA
 SO PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN: CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004045616	A1	20040603	2003WO-IB05355	20031119
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NI, NO, NE, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TR, TT, TZ, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, ME, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2502017	A1	20040603	2003CA-2502017	20031119
AU2003280143	A1	20040615	2003AU-0280143	20031119
US2004142839	A1	20040722	2003US-017237	20031119
US---7141570	B2	20061128		
EP---1565186	A1	20050824	2003EP-0772516	20031119
EP---1565186	B1	20061102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR2003016483	A	20051011	2003BR-0016483	20031119
JP2006509035	T	20060316	2004JP-0570322	20031119
AT---344036	T	20061115	2003AT-0772516	20031119
ES---2271660	T3	20070416	2003ES-0772516	20031119
MX200509A05472	A	20050725	2005MX-PA05472	20050523
PPAI 2002US-428025P	P	20021121		
2003US-445530P	P	20030206		
2003WO-IB05355	W	20031119		
OS MAPPAT 141:23519				
GI				



AB Oxazolidinone-5-carboxamide derivs., such as I [R = amine substituted Ph or phthalimido; R1 = H, F; R2 = acyl or thioacyl; X = alkylene or heteroalkyl linking group;], were prepared for use in pharmaceutical compns. as antibacterial agents. Thus, thioamide II (R2 = CSCH2Me, R3 = NMe2) was prepared via a reaction sequence which comprised an N-acylation reaction of [(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]carbamic acid 1,1-dimethylethyl ester with 4-(hydroxymethyl)phenoxyacetic acid to give alc. II (R2 = CO2Me3, R3 = OH), followed by conversion of the alc. to the corresponding bromide II (R2 = CO2Me3, R3 = Br), amination of the bromide with Et2NH to give monoprotected-amine II (R2 = CO2Me3, R3 = NMe2), deprotection to form amine II (R2 = H, R3 = NMe2) and, finally, thioacylation of the amine with MeCH2CS2Et to give the target thioamide. The prepared carboxamides were

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 assayed for inhibitory activity against a panel of organisms, such as *S. aureus*, *S. pneumonia* and *H. influenzae*.
 IC ICM A61K-031/496
 CCS A61K-031/422; A61K-031/5355; C07D-263/20; C07D-413/10
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 10, 63
 IT 697804-57-2P 697804-60-7P 697804-62-9P 697804-65-2P
 697804-92-5P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)
 IT 697804-53-2P 697804-54-3P 697804-55-4P
 697804-26-5P 697804-27-6P 697804-28-7P
 697804-29-8P 697804-30-1P 697804-31-2P
 697804-32-3P 697804-33-4P 697804-34-5P
 697804-35-6P 697804-36-7P 697804-37-8P
 697804-38-9P 697804-39-0P 697804-40-3P
 697804-41-4P 697804-42-5P 697804-43-6P
 697804-44-7P 697804-46-9P 697804-48-1P
 697804-49-2P 697804-50-5P 697804-51-6P
 697804-52-7P 697804-53-8P 697804-54-9P
 697804-55-0P 697804-56-1P 697804-58-2P
 697804-59-4P 697804-61-8P 697804-63-0P 697804-64-1P
 697804-66-3P 697804-67-4P 697804-68-5P
 697804-69-6P 697804-71-0P 697804-72-1P
 697804-73-2P 697804-74-3P 697804-75-4P
 697804-76-5P 697804-77-6P 697804-78-7P
 697804-79-8P 697804-80-1P 697804-81-2P
 697804-82-3P 697804-83-4P 697804-84-5P
 697804-85-6P 697804-86-7P 697804-87-8P
 697804-88-9P 697804-89-0P 697804-90-3P
 697804-91-4P 697804-93-6P 697804-94-7P
 697804-95-8P 697804-96-9P 697804-97-0P
 697804-98-1P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)
 IT 56-40-6, Glycine, reactions 103-84-4, Acetanilide 105-56-6, Ethyl cyanoacetate 107-95-9, β -Alanine 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 109-01-3, N-Methylpiperazine 109-89-7, Diethylamine, reactions 110-91-8, Morpholine, reactions 123-62-6, Propionic anhydride 298-12-4, Glyoxylic acid 350-46-9, 1-Fluoro-4-nitrobenzene 577-59-3, o-Nitroacetophenone 870-73-5, Ethyl dithioacetate 998-79-8, Ethyl dithiopropionate 1118-68-9, N,N-Dimethylglycine 1138-80-3 1142-20-7 3984-34-7, 3-(4-Chlorobenzoyl)propionic acid 4521-28-2, 4-(4-Methoxyphenyl)butanoic acid 4530-20-5 4619-20-9, 4-(4-Methylphenyl)-4-oxobutanoic acid 5415-95-2, Methyl dithiopropionate 5466-44-2, 4-Nitrophthalic anhydride 5600-62-4, 4-(4-Nitrophenyl)butanoic acid 6328-00-3 6340-79-0, 3-(4-Bromobenzoyl)propionic acid 29022-11-5 68858-21-9, 4-(Hydroxymethyl)phenylacetic acid 87512-31-0 100632-57-3 103321-49-9 103321-50-2 154590-66-6 174649-07-1 188974-04-1 273376-95-7 345224-36-4, Ethyl cyclopropanecarboxylthioate 415684-05-8 570390-86-2, O-(3,3-Diphenylpropyl) difluoroethanethioate 610356-04-9 697806-14-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)
 IT 697804-57-2P 697804-65-2P 697804-92-5P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 697804-23-2P 697804-24-3P 697804-25-4P
 697804-26-5P 697804-27-6P 697804-28-7P
 697804-29-8P 697804-30-1P 697804-31-2P
 697804-32-3P 697804-33-4P 697804-34-5P
 697804-35-6P 697804-36-7P 697804-37-8P
 697804-38-9P 697804-39-0P 697804-40-3P
 697804-41-4P 697804-42-5P 697804-43-6P
 697804-44-7P 697804-46-9P 697804-48-1P
 697804-49-2P 697804-50-5P 697804-51-6P
 697804-52-7P 697804-53-8P 697804-54-9P
 697804-55-0P 697804-56-1P 697804-58-2P
 697804-66-3P 697804-67-4P 697804-68-5P
 697804-69-6P 697804-71-0P 697804-72-1P
 697804-73-2P 697804-74-3P 697804-75-4P
 697804-76-5P 697804-77-6P 697804-78-7P
 697804-79-8P 697804-80-1P 697804-81-2P
 697804-82-3P 697804-83-4P 697804-84-5P
 697804-85-6P 697804-86-7P 697804-87-8P
 697804-88-9P 697804-89-0P 697804-90-3P
 697804-91-4P 697804-93-6P 697804-94-7P
 697804-95-8P 697804-96-9P 697804-97-0P
 697804-98-1P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)
 RN 697804-23-2 HCAPLUS
 CN Propanethioamide, N-[(5S)-3-[4-[4-[(4-(diethylamino)methyl]phenoxy)acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 697804-57-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(4-(aminomethyl)phenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)
 Absolute stereochemistry.
 RN 697804-65-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[4-(4-methoxyphenyl)-1-oxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)
 Absolute stereochemistry.



RN 697804-92-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[4-(3-nitrophenyl)-1,4-dioxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

RN 697804-24-3 HCAPLUS
 CN Piperazine, 1-[4-[(5S)-5-[(cyclopropylthiomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(4-[(diethylamino)methyl]phenoxy)acetyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

PAGE 1-A




L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 697804-25-4 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-[(diethylamino)methyl]phenoxy]acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-26-5 HCAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[4-[4-[(dimethylamino)methyl]phenoxy]acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 697804-27-6 HCAPLUS
 CN Piperazine, 1-[[4-[(5S)-5-[[[(cyclopropylthio)methyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[[4-[(dimethylamino)methyl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 697804-28-7 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-[(dimethylamino)methyl]phenoxy]acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-29-8 HCAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(4-morpholinyl)methyl]phenoxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 697804-30-1 HCAPLUS
 CN Piperazine, 1-[[4-[(5S)-5-[[[(cyclopropylthio)methyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[[4-[(4-morpholinyl)methyl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 697804-31-2 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(4-morpholinyl)methyl]phenoxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 697804-32-3 HCAPLUS
 CN Propanethioamide, N-([(5S)-3-[3-fluoro-4-{4-[(4-methyl-1-piperazinyl)methyl]phenoxy}acetyl]-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 697804-33-4 HCAPLUS
 CN Piperazine, 1-[4-[(5S)-5-[(cyclopropylthiomethyl)amino]methyl]-2-oxo-3-


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 697804-35-6 HCAPLUS
 CN Propanethioamide, N-([(5S)-3-[4-{4-[(4-(dimethylamino)methyl]phenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 697804-36-7 HCAPLUS
 CN Piperazine, 1-[4-[(5S)-5-[(cyclopropylthiomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[4-{4-[(dimethylamino)methyl]phenyl}-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 oxazolidinyl]-2-fluorophenyl]-4-[4-{4-methyl-1-piperazinyl)methyl]phenoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 697804-34-5 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-[(4-methyl-1-piperazinyl)methyl]phenoxy}acetyl]-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




PAGE 2-A



RN 697804-37-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-{4-[(4-(dimethylamino)methyl]phenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-38-9 HCAPLUS
 CN Propanethioamide, N-([(5S)-3-[3-fluoro-4-{4-[(4-morpholinyl)methyl]phenyl]-1,4-dioxobutyl]-1-piperazinyl]phenyl)-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

RN 697804-39-0 HCAPLUS
 CN Acetamide, N-([4-(5S)-3-[3-fluoro-4-[4-[4-(4-morpholinylmethyl)phenyl]-1,4-dioxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-40-3 HCAPLUS
 CN Piperazine, 1-[4-[(5S)-5-[(cyclopropylthiomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[4-[4-(4-morpholinylmethyl)phenyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 697804-43-6 HCAPLUS
 CN Acetamide, N-([4-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl]-2-(dimethylamino)-N-methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-44-7 HCAPLUS
 CN Acetamide, N-([4-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl]-2-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

RN 697804-41-4 HCAPLUS
 CN Acetamide, N-([4-(5S)-3-[3-fluoro-4-[4-[4-(4-morpholinylmethyl)phenyl]-1,4-dioxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-42-5 HCAPLUS
 CN Acetamide, N-([4-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



RN 697804-46-9 HCAPLUS
 CN Acetamide, 2-(dimethylamino)-N-([4-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 697804-48-1 HCAPLUS
 CN Propanamide, 2-amino-N-([4-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 697804-49-2 HCAPLUS
 CN Acetamide, N-([4-[4-[2-fluoro-4-((5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 697804-51-6 HCAPLUS
 CN 1-Alaninamide, 1-alanyl-N-([4-[4-[4-((5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 697804-52-7 HCAPLUS
 CN Acetamide, N-([4-[4-[4-((5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-53-8 HCAPLUS
 CN Acetamide, N-([4-[4-[4-((5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

RN 697804-54-9 HCAPLUS
 CN Acetamide, N-([4-[4-[4-((5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-55-0 HCAPLUS
 CN Propanethioamide, N-([4-[4-[4-((5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 697804-56-1 HCAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[4-[4-(4-(aminomethyl)phenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 697804-68-5 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-(4-(4-bromophenyl)-3,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.



RN 697804-69-6 HCAPLUS
 CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(4-(4-bromophenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A




RN 697804-58-3 HCAPLUS
 CN Acetamide, N-[[[(4S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]methyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.



RN 697804-66-3 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[4-(4-hydroxyphenyl)-1-oxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-67-4 HCAPLUS
 CN Piperazine, 1-[4-[(5S)-5-[(2,2-difluoro-1-thioxoethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[4-(4-methoxyphenyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

RN 697804-71-0 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[4-(4-(4-cyanophenyl)-3,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-72-1 HCAPLUS
 CN Benzanide, 4-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 697804-73-2 HCAPLUS
 CN Benamide, 4-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxobutyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 697804-74-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-(4-chlorophenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 [(methylsulfonyl)amino]phenyl]-1,4-dioxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

RN 697804-77-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[4-[(methylsulfonyl)amino]phenyl]-1,4-dioxobutyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-78-7 HCAPLUS
 CN Acetamide, N-[4-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]- (CA INDEX NAME)

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


Absolute stereochemistry.



RN 697804-75-4 HCAPLUS
 CN Ethanethioamide, N-[(5S)-3-[4-[4-(4-chlorophenyl)-1,4-dioxobutyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 697804-76-5 HCAPLUS
 CN Propanethioamide, N-[(5S)-3-[3-fluoro-4-[4-[4-(4-

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 697804-79-8 HCAPLUS
 CN Acetamide, 2-amino-N-[4-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A


RN 697804-80-1 HCAPLUS
 CN Acetamide, N-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.



RN 697804-81-2 HCAPLUS
 CN Propanamide, N-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]-2-amino-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 697804-82-3 HCAPLUS
 CN Propanamide, 2-amino-N-[4-[4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 697804-84-5 HCAPLUS
 CN Acetamide, N-[4-[5-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,5-dioxopentyl]phenyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 697804-83-4 HCAPLUS
 CN Acetamide, 2-amino-N-[4-[5-[4-[4-[(5S)-5-[(2,2-difluoro-1-thioxopropyl)amino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,5-dioxopentyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A


RN 697804-85-6 HCAPLUS
 CN Acetamide, N-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-4-oxobutyl]phenyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.



RN 697804-86-7 HCAPLUS
 CN Acetamide, 2-amino-N-[4-[4-[4-2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino)methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-4-oxobutyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-87-8 HCAPLUS
 CN Propanamide, 2-amino-N-[4-[4-[4-2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxopropyl)amino)methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-4-oxobutyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 697804-88-9 HCAPLUS
 CN Acetamide, N-[4-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-4-oxobutyl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-89-0 HCAPLUS
 CN Acetamide, 2-(dimethylamino)-N-[3-[4-[4-[(2S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-4-oxobutyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 697804-90-3 HCAPLUS
 CN Acetamide, N-[3-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-hydroxy-4-oxobutyl]phenyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.




RN 697804-91-4 HCAPLUS
 CN Acetamide, 2-amino-N-[3-[4-[4-[(5S)-5-[(2,2-difluoro-1-thioxoethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




||
S

PAGE 2-A

RN 697804-93-6 HCAPLUS
 CN Acetamide, N-[3-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1,4-dioxobutyl]phenyl]-2-amino- (CA INDEX NAME)


Absolute stereochemistry.



RN 697804-94-7 HCAPLUS
 CN Acetamide, N-[3-[4-[4-[(2S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 697804-95-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[4-[(5-amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1-piperazinyl]-2-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697804-96-9 HCAPLUS
 CN Acetamide, N-[2-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxo-5-oxazolidinyl]methyl]-2-amino- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
PAGE 1-B


NHAc

RN 697804-97-0 HCAPLUS
CN Acetamide, 2-amino-N-[2-[3-[4-[(5S)-5-[(2,2-difluoro-1-thioxoethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3-oxopropyl]-2,3-dihydro-1,3-dioxo-1H-isindol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 697804-98-1 HCAPLUS
CN Propanamide, N-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-3,4-dioxobutyl]phenyl]methyl]-2-amino-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



IT 154590-66-6 612056-04-9
RL: ACT (Reactant); RACT (Reactant or reagent)
(preparation of N-[[4-(piperazin-1-yl)-phenyl]-2-oxazolidinone-5-carboxamide derivs. for therapeutic use as antibacterial agents)
RN 154590-66-6 HCAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612056-04-9 HCAPLUS
CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
AN 2004:162853 HCAPLUS
DN 140:217664
TI Preparation of piperazinophenyl-substituted oxazolidinones as antibacterial agents
IN Agarwal, Shiv Kumar; Guha, Mrinal Kanti; Pandey, Surendrakumar
PA Satyanarayan; Samuel, Matte Marianne
SO Orchid Chemicals & Pharmaceuticals Ltd, India
50 PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN,CMI 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004018439	A1	20040304	2003WO-IB03459	20030821
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BG, BH, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NI, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SJ, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
PM:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KE, MD, NU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN2002MA00618	A	20050304	2002IN-MA00618	20020822
CN--2531416	A1	20040304	2003CN-2531416	20030821
AU2003253141	A1	20040311	2003AU-0253141	20030821
EP--1578734	A1	20050928	2003EP-0792559	20030821
R:	AZ, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US2005070526	A1	20050331	2003US-0469648	20030903
US--7217726	B2	20070515		
US2007167414	A1	20070719	2007US-0729856	20070330
PPAI 2002IN-MA00618	A	20020822		
2003WO-IB03459	W	20030821		
2003US-0469648	A3	20030903		
OS MAPPAT 140:217664				
GI				



AB The present invention provides piperazinophenyl-substituted oxazolidinones (shown as I; variables defined below; all examples are oxazolidinones, e.g. II), their derivs., analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them, methods for their preparation, and their use against infections, particularly bacterial infections. Min. inhibitory concns. were obtained for 12 examples of I for Staphylococcus aureus, Enterococcus faecalis, Moraxella catarrhalis and Staphylococcus epidermidis. Characterization data and/or preparative details are given for 51 examples of I and 39 intermediates. For example, II was prepared in 81% yield from N-[[[(S)-3-[3-fluoro-4-[4-(thiophen-3-ylcarbonyl)piperazin-1-

127 ANSWER 21 of 26 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ylphenyl]-2-oxooxazolidin-5-yl)methylacetamide using lawesson's reagent; the reactant was prep'd. in 10 steps starting with substitution of 3,4-difluoronitrobenzene by piperazine (984) and followed by N-protection with Boc, redn, amination, carbamate formation with (984), chloroformate, cyclization with (R)-glycidyl butyrate to give [(R)-3-[3-fluoro-4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl]methanol, conversion to mesylate, conversion to azide, redn, acetylation, deprotection, and acylation with thiophene-3-carboxylic acid (544). For i: 21 and 22 = 0 or 5; R¹ = halogen, arido, nitro, cyano, xR6 (X = 0 or 5; R⁶ = H, formyl, (un)substituted (C1-C6)alkyl, cycloalkyl, aryl, aralkyl, aryl, thioalkyl, heteroaryl, heteroalkyl, arylsulfonyl, aralkylsulfonyl, N(R7aR7b) (R7a and R7b = H, formyl, (un)substituted (C1-C6)alkyl, aryl, aralkyl, heteroaryl, heteroalkyl or an amino acid residue which is attached through acid moiety, or R7a and R7b together with N = mono or bicyclic (unsatd. ring system which may contain 21 O, 5 or N), or -NHC(X)R8 (X = 0 or 5; R8 is H, (un)substituted (C1-C6)alkyl, (C1-C6)alkoxy, aryl, (C3-C6)cycloalkyl, amino, monalkylamino, dialkylamino, cycloalkylamino, arylamino, aracylamino, alkylcarbonylamino, arylcarbonylamino, heteroaryl, heterocyclyl, heteroalkyl, heteroarylamino, or R1 is NHS(0)p(C1-C4)alkyl, -NHS(0)p(C1-C4)aryl or -NHS(0)p(C1-C4)heteroaryl (p = 0-2), R2 and R3 = H, halogen, hydroxy, alkyl, alkoxy; R4 and R5 = H, cyano, nitro, amino, halogen, hydroxy, (un)substituted (C1-C6)alkyl, haloalkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C3-C6)cycloalkyl or either of R4 or R5 = oxo or thiooxo; n = 0-2; when 22 = 5, Y1 = NHSR or (un)substituted cycloalkyl, aryl, 5-7 membered heteroaryl, heterocyclyl (attached through C atom), heteroarylalkenyl, heterocyclylalkenyl; wherein R9 = H or (un)substituted alkyl, aryl, alkoxy, alkenyl, cycloalkyl, heteroaryl or heterocyclyl; when 22 = 0, A = NHSR, where R9 = Rn substituted by nitro; (un)substituted alkoxy, alkenyl, cycloalkyl, heteroaryl or heterocyclyl group. M = 0-2; n = 0-4, with a proviso that when n is 0, R9 does not = H or alkyl.

IC ICM C07D-263/22
 IC5 C07D-413/12; A61K-031/44; A61P-031/04
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 CC Section cross-reference(s): 1, 10, 63
 IT 665011-67-6P, N-[(5)-(3-[3-fluoro-4-[4-(pyrazin-2-yl)carbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylacetamide 665011-68-7P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylpyrazin-2-yl)carbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylacetamide
 RU: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of piperazinophenyl-substituted oxazolidinones as antibacterial agents)

IT 665011-72-3P, N-[(5)-(3-[3-fluoro-4-[4-(thiophen-3-ylthiocarbonyl)piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-73-4P, N-[(5)-(3-[3-fluoro-4-[4-(pyrrolidin-2-yl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide hydrochloride 665011-74-5P, N-[(5)-(3-[3-fluoro-4-[4-(5-nitrofuran-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-75-6P, N-[(5)-(3-[3-fluoro-4-[4-(aminothiazolid-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide hydrochloride 665011-76-7P, N-[(5)-(3-[3-fluoro-4-[4-(4-(N,N-dimethylamino)phenyl]thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-78-9P, N-[(5)-(3-[3-fluoro-4-[4-(4-nitrophenyl)carbamidol]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-81-4P, N-[(5)-(3-[3-fluoro-4-[4-(4-nitrophenyl)carbamidol]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-80-3P, N-[(5)-(3-[3-fluoro-4-[4-(4-morpholin-4-ylcarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-82-5P, N-[(5)-(3-[3-fluoro-4-[4-(quinolin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-83-6P, N-[(5)-(3-[3-fluoro-4-[4-(thiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-84-7P, N-[(5)-(3-[3-fluoro-4-[4-(quinolin-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-

127 ANSWER 21 of 26 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 yl]methylthioacetamide 665011-85-8P, N-[(5)-(3-[3-fluoro-4-[4-(5-nitrofuran-2-yl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-86-9P, N-[(5)-(3-[3-fluoro-4-[4-(cyclopentylthio)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-87-0P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylthiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-88-1P, N-[(5)-(3-[3-fluoro-4-[4-(5-chlorothiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-89-2P, N-[(5)-(3-[3-fluoro-4-[4-(3-methylthiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-90-5P, N-[(5)-(3-[3-fluoro-4-[4-(2-chloropyridin-3-yl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-91-6P, N-[(5)-(3-[3-fluoro-4-[4-(3-chlorothiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-92-7P, N-[(5)-(3-[3-fluoro-4-[4-(5-bromothiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-93-9P, N-[(5)-(3-[3-fluoro-4-[4-(thiophen-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-94-9P, N-[(5)-(3-[3-fluoro-4-[4-(pyrazin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-95-0P, N-[(5)-(3-[3-fluoro-4-[4-(phenylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665011-96-1P, N-[(5)-(3-[3-fluoro-4-[4-(6-chloropyridin-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-00-0P, N-[(5)-(3-[3-fluoro-4-[4-(cyclobutylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-01-1P, N-[(5)-(3-[3-fluoro-4-[4-(cyclopentylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-02-2P, N-[(5)-(3-[3-fluoro-4-[4-(imidazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-03-3P, N-[(5)-(3-[3-fluoro-4-[4-(pyrrolidin-2-yl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-04-4P, N-[(5)-(3-[3-fluoro-4-[4-(5-pyrrolidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-05-5P, N-[(5)-(3-[3-fluoro-4-[4-(aminothiazolid-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide hydrochloride 665012-06-6P, N-[(5)-(3-[3-fluoro-4-[4-(3-chloro-4-methylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-07-7P, N-[(5)-(3-[3-fluoro-4-[4-(3,4-dichlorophenyl]thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-08-8P, N-[(5)-(3-[3-fluoro-4-[4-(4-cyanophenyl]thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-09-9P, N-[(5)-(3-[3-fluoro-4-[4-(cyclopropylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-10-2P, N-[(5)-(3-[3-fluoro-4-[4-(cyclohexylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-11-3P, N-[(5)-(3-[3-fluoro-4-[4-(pyridin-3-yl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-12-4P, N-[(5)-(3-[3-fluoro-4-[4-(cyclopentylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-13-5P, N-[(5)-(3-[3-fluoro-4-[4-(cyclohexylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-14-6P, N-[(5)-(3-[3-fluoro-4-[4-(4-nitrophenylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-15-7P, N-[(5)-(3-[3-fluoro-4-[4-(benzoylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-16-8P, N-[(5)-(3-[3-fluoro-4-[4-(3-benzoylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-17-9P, N-[(5)-(3-[3-fluoro-4-[4-(2-propenylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-18-0P, N-[(5)-(3-[3-fluoro-4-[4-

127 ANSWER 21 of 26 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 (phenyl)thiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-19-1P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-20-4P, N-[(5)-(3-[3-fluoro-4-[4-(4-nitrophenyl)carbamidol]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-21-5P, N-[(5)-(3-[3-fluoro-4-[4-(benzoylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-22-6P, N-[(5)-(3-[3-fluoro-4-[4-(3-benzoylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-23-7P, N-[(5)-(3-[3-fluoro-4-[4-(2-propenyl)carbamidol]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-24-8P, N-[(5)-(3-[3-fluoro-4-[4-(imidazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-25-9P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,2,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-26-0P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,2,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-27-1P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-28-2P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-29-3P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-30-4P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-31-7P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-oxadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-32-8P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-oxadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-33-9P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-oxadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-34-0P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-oxadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-35-1P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-thiadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-36-2P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-thiadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-37-3P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-oxadiazol-2-ylthioacetyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-38-4P, N-[(5)-(3-[3-fluoro-4-[4-(1,3,4-oxadiazol-2-ylthioacetyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-39-5P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylimidazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-40-6P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylimidazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-41-9P, N-[(5)-(3-[3-fluoro-4-[4-(1,2,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-42-0P, N-[(5)-(3-[3-fluoro-4-[4-(1,2,4-triazol-3-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-43-1P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-44-2P, N-[(5)-(3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-45-3P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylthiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-46-4P, N-[(5)-(3-[3-fluoro-4-[4-(5-methylthiazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-47-5P, N-[(5)-(3-[3-fluoro-4-[4-(oxazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-48-6P, N-[(5)-(3-[3-fluoro-4-[4-(oxazol-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-49-7P, N-[(5)-(3-[3-fluoro-4-[4-(2-methoxyoxazol-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-50-0P, N-[(5)-(3-[3-fluoro-4-[4-(2-methoxyoxazol-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-51-3P, N-[(5)-(3-[3-fluoro-4-[4-(2-aminothiazolid-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-52-2P, N-[(5)-(3-[3-fluoro-4-[4-(2-aminothiazolid-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-

127 ANSWER 21 of 26 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 yl]methylthioacetamide 665012-53-3P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-54-4P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-55-5P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-56-6P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-57-7P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-58-8P, N-[(5)-(3-[3-fluoro-4-[4-(piperidin-2-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-59-9P, N-[(5)-(3-[3-fluoro-4-[4-(oxazol-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 665012-60-2P, N-[(5)-(3-[3-fluoro-4-[4-(oxazol-5-ylthiocarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prep'n of piperazinophenyl-substituted oxazolidinones as antibacterial agents)

IT 88-13-1, Thiophene-3-carboxylic acid 98-88-4, Benzoyl chloride 100-28-7, 4-Nitrophenyl isocyanate 110-85-0, Piperazine, reactions 369-34-6, 3,4-Difluoronitrobenzene 501-53-1, Benzyl chloroformate 521-72-0, Thiophene-2-carboxylic acid 645-12-5, Nitrofluoroacetic acid 231-61-5, 4-Nitrobenzyl isocyanate 4023-34-4, N-Dimethylamino-phenyl isothiocyanate 4023-34-4, Cyclopropylcarbamoyl chloride 4530-20-5, N-(tert-butoxycarbonyl)glycine 5006-22-4, Cyclopropylcarbamoyl chloride 15159-40-7, 4-Morpholinocarbonyl chloride 15161-39-4, N-(tert-butoxycarbonyl)-L-proline 60456-26-0, (R)-Glycidyl butyrate 221201-21-4, N-[(R)-3-[3-fluoro-4-(piperazin-1-yl)phenyl]-2-oxooxazolidin-5-yl]methylthioacetamide 665012-04-9, N-[(5)-(3-[3-fluoro-4-(piperazin-1-yl)phenyl]-2-oxooxazolidin-5-yl]methylthioacetamide 665011-77-8, 2-[(5)-(3-[4-[4-(benzoylthiocarbonyl]piperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthioacetamide 665011-79-0, 2-[(5)-(3-[4-(tert-butoxycarbonyl]piperazin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methylthioacetamide
 RU: RCT (Reactant)
 (preparation of piperazinophenyl-substituted oxazolidinones as antibacterial agents)

IT 154590-33-7P, 3-Fluoro-4-(piperazin-1-yl)nitrobenzene 154590-34-8P, 3-Fluoro-4-[4-(tert-butoxycarbonyl]piperazin-1-yl]nitrobenzene 154590-35-9P, 3-Fluoro-4-[4-(tert-butoxycarbonyl]piperazin-1-yl]aniline 154590-36-0P, Benzyl 3-Fluoro-4-[4-(tert-butoxycarbonyl]piperazin-1-yl]methylthioacetamide 154590-62-2P, [(R)-3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl]methanol 154590-63-3P, [(R)-3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl]methylthioacetamide 154590-64-4P, [(R)-3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl]methylthioacetamide 154590-65-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-66-6P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-67-7P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-68-8P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-69-9P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-70-0P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-71-1P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-72-2P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-73-3P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-74-4P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-75-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-76-6P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-77-7P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-78-8P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-79-9P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-80-0P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-81-1P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-82-2P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-83-3P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-84-4P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-85-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-86-6P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-87-7P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-88-8P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-89-9P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-90-0P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-91-1P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-92-2P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-93-3P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-94-4P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-95-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-96-6P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-97-7P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-98-8P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-99-9P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-100-0P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-101-1P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-102-2P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-103-3P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-104-4P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-105-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-106-6P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-107-7P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-108-8P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-109-9P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-110-0P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-111-1P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-112-2P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-113-3P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-114-4P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-115-5P, N-[(5)-(3-[3-fluoro-4-(tert-butoxycarbonyl]piperazin-1-yl]phenyl)-2-oxooxazolidin-5-yl]methylthioacetamide 154590-116-6P, N-[(5)-(3-[3-fluoro-4-(tert-b

027 ANSMER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STDN (Continued)

yl)methylacetamide 665011-49-4P, N-[(S)-[3]-Fluoro-4-[4-(5-bromothien-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-50-7P, N-[(S)-[3]-Fluoro-4-[4-(pyrazin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-51-8P, N-[(S)-[3]-Fluoro-4-[4-(6-chloropyridin-3-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-52-9P, N-[(S)-[3]-Fluoro-4-[4-(5-methylpyridin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-53-0P, N-[(S)-[3]-Fluoro-4-[4-(5-methylpyridin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-54-1P, N-[(S)-[3]-Fluoro-4-[4-(cyclobutylcarbamoyl)piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-55-2P, N-[(S)-[3]-Fluoro-4-[4-(quinolin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-56-3P, N-[(S)-[3]-Fluoro-4-[4-(quinolin-3-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-57-4P, N-[(S)-[3]-Fluoro-4-[4-(cyclopentylcarbamoyl)piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-58-5P, N-[(S)-[3]-Fluoro-4-[4-(benzyl)piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-59-6P, N-[(S)-[3]-Fluoro-4-[4-(cyclobutylcarbamoyl)piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-60-9P, N-[(S)-[3]-Fluoro-4-[4-(cyclopentylcarbamoyl)piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-61-0P, N-[(S)-[3]-Fluoro-4-[4-[(N-tert-butoxycarbonyl)pyrrolidin-2-yl]carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-61-1P, N-[(S)-[3]-Fluoro-4-[4-[(N-tert-butoxycarbonyl)pyrrolidin-2-yl]carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-62-2P, N-[(S)-[3]-Fluoro-4-[4-[(N-tert-butoxycarbonyl)pyrrolidin-2-yl]carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylthioacetamide 665011-64-2P, N-[(S)-[3]-Fluoro-4-[4-[(tert-butoxycarbonyl)amino]thioacetyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylthioacetamide 665011-65-0P, N-[(S)-[3]-Fluoro-4-[4-[(5-nitrofuranyl)thio]thiocarbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methyl azide 665011-66-5P, N-[(R)-[3]-Fluoro-4-[4-(5-nitrofuran-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methyl azide 665011-68-7P, N-[(R)-[3]-Fluoro-4-[4-(5-nitrobutan-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylazide 665011-70-2P, N-[(R)-[3]-Fluoro-4-[4-(5-tert-butoxycarbonyl)amino]thioacetyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylazide 665011-71-3P, N-[(R)-[3]-Fluoro-4-[4-[(N-tert-butoxycarbonyl)amino]acetyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylazide 665011-72-4P, N-[(R)-[3]-Fluoro-4-[4-[(N-tert-butoxycarbonyl)amino]thioacetyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methyl azide

RU: (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prep.n. of piperazine-substituted oxazolindiones as antibacterial agents)

II 665011-63-6P, N-[(S)-[3]-Fluoro-4-[4-(pyrazin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methylacetamide 665011-68-7P, N-[(S)-[3]-Fluoro-4-[4-(5-methylpyrazin-2-yl)carbonyl]piperazin-1-yl]phenyl]-2-oxxoacalidin-5-yl)methyl acetate

RU: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of piperazinephenyl-substituted oxazolindiones as antibacterial agents)

RN 665011-67-6 HCAPLUS

CN Acetamide, N-[(S)-[3]-Fluoro-4-[4-(pyrazinethioxomethyl)-1-piperazin-1-yl]-2-oxo-5-oxazolindinylmethyl]- (SCI) (CA INDEX NAME)

Absolute stereochemistry.


ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON 57N (Continued)

nitrophenylthiocarbamoyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methylthioacetamide 665011-81-4P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclohexylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665011-82-5P, N-[(5S)-3-[3-Fluoro-4-[4-(quinolin-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-83-7P, N-[(5S)-3-[3-Fluoro-4-[4-(thiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-84-7P, N-[(5S)-3-[3-Fluoro-4-[4-(3-chlorothiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-85-8P, N-[(5S)-3-[3-Fluoro-4-[4-(5-nitrofuran-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-86-9P, N-[(5S)-3-[3-Fluoro-4-[4-(5-methylthiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-87-0P, N-[(5S)-3-[3-Fluoro-4-[4-(5-methylthiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-88-1P, N-[(5S)-3-[3-Fluoro-4-[4-(5-methylthiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-87-0P, N-[(5S)-3-[3-Fluoro-4-[4-(5-chlorothiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-89-2P, N-[(5S)-3-[3-Fluoro-4-[4-(5-chlorothiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-90-5P, N-[(5S)-3-[3-Fluoro-4-[4-(2-chloropyrimidin-3-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-91-6P, N-[(5S)-3-[3-Fluoro-4-[4-(3-chlorothiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-92-7P, N-[(5S)-3-[3-Fluoro-4-[4-(3-bromothiophen-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-93-8P, N-[(5S)-3-[3-Fluoro-4-[4-(3-thiophen-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-94-9P, N-[(5S)-3-[3-Fluoro-4-[4-(pyrazin-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-95-1P, N-[(5S)-3-[3-Fluoro-4-[4-(phenylthio)thiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-96-2P, N-[(5S)-3-[3-Fluoro-4-[4-(6-chloropyridin-3-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-97-2P, N-[(5S)-3-[3-Fluoro-4-[4-(3-methylisoxazol-5-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-98-3P, N-[(5S)-3-[3-Fluoro-4-[4-(3-methylisoxazol-5-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665011-99-0P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclobutylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-00-0P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclobutylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-01-1P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclopentylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-02-2P, N-[(5S)-3-[3-Fluoro-4-[4-(imidazol-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-03-3P, N-[(5S)-3-[3-Fluoro-4-[4-(5-pyrroldin-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-04-4P, N-[(5S)-3-[3-Fluoro-4-[4-(5-pyrroldin-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-05-5P, N-[(5S)-3-[3-Fluoro-4-[4-(aminethioacetyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-06-6P, N-[(5S)-3-[3-Fluoro-4-[4-(3-chloro-4-methylphenyl)thiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-07-7P, N-[(5S)-3-[3-Fluoro-4-[4-(3,4-dimethylphenyl)thiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]thioacetamide 665012-08-8P, N-[(5S)-3-[3-Fluoro-4-[4-(4-cyanophenylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-09-9P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclohexylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-10-2P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclooctylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-11-4P, N-[(5S)-3-[3-Fluoro-4-[4-(pyridin-3-ylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-12-4P, N-[(5S)-3-[3-Fluoro-4-[4-(cyclohexylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-13-5P, N-[(5S)-3-[3-Fluoro-4-[4-(cycloheptylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-14-6P, N-[(5S)-3-[3-Fluoro-4-[4-(4-nitrophenylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-15-7P, N-[(5S)-3-[3-Fluoro-4-[4-(4-benzoylthiocarbamido]piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl)methyl]acetamide 665012-16-8P

[illegible]

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 [(5-methylthioacetyl)-5-yl]thiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]acetamide 665012-51-1P, N-[[[5]-3-[3-Fluoro-4-[4-(2-aminothiopropionyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-52-2P, N-[[[5]-3-[3-Fluoro-4-[4-(2-aminothiopropionyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-53-3P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-2-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-54-4P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-3-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-55-5P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-4-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-56-6P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-3-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-57-7P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-4-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-58-8P, N-[[[5]-3-[3-Fluoro-4-[4-(piperidin-4-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-59-9P, N-[[[5]-3-[3-Fluoro-4-[4-(oxazol-5-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide 665012-60-2P, N-[[[5]-3-[3-Fluoro-4-[4-(oxazol-5-ylthiocarbonyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5-yl)methyl]thioacetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USE5 (Uses)
 (drug candidate; prep. of piperazinophenyl-substituted oxazolidinones as antibacterial agents)
 RN 665011-72-3 HCAPLUS
 CN Ethanethioamide, N-[[[5]-3-[3-Fluoro-4-[4-(3-thienylthioacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665011-73-4 HCAPLUS
 CN Ethanethioamide, N-[[[5]-3-[3-Fluoro-4-[4-[(2S)-2-pyrrolidinylthioacetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



● HCl


RN 665011-74-5 HCAPLUS
 CN Acetamide, N-[[[5]-3-[3-Fluoro-4-[4-[(5-nitro-2-furyl)thioacetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665011-75-6 HCAPLUS
 CN Acetamide, N-[[[5]-3-[3-Fluoro-4-[4-[(2-amino-1-thioxoethyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


RN 665011-76-7 HCAPLUS
 CN Acetamide, N-[[[5]-3-[4-[4-[(4-dimethylamino)phenyl]amino]thioacetyl]-1-piperazinyl]-3-Fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665011-78-9 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(4-nitrophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 665011-80-3 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-Fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-N-(4-nitrophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)









RN 665011-81-4 HCAPLUS
 CN Acetamide, N-[[[5]-3-[3-Fluoro-4-[4-[(4-morpholinylcarbonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 665011-82-5 HCAPLUS
 CN Ethanethioamide, N-[[[5]-3-[3-Fluoro-4-[4-[(2-quinolinylthioacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 665011-93-8 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(2-thienyl)-1-thioxoethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 665011-94-9 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(pyrazinylthioxomethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

Absolute stereochemistry.



RN 665011-97-2 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(3-methyl-5-isoxazolyl)thioxomethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 665011-98-3 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(5-methyl-3-isoxazolyl)thioxomethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


PAGE 1-A



PAGE 2-A

RN 665011-95-0 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(phenylthioxomethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 665011-96-1 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(4-(4-(6-chloro-3-pyridinyl)thioxomethyl)-1-piperazinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


Absolute stereochemistry.



RN 665011-99-4 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(3-fluoro-4-(4-(5-methylpyrazinyl)thioxomethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 665012-00-0 HCAPLUS
 CN Ethanethioamide, N-(((S)-3-(4-(4-(cyclobutylthioxomethyl)-1-piperazinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.


CC(=N)N[C@H]1O[C@@H](C2=CC=C(C=C2)N3CCN(C3C(=S)C4CC4)C5=CC=C(C=C5)F)C1=O

5

PAGE 2-A


RN 665012-01-1 HCAPLUS
CN Ethanethioamide, N-[[[(5S)-3-[4-(4-(cyclopentylthiomethyl)-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 665012-02-2 HCAPLUS
CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(1H-imidazol-2-ylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-03-3 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2S)-2-pyrrolidinylthioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      665012-04-4  HCAPLUS
CN      Ethanethioamide, N-|[(5S)-3-[3-fluoro-4-[4-[(2S)-2-
      pyrrolidinylthioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-
      oxalidindinyl]methyl]- (CA INDEX NAME)

```


Absolute stereochemistry.



RN 665012-05-5 HCAPLUS
CN Ethanethioamide, N-[(5S)-3-[4-[4-(2-amino-1-thioxoethyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

127 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-06-6 HCAPLUS
CN Acetamide, N-([[(5S)-3-[4-[4-[(3-chloro-4-methylphenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-07-7 HCAPLUS
CN Acetamide, N-([[(5S)-3-[4-[4-[(3,4-dichlorophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

127 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-08-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(4-cyanophenyl)amino]thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      665012-09-9  HCAPLUS
CN      Acetamide, N-[[[5S]-3-[4-[4-[(cyclopropylamino)thioxomethyl]-1-
          piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX
          NAME)

```


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-10-2 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(cyclooctylamino)thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-11-3 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(3-pyridinylamino)thioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-12-4 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(cyclopentylamino)thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-13-5 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(cyclohexylamino)thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-14-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(4-nitrophenylamino)thioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-15-7 HCAPLUS
 CN Benzamide, N-[(4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl)-1-piperazinyl]thioxomethyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 665012-16-8 HCAPLUS
 CN Acetamide, N-[(5S)-3-[4-[(1,3-benzodioxol-5-ylmethylamino)thioxomethyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-17-9 HCAPLUS
 CN 1-Piperazinecarboxamide, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-18-0 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-[(phenylamino)thioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (CA INDEX NAME)


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-19-1 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-[(methylamino)thioxomethyl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-20-4 HCAPLUS
CN 1-Piperazinecarboxamide, 4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-N-(4-nitrophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-21-5 HCAPLUS
CN Benzamide, N-([(4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]thioxomethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-22-6 HCAPLUS
CN 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 665012-23-7 HCAPLUS
CN 1-Piperazinecarboxamide, 4-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-24-8 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-[(1H-imidazol-2-ylthioxomethyl)-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-25-9 HCAPLUS
CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-{4-[(5-methyl-1H-1,2,4-triazol-3-yl)thioxomethyl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 665012-26-0 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-[(5-methyl-1H-1,2,4-triazol-3-yl)thioxomethyl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-27-1 HCAPLUS
CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-{4-[(5-ethyl-1H-1,2,4-triazol-3-yl)thioxomethyl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-28-2 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-[(5-ethyl-1H-1,2,4-triazol-3-yl)thioxomethyl]-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-29-3 HCAPLUS
CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(2-piperazinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 665012-30-6 HCAPLUS
CN Acetamide, N-([(5S)-3-[3-fluoro-4-{4-(2-piperazinylthioxomethyl)-1-piperazinyl]phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

127 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 665012-31-7 HCAPLUS
CN Ethanethioamide, N-[(5S)-3-(3-fluoro-4-{4-(1,3,4-oxadiazol-2-ylthioxomethyl)-1-piperazinyl}phenyl)-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-32-8 HCAPLUS
CN Acetamide, N-[(1S)-3-[3-fluoro-4-[4-(1,3,4-oxadiazol-2-ylthiomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-33-9 HCAPLUS


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)
CN Ethanethioamide, N-[[5S]-3-{3-fluoro-4-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)thiomethyl]-1-piperazinyl}phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 665012-34-0 HCAPLUS
CN Acetamide, N-([5S]-3-[3-fluoro-4-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)thioxomethyl]-1-piperazinyl}phenyl]-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-35-1 HCAPLUS
CN Ethanethioamide, N-[[[(5S)-3-{3-Fluoro-4-{4-(1,3,4-thiadiazol-2-ylthioxomethyl)-1-piperazinyl}phenyl}-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-36-2 HCAPLUS
CN Acetamide, N-[(5S)-3-[3-fluoro-4-[4-(1,3,4-thiadiazol-2-ylthiomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

127 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




```

RN      665012-37-3  HCAPLUS
CN      Ethanethioamide, N-(((5S)-3-(3-fluoro-4-(4-(2-(1,3,4-oxadiazol-2-yl)-1-
        thioxoethyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)- (CA
        INDEX NAME)


```

Absolute stereochemistry.



RN 665012-38-4 HCAPLUS
CN Acetamide, N-([5S]-3-[3-fluoro-4-[4-(2-(1,3,4-oxadiazol-2-yl)-1-thioxoethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl)- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      665012-39-5  HCAPLUS
CN      Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(4-methyl-1H-imidazol-2-
yl)thioxomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
          (CA INDEX NAME)

```


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 665012-40-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(4-methyl-1H-imidazol-2-yl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-41-9 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-[(1-oxo-3-thioxo-3-(1H-1,2,4-triazol-3-yl)propyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-42-0 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[1-oxo-3-thioxo-3-(1H-1,2,4-triazol-3-yl)propyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 665012-46-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-methyl-2-oxazolyl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-47-5 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-[(2-oxazolyl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-48-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2-oxazolylthiomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 665012-43-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-44-2 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-45-3 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-[(5-methyl-2-oxazolyl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 665012-49-7 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-[(2-methyl-5-oxazolyl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 665012-50-0 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2-methyl-5-oxazolyl)thiomethyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-51-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-(2-amino-1-thioxopropyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-52-2 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[4-(4-(2-amino-1-thioxopropyl)-1-piperazinyl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 665012-53-3 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-(2-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 665012-56-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(3-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 665012-57-7 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-(4-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 665012-54-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(2-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-55-5 HCAPLUS
 CN Ethanethioamide, N-([(5S)-3-[3-fluoro-4-[4-(3-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 665012-58-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(4-piperidinylthioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 665012-59-9 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(5-oxazolythioxomethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 665012-60-2 HCAPLUS
 CN Ethanethioamide, N-(((5S)-3-(3-fluoro-4-((5-oxazolidin-5-yl)methyl)thioacetamide)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 612056-04-9, N-(((5S)-3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-2-oxo-5-oxazolidin-5-yl)methyl)thioacetamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of piperazinophenyl-substituted oxazolidinones as antibacterial agents)

RN 612056-04-9 HCAPLUS
 CN Ethanethioamide, N-(((5S)-3-(3-fluoro-4-(1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:142973 HCAPLUS
 DN 140:181436
 TI Preparation of phenyl oxazolidinone derivatives as antimicrobials
 IN Mehta, Anita; Rudra, Sonali; Raja Rao, Ajjarapu Venkata Subrahmanya; Yadav, Ajay Singh; Rattan, Ashok
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004014392	A1	20040219	2002MO-IB02940	20020729
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HP, HU, ID, IL, IN, JS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, VE, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2002319848	A1	20040225	2002AU-0319848	20020729
EP-1542696	A1	20050622	2002EP-0749195	20020729
BR: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR2002015921	A	20050913	2002BR-0015921	20020729
CN-1668208	A	20050914	2002CN-0829548	20020729
MX2005PA01199	A	20050516	2005MX-PA01199	20050128
IN2005DN00699	A	20071130	2005IN-DN00699	20050222
US2006293307	A1	20061128	2006US-0523207	20060302
PRAI 2002WO-IB02940	A	20020729		
OS MARPAT 140:181436				
GI				



AB Substituted Ph oxazolidinones of formula I [T = (substituted) heterocyclic ring; R = H, CHO, alkyl, halo, CN, COOH, etc.; R1 = (substituted) acylamino, (substituted) amino, etc.; R2, R3 = H, alkyl, halo, etc.; R4, R5 = H, alkyl, cycloalkyl; Y = (CH2)n; Z = (CH2)m; n, m = 0-3] are prepared. This invention also relates to pharmaceutical compositions containing I as antimicrobials. The comps. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as bacteroides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, II was prepared and was found to be active against many bacterial organisms.


IC A61K-031/55
 ICS A61K-031/495; A61K-031/50; A61K-031/445; A61K-031/42; A61P-031/04; C07D-263/00; C07D-413/00
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 657390-43-7P

L27 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 154590-66-6P, N-(((5S)-3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-2-oxo-5-oxazolidin-5-yl)methyl)thioacetamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of piperazinophenyl-substituted oxazolidinones as antibacterial agents)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-(((5S)-3-(3-fluoro-4-(1-piperazinyl)phenyl)-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of Ph oxazolidinones as antimicrobials)
 IT 657390-39-1P 657390-40-4P 657390-41-5P
 657390-42-6P 657390-44-8P 657390-45-9P
 657390-46-0P 657390-47-1P 657390-48-2P
 657390-49-3P 657390-50-6P 657390-51-7P 657390-52-8P
 657390-53-9P 657390-54-0P 657390-55-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of Ph oxazolidinones as antimicrobials)
 IT 823-73-4, 2-Bromo-5-nitrofurane 1003-09-4, 2-Bromothiophene 1899-24-7, 5-Bromo-2-furaldehyde 4701-17-3, 5-Bromo-2-thiophenecarboxaldehyde 13195-50-1, 5-Bromo-2-nitrothiophene 154590-66-6 172966-99-3
 174649-07-1 202133-29-7 276888-73-4 392660-17-2 392660-35-4
 640772-88-9 657390-56-2 657390-57-3 657390-58-4 657390-59-5
 657390-60-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of Ph oxazolidinones as antimicrobials)
 IT 657390-43-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of Ph oxazolidinones as antimicrobials)
 RN 657390-43-7 HCAPLUS
 CN Acetamide, N-(((5S)-3-[4-[4-(5-[bis(acetyloxymethyl)-2-nitro-3-thienyl]-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 657390-39-1P 657390-40-4P 657390-41-5P
 657390-42-6P 657390-44-8P 657390-45-9P
 657390-46-0P 657390-47-1P 657390-48-2P
 657390-49-3P 657390-53-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of Ph oxazolidinones as antimicrobials)

RN 657390-39-1 HCAPLUS
 CN Acetamide, N-(((5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 657390-40-4 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(5-formyl-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 657390-41-5 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(5-formyl-2-furanyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 657390-42-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(5-nitro-2-furanyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 657390-44-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 657390-45-9 HCAPLUS
 CN Propanamide, 2-chloro-N-([(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 657390-46-0 HCAPLUS
 CN Acetamide, 2,2-difluoro-N-([(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 657390-47-1 HCAPLUS
 CN Acetamide, 2,2-dichloro-N-([(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 657390-48-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[3-methyl-4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 657390-49-3 HCAPLUS
 CN Acetamide, 2-fluoro-N-([(5S)-3-[3-fluoro-4-[4-(5-nitro-2-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 657390-53-9 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(5-formyl-2-nitro-3-thienyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of Ph oxazolidinones as antimicrobials)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L27 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2004:79119 HCAPLUS
 DN 140:1230470
 TI An approach To enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid)
 AU Lee, Jongkook; Kwon, Miyeon; Lee, Kyung Hyun; Jeong, Sunjoo; Hyun, Soonsil; Shin, Kye Jung; Yu, Jaehoon
 CS Life Science Division, Korea Institute of Science Technology, Seoul, 130-650, S. Korea
 SO Journal of the American Chemical Society (2004), 126(7), 1956-1957
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 AB We describe the design and synthesis of new heterodimeric conjugates, which are comprised of a neomycin B (Neo) stem-binding component and a chloramphenicol (Cam) or linezolid (Lnz) loop-binding component. Some of the heterodimeric conjugates display enhanced affinities to RNA targets and that binding occurs in both stem and loop regions of the RNA. In addition, the results of foot-printing and mutation studies suggest that the enhanced binding affinity of the conjugates is RNA sequence-specific.
 CC 1-5 (Pharmacology)
 IT Section cross-reference(s): 3, 6
 IT 667926-76-3P 667926-78-5P 667926-80-9P 667926-82-1P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid))
 IT 109-80-8, 1,3-Propanedithiol 598-21-0, Bromoacetyl bromide 716-61-0
 1191-43-1, 1,6-Hexanedithiol 3489-28-9, 1,9-Nonanedithiol 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid))
 IT 667926-78-5P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid))
 RN 667926-78-5 HCAPLUS
 CN D-Streptamine, O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-(1-3)-O-5-S-[6-[(12-[4-[14-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-piperazinyl]-2-oxomethyl]thio]hexyl)-5-thio-β-D-ribofuranosyl-(1-5)-O-[2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl-(1-4)]-], heptakis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 577786-69-7
 CMF C47 H79 F N10 O16 S2
 Absolute stereochemistry.

L27 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A



PAGE 2-A



PAGE 2-B


—NHAc

CM 2
 CRN 76-05-1
 CMF C2 H F3 O2

L27 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)





IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid))
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)
 Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2003:877315 HCAPLUS
 DN 140:111313
 TI Novel oxazolidinone-quinolone hybrid antimicrobials
 AU Gordeev, Mikhail F.; Hackbarth, Corinne; Barbachyn, Michael R.; Banitt, Lee S.; Gage, James R.; Luehr, Gary W.; Gomez, Marcela; Trias, Joaquin; Morin, Sara E.; Zurek, Gary E.; Parker, Christian N.; Evans, Jonathan M.; White, Richard J.; Patel, Dinesh V.
 CS Vicuron Pharmaceuticals Inc., Fremont, CA, 94555, USA
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(23), 4213-4216
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 140:111313
 GI




AB Antimicrobial compds. incorporating oxazolidinone and quinolone pharmacophore substructures have been synthesized and evaluated. Representative analogs I and II [racemic and 3-(5)-isomer] display an improved potency vs. linezolid against gram-pos. and fastidious gram-neg. pathogens. The compds. are also active against linezolid- and ciprofloxacin-resistant Staphylococcus aureus and Enterococcus faecium strains. The MOA for these new antimicrobials is consistent with a combination of protein synthesis and gyrase A/topoisomerase IV inhibition, with a structure-dependent degree of the contribution from each inhibitory mechanism.
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
 IT Section cross-reference(s): 1, 10
 IT 444335-14-2P 647827-95-0P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, antimicrobial activity and MSBAR of oxazolidinone-quinolone hybrid antimicrobials)
 IT 444335-12-0P 444335-22-2P 444335-42-6P 484639-57-8P
 647827-92-7P 647827-94-9P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, antimicrobial activity and MSBAR of oxazolidinone-quinolone hybrid antimicrobials)
 IT 109-01-3, N-Methylpiperazine 372-19-0, 3-Fluoroaniline 924-99-2, Ethyl 3-Dimethylaminoacrylate 1427-07-2, 3-Fluoro-4-methylnitrobenzene 1907-33-1, Lithium tert-Butoxide 6056-26-0, N-Glycidyl butyrate 60827-48-4, (S)-3-Chloro-1,2-propanediol 70458-96-7, Norfloxacin 82419-34-9 86393-33-1 88419-56-1, 2,4,5-Trifluorobenzoyl chloride 106939-34-8 130579-27-0 154590-66-6 181997-31-9

L27 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn., antimicrobial activity and MSBAR of oxazolidinone-quinolone
 hybrid antimicrobials)

IT 444335-14-2P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT
 (Reactant); SPN (Synthetic preparation); BIOL (Biological study)
 ; PREP (Preparation); RACT (Reactant or reagent)
 (preparation, antimicrobial activity and MSBAR of oxazolidinone-quinolone
 hybrid antimicrobials)

RN 444335-14-2 HCAPLUS
 CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
 10-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-1-piperazinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo- (CA
 INDEX NAME)


Absolute stereochemistry.



IT 444335-12-0P 484639-57-BP 647827-92-7P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN
 (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation)
 (preparation, antimicrobial activity and MSBAR of oxazolidinone-quinolone
 hybrid antimicrobials)

RN 444335-12-0 HCAPLUS
 CN 3-Quinolonecarboxylic acid, 7-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-
 oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-
 dihydro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 484639-57-8 HCAPLUS
 CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
 10-[4-[(4S)-4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-1-piperazinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, methyl
 ester (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L27 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 647827-92-7 HCAPLUS
 CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
 10-[4-[(4S)-4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-1-piperazinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-
 (CA INDEX NAME)


Absolute stereochemistry.



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation, antimicrobial activity and MSBAR of oxazolidinone-quinolone
 hybrid antimicrobials)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-
 oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:485880 HCAPLUS

DN 139:230724

TI Synthesis and antibacterial activity of oxazolidinone containing sulfonyl

group

AU Cui, Yingjie; Yang, Yushe; Chen, Kaixian; Ji, Ruyun; Zhang, Shuhua

CS Shanghai Institute for Biological Sciences, Shanghai Institute of Materia

Medica, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2311-2313

CODEN: BMCLDH; ISSN: 0960-894X


PB Elsevier Science B.V.

DT Journal

LA English

OS

GI CASREACT 139:230724



AB A series of oxazolidinone derivs. carrying sulfonyl group was synthesized

and their antibacterial activity was evaluated in vitro. Many of such

comps. demonstrated potent antibacterial activity. The activity of a

novel compound I (XC-20) was 2-4-fold more potent than that of Linezolid.

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 595582-79-9P 595582-84-6P 595582-85-7P

595582-86-8P 595582-88-0P 595582-89-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN

(Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent)

(synthesis and antibacterial activity of oxazolidinone containing sulfonyl

group)

IT 189038-59-3P 595582-80-2P 595582-81-3P

595582-82-4P 595582-83-5P 595582-87-3P

595582-90-4P 595582-91-5P 595582-92-6P

RL: BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antibacterial activity of oxazolidinone containing sulfonyl

group)

IT 98-09-9, Phenylsulfonyl chloride 98-58-8, 4-Bromophenylsulfonyl chloride

98-59-9, 4-Methylphenylsulfonyl chloride 98-61-0, 4-

Methoxyphenylsulfonyl chloride 98-74-8, 4-Nitrophenylsulfonyl chloride

121-51-7, 3-Nitrophenylsulfonyl chloride 124-63-0, Methylsulfonyl

chloride 1694-92-4, 2-Nitrophenylsulfonyl chloride 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis and antibacterial activity of oxazolidinone containing sulfonyl

group)

IT 595582-79-9P 595582-84-6P 595582-85-7P

595582-86-8P 595582-88-0P 595582-89-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN

(Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent)

(synthesis and antibacterial activity of oxazolidinone containing sulfonyl


group)

RN 595582-79-9 HCAPLUS

CN Acetamide, N-[(5S)-3-[4-[(3-aminophenyl)sulfonyl]-1-piperazinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 595582-84-6 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(2-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 595582-85-7 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(3-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 595582-89-1 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-[(4-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 189038-59-3P 595582-80-2P 595582-81-3P
 595582-82-4P 595582-83-5P 595582-87-9P
 595582-90-4P 595582-91-5P 595582-92-6P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antibacterial activity of oxazolidinone containing sulfonyl group)


L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 595582-86-8 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-88-0 HCAPLUS
 CN Acetamide, N-([(5S)-3-[4-[4-[(2-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 189038-59-3 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 595582-80-2 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-(phenylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-81-3 HCAPLUS
 CN Acetamide, N-([(5S)-3-[3-fluoro-4-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 595582-82-4 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-83-5 HCAPLUS
 CN Acetamide, N-[(1S)-3-[4-[4-(4-bromophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 595582-87-9 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-[(2-thienylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 595582-90-4 HCAPLUS
 CN Acetamide, N-[2-[4-[4-[(1S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A



RN 595582-91-5 HCAPLUS
 CN Acetamide, N-[3-[4-[4-[(1S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 595582-92-6 HCAPLUS
 CN Acetamide, N-[4-[4-[4-[(1S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]sulfonyl]phenyl- (CA INDEX NAME)

Absolute stereochemistry.


L27 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antibacterial activity of oxazolidinone containing sulfonyl group)

RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(1S)-3-[3-fluoro-4-[(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
 RN 2003:311228 HCAPLUS
 DN 139:335243
 TI Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids
 AU Hubschwerlen, Christian; Specklin, Jean-Luc; Sigwalt, Christine; Schroeder, Susanne; Locher, Hans R.
 CS Morphochem AG, Basel, CH-4058, Switz.
 SO Bioorganic & Medicinal Chemistry (2003), 11(10), 2313-2319
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 139:335243
 AB Oxazolidinone-quinolone hybrids that combine the pharmacophores of a quinolone and an oxazolidinone were synthesized and shown to be active against a variety of resistant and susceptible Gram-pos. and fastidious Gram-neg. organisms. The best compds. in this series overcome all types of resistance in relevant clin. Gram-pos. pathogens. The nature of the spacer greatly influences the antibacterial activity. The dual mode of action could be demonstrated for compds. having a piperazinyl spacer. Antibacterial activity was higher at acidic pH.
 CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
 IT 444335-12-0P 484639-31-8P 510729-38-1P
 510729-73-4P 615559-94-9P 615559-95-0P 615559-96-1P
 615559-97-2P

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and biol. evaluation of oxazolidinone-quinolone hybrids against Gram-pos. and fastidious Gram-neg. organisms)
 IT 99-37-8, N,N-Dimethyl-p-toluidine 109-72-8, n-Butyl lithium, reactions 369-34-6, 3,4-Difluoronitrobenzene 688-73-3, Tributyltin hydride 24424-99-5 26628-22-8, Sodium azide 40432-52-8, 1-Diphenylmethyl-3-azetidinamine 60456-26-0, R-Glycidyl butyrate 100361-18-0 119285-07-3 136247-64-8 137435-09-7 154590-66-6 209467-90-3 268209-15-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and biol. evaluation of oxazolidinone-quinolone hybrids against Gram-pos. and fastidious Gram-neg. organisms)
 IT 444335-12-0P 484639-31-8P 510729-73-4P
 615559-94-9P
 RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and biol. evaluation of oxazolidinone-quinolone hybrids against Gram-pos. and fastidious Gram-neg. organisms)
 RN 444335-12-0 HCAPLUS
 CN 3-Quinolonecarboxylic acid, 7-[4-(4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



L27 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 484639-31-8 HCAPLUS
 CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 510729-73-4 HCAPLUS
 CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-7-[4-[2-fluoro-4-[(5S)-5-[(methoxythioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-piperazinyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 615559-94-9 HCAPLUS
 CN 6H-Pyrazolo[4,5,1-i]quinoline-7-carboxylic acid, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-4-fluoro-1,2-dihydro-1-methyl-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.

L27 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 154590-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and biol. evaluation of oxazolidinone-quinolone hybrids against Gram-pos. and fastidious Gram-neg. organisms)
 RN 154590-66-6 HCAPLUS
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:50:57 ON 21 FEB 2008)

FILE 'HCAPLUS' ENTERED AT 12:51:16 ON 21 FEB 2008

L1 1 US20060229316/PN

FILE 'REGISTRY' ENTERED AT 12:52:00 ON 21 FEB 2008

FILE 'HCAPLUS' ENTERED AT 12:52:00 ON 21 FEB 2008

L2 TRA L1 1- RN : 220 TERMS

FILE 'REGISTRY' ENTERED AT 12:52:01 ON 21 FEB 2008

L3 220 SEA L2
 L4 216 L3 AND NC2NC2/ES AND 46.150.18/RID AND NCOC2/ES
 L5 STR
 L6 0 L5
 L7 11618 NC2NC2/ES AND NCOC2/ES
 L8 50 L5 SAM SUB=L7
 L9 2527 L5 FULL SUB=L7
 SAV TEM L9 J892C1G1/A
 L10 216 L9 AND L3
 L11 2311 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 12:59:42 ON 21 FEB 2008

L12 52 L10
 L13 1 L12 AND L1
 E LOHRAV B/AU
 L14 159 E3-9
 E LOHRAV V/AU
 L15 85 E4-11
 E SRIVASTAVA B/AU
 L16 806 E3-18
 E SRIVASTAVA BRIJESH/AU
 L17 33 E3-6
 L18 274 CADILA/CS,PA
 L19 6 L12 AND L14-18
 L20 5 L19 NOT L13

FILE 'STNGUIDE' ENTERED AT 13:04:25 ON 21 FEB 2008

FILE 'STNGUIDE' ENTERED AT 13:06:21 ON 21 FEB 2008

FILE 'HCAPLUS' ENTERED AT 13:30:45 ON 21 FEB 2008

L21 46 L12 NOT L13,L19-20
 L22 20 L21 AND (PD<=20020401 OR AD<=20020401 OR PRD<=20020401)
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 13:32:44 ON 21 FEB 2008

L23 3 E1-3

FILE 'STNGUIDE' ENTERED AT 13:33:15 ON 21 FEB 2008

FILE 'HCAPLUS' ENTERED AT 13:33:44 ON 21 FEB 2008

L24 26 L21 NOT L22
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 13:34:01 ON 21 FEB 2008

L25 35 E4-38

FILE 'STNGUIDE' ENTERED AT 13:34:41 ON 21 FEB 2008

FILE 'STNGUIDE' ENTERED AT 13:36:21 ON 21 FEB 2008

FILE 'HCAPLUS' ENTERED AT 13:38:54 ON 21 FEB 2008

L26 24 L11 (L) (USES+NT OR BIOL+NT)/RL AND L24
 L27 26 L24,L26

FILE 'HCAOLD' ENTERED AT 13:40:52 ON 21 FEB 2008

L28 0 L11

FILE 'REGISTRY' ENTERED AT 13:41:59 ON 21 FEB 2008

L29 0 L10
FILE 'HCAOLD' ENTERED AT 13:42:22 ON 21 FEB 2008

FILE 'HCAPLUS' ENTERED AT 13:42:30 ON 21 FEB 2008

=>